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1 Abstract 
 
Diabetic nephropathy is a consequence of hyperglycaemia-induced renal cell damage and a 
major contributor to end-stage renal disease in later stages of diabetes. Previous studies, in 
type I diabetes, observed PKC-βI-dependent GLUT2 recruitment to the proximal tubule 
brush-border membrane (BBM) as a direct result of elevated plasma glucose. The up-
regulation of glucose transporters at the proximal tubule BBM causes a rise in intracellular 
glucose concentration; tubular injury in diabetic nephropathy is postulated to be a result of 
increased GLUT-mediated glucose entry into the proximal tubule cell. Augmented glucose 
transport across the proximal tubule BBM is likely to elevate glucose reabsorption and 
exacerbate hyperglycaemia during diabetes. Thus identification of regulators of this process 
may offer novel therapeutic targets to reduce renal glucose handling during hyperglycaemia. 
Studies described in this thesis were designed to elucidate the modulation of glucose 
transporters in models of metabolic syndrome associated with diabetes. 
 
Type II diabetes, the prevalent form of the disease, was found to elevate both SGLT- and 
GLUT-mediated glucose transport across the proximal tubule BBM, with an accompanying 
increase in glucose transporter expression. In rodent models of metabolic syndrome, induced 
by feeding studies, an elevation in PKC-βI-dependent GLUT2 recruitment to the proximal 
tubule BBM was also observed. However SGLT1 expression at the proximal tubule BBM did 
not consistently mirror that of GLUT2. In studies presented in this thesis, the sweet taste 
receptor heterodimer (T1R2/3) was identified at the proximal tubule BBM and this sweet 
taste sensor exhibited a tight correlation with SGLT1 in all models of metabolic dyregulation 
studied. Furthermore, stimulation of T1R2/3, by the artificial sweetener saccharin, resulted in 
an increase in SGLT-mediated glucose transport across the proximal tubule BBM.    
 
The data reported in this thesis provide evidence that GLUT2 expression at the proximal 
tubule BBM is not solely a response to hyperglycaemia but also a renal response to whole-
body metabolic dysregulation.  From these studies it is hypothesised that PKC-βI-mediated 
GLUT2 recruitment to the proximal tubule BBM occurs via a SGLT-T1R2/3-dependent and 
–independent pathway. 
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JAK/STAT - janus kinase/signal transducers and activators of transcription  
JNK - c-Jun N-terminal kinase 
kDa - kilodaltons 
KIU - kallikrain inactivator units  
KO – knock out rodent model  
KT – transport constant, glucose concentration at half Vmax 
Lep
ob/ob
 (or ob/ob) - leptin-deficient mouse model of obesity 
LepR
 db/db
 (or db/db) - leptin receptor-deficient mouse model of type II diabetes   
LETL rat - Long Evans Tokushima Lean rat 
LLC-PK1 cells - porcine kidney proximal tubule cell line 
LPS - lipopolysaccharides 
M16 – obese mouse model of type II diabetes 
MAPK- mitogen-activated protein kinase 
MCP1 - monocyte chemotactic protein-1 
MIP3α – macrophage inflammatory protein-3α 
MLCK – myosin light chain kinase 
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mOsm - milliosmole 
mRNA – messenger ribonucleic acid 
Na
+
/K
+
- ATPase – sodium-potassium adenosine triphosphatase  
NADH – reduced nicotinamide adenine dinucleotide 
NaPiIIa - renal Na
+
/phosphate cotransporter 
NaSCN – sodium thiocyanate 
NF-КB - nuclear factor-kappa B 
NHE3 - sodium-hydrogen exchanger-3 
NIDDM – non insulin-dependent diabetes mellitus 
NOD – non-obese diabetic mouse model 
NP-40 – nonyl phenoxylpolyethoxylethanol 
Ob-R – leptin receptor 
ODB-1 – diabetogenic gene 
OK cells – opossum kidney cells 
OLETF – Otsuka Long Evans Tokushima Fatty rat 
PBS – phosphate-buffered saline 
PBS-T – phosphate-buffered saline with 0.1% Tween 20 
PCR – polymerase chain reaction 
PDGF – platelet-derived growth factor 
PDX-1 – pancreatic and duodenal homeobox-1 (insulin promoter factor-1) 
PKA – protein kinase A 
PKC – protein kinase C 
PLCβ2 – phospholipase C β2 
PMA – phorbol 12-myristate 13-acetate 
PPARγ - peroxisome proliferator-activated receptor-γ  
PVDF - polyvinylidene fluoride membrane 
PYY – peptide YY 
RAS – renin-angiotensin system 
RELMβ – resistin-like molecule-β 
RIPA – radioimmunoprecipitation assay buffer 
RLC20 – regulatory light chain-20  
RNA – ribonucleic acid 
  
  20 
ROS – reactive oxygen species 
rpm - revolutions per minute 
RT-PCR – reverse transcription polymerase chain reaction 
RYGB – roux-en-Y gastric bypass  
SDS – sodium dodecyl sulfate  
SDS-PAGE - sodium dodecyl sulfate polyacrylamide gel electrophoresis 
S.E.M. - standard error of the mean 
SGK1 – serum and glucocorticoid-inducible kinase-1 
SGLT – sodium-dependent glucose cotransporter 
SHROB – spontaneously hypertensive, obese rat  
SP1 - specificity protein-1 transcription factor 
STZ – streptozotocin 
T1R - family of taste-specific class C G protein-coupled receptors 
TGF-β – transforming growth factor-β 
Tm - glucose concentration at half Vmax 
TMB - tetramethylbenzidine  
TNF-α – tumour necrosis factor-α 
Tris HCl – tris hydrochloride 
VEGF - vascular endothelial growth factor 
VLDL – very low density lipoproteins 
Vmax – maximum transport capacity 
UKPDS – UK prospective diabetes study  
ZDF – Zucker diabetic fatty rat 
Zn(O2CCH3)2 – zinc acetate 
ZSF1 – Zucker fatty/spontaneously hypertensive heart failure rat  
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5 Introduction 
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5.1 Glucose homeostasis  
 
Glucose is a vital fuel for all organisms, from bacteria to mammals, as glucose is a metabolic 
substrate in aerobic or anaerobic respiration, or fermentation.  It is fundamental for mammals 
to maintain a constant blood glucose level for physiological processes such as cerebral 
metabolism (Figure 5.1).  Glucose homeostasis is maintained in mammals by glucose 
absorption from dietary carbohydrates in the small intestine and glucose filtration and 
reabsorption by the kidney.  Glucose is stored in the kidney, liver and adipocytes and 
regulated by pancreatic hormones, and utilised throughout the body, especially skeletal and 
cardiac muscle.  Glucose sensing, which is an important survival mechanism, enables 
mammals to mobilise tissue energy stores in response to the metabolic needs of the body.  
Intracellular glucose is sensed and the resulting signal is relayed by metabolic messengers in 
tissues; for example, glucokinase and mitochondrial oxidative fluxes (ADP:ATP ratio) are 
involved in regulation of ATP-sensitive potassium channels controlling insulin secretion and 
thus are well-established glucose sensors in pancreatic β-cells (Matschinsky et al., 
1998;Schuit et al., 2002).  The inhibition of glucose sensing, by metabolic modulators, would 
likely be fatal. 
 
Any given concentration of glucose in plasma is the result of simultaneous release of glucose 
into circulation and uptake of glucose from plasma by peripheral tissue.  The liver is the 
primary source of endogenous glucose production, although the kidneys also contribute 
approximately 5% to 20% in the basal state.  Following carbohydrate ingestion, a rise in 
plasma glucose leads to insulin release from β-cells and the resulting hyperinsulinemia 
stimulates glucose uptake by the liver, gut and peripheral tissue, primarily muscle.  From a 
physiological perspective, it is clear that any defects in insulin secretion in response to a meal 
or defects in insulin action in peripheral tissue will lead to increased plasma glucose 
concentration. 
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Figure 5.1 – The regulation of glucose homeostasis including the main contributors to the control of the whole-body glucose pool.  Glucose is absorbed from the 
diet by the small intestine, filtered and reabsorbed by the kidneys, utilised by the brain and skeletal muscle for ATP production and stored and generated by the 
liver, adipose tissue and kidney.  In addition, the glucose pool is regulated by factors such as insulin released from pancreatic β-cells and leptin and tumour 
necrosis factor-α (TNF-α) secreted by adipocytes.  
 
GLUCOSE
Brain
Skeletal 
muscle
Pancreas
(β-cell)
-
insulin
Small 
intestine
absorption
diet
Adipose
tissue
-
le
pt
in
+
T
N
F
-α
Liver
Kidney
re
ab
so
rp
tio
n
Glucose utilisation: glucose  ATP
Glucose storage and / or production
 
 
  
  24 
5.1.1 Utilisation of glucose 
 
Glucose enters the glycolysis pathway, forming pyruvate to release NADH and ATP, 
and the citric acid cycle, oxidising into carbon dioxide and water and yielding energy, 
mostly ATP, as well as precursors for compounds including some amino acids.  
Glycogenolysis is the breakdown of glycogen to glucose, with adrenalin and glucagon 
both stimulators of the process. The glucose cycle maintains the dynamic equilibrium 
between glucose and glucose-6-phosphate to preserve constant blood glucose levels.  
Gluconeogenesis, the production of glucose from non-carbohydrate sources such as 
lactate, pyruvate, glycerol and amino acids, also primarily occurs in the liver.  Fasting 
has been shown to promote the hepatic production of glucose via cAMP-dependent 
mechanisms whereas postprandial glucose production is down-regulated by insulin.  
Glucose production, traditionally viewed to occur solely in the liver has now also 
been shown to involve the kidney; however, under normal conditions, renal glucose 
production cannot be due to glycogenolysis since glycogen levels in the kidney are 
low (Biava et al., 1966;Greven et al., 1975).  Therefore, glucose is produced in the 
kidney by gluconeogenesis and in vivo studies have shown that this process 
contributes to the maintenance of constant blood glucose levels (Kida et al., 1978). 
 
5.1.2 Hepatic glucose production and storage 
 
Hepatic glucose production is determined by the rate of net glycogenolysis, 
gluconeogenesis and glucose cycling between glucose and glucose-6-phosphate; all of 
which are altered postprandially, resulting in the 60% reduction in net hepatic glucose 
output seen following a meal (Shulman et al., 1978;Sacca et al., 1978;Rossetti et al., 
1993;Clore et al., 1995;Hellerstein et al., 1997).  The regulation of hepatic glucose 
production is hormonal, for example, insulin is important in controlling glucokinase 
and is involved in glucose cycling, glycogen synthase activity, and in the formation of 
glycogen (Davidson, 1981;Vaulont and Kahn, 1994).  
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5.1.3 Renal glucose production and release 
 
In both rodent models and man, renal glucose release accounts for approximately 25% 
of all glucose released into the circulation (Kida et al., 1978;Stumvoll et al., 1995).  
Renal glucose handling will be discussed in more detail in section 5.7.1.3; however in 
brief, as one of the two only two organs in the body that expresses glucose-6-
phosphatase, the other being the liver, renal glucose production is vital for glucose 
homeostasis (Mayer PA, 1993).  Under normal conditions, the kidney stores glycogen 
at low levels, therefore most glucose production occurs via gluconeogenesis (Biava et 
al., 1966).  Indeed, the renal uptake of gluconeogenic precursors, such as lactate and 
glutamine, was shown to be sufficient to account for glucose release by the kidney 
(Bjorkman et al., 1980;Bjorkman and Felig, 1982;Brundin and Wahren, 1994). 
 
5.1.4 Adipocyte and skeletal muscle contribution to glucose homeostasis 
 
Between 2 to 4% of whole body glucose uptake is performed by adipose tissue 
(Gerich, 1993).  Despite this relatively low contribution, adipocytes play an important 
role in glucose homeostasis as seen with elevated fat levels in obesity or lowered fat 
in lipodystrophy, both of which are associated with insulin resistance and 
hyperglycaemia (Rosen and Spiegelman, 2006).  Adipocytes secrete both pro- and 
anti-hyperglycaemic factors; examples of the former include resistin and TNF-α 
(Hotamisligil and Erbay, 2008;Banerjee et al., 2009) whilst the latter includes leptin 
and visfatin (Shimomura et al., 1999;Stephens and Vidal-Puig, 2006).   
 
Skeletal muscle is responsible for 15 to 20% of glucose uptake in the body however 
this is elevated following consumption of a meal (Gerich, 1993;Taylor et al., 1993).  
Glucose is utilised by skeletal muscle for energy during exercise and muscle 
contraction, indeed glucose uptake increases as much as 50-fold during dynamic 
exercise (Katz et al., 1986). 
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5.2 Diabetes 
 
In healthy individuals, plasma glucose levels are maintained within a very narrow 
range between 4 to 9 mM, by mechanisms described in section 5.1, despite the 
fluctuations which occur postprandially and following exercise.  A reduction of 
glucose concentration in the plasma results in hypoglycaemic consequences such as 
limited fuel supply to the brain which, as an organ which cannot store glucose or 
uptake nutrients, is dependent on circulating glucose for its metabolic needs (Owen et 
al., 1967).  An elevation in plasma glucose levels results in hyperglycaemic 
consequences often seen in patients suffering diabetes, such as retinopathy, 
neuropathy and nephropathy (UK Prospective Diabetes study, 1998). 
  
5.2.1 Type I diabetes 
 
Type I diabetes is the less common, juvenile-onset form of diabetes which afflicts the 
young age group with 0.025% of 0-14 year olds developing the disease every year in 
the UK (The Diabetes Control and Complications Trial Research Group 2009).  This 
insulin-dependent form of the disease occurs via the autoimmune destruction of 
pancreatic β-cells and results in defective insulin secretion and attendant insulin 
deficiency (Gepts, 1965).   
 
5.2.1.1 Genetic and environmental factors in the onset of type I diabetes 
 
Both genetic and environmental factors influence the aetiology of human type I 
diabetes (Hirschhorn, 2003).  Genetic factors play a large role in the onset of type I 
diabetes; Csorba et al showed that the development of type I diabetes requires 
coordinated abnormal variations, thus limiting the occurrence of the disease to a small 
minority of susceptible individuals (Csorba et al., 2010).  The genetic nature of type I 
diabetes has been postulated to involve six stages in development of the disease 
starting with genetic susceptibility due to the interaction of several genes conferring 
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the sensitivity and risk for the disease such as aberrant antigen presentation (Gianani 
and Eisenbarth, 2005).  Stages two to four involve the triggering of autoimmunity by 
contentiously-discussed environmental agents, the destruction of β-cells and the 
progressive decline in insulin secretion.  The final two stages are when patients 
develop overt diabetes with insulin dependence and symptoms of type I diabetes such 
as ketoacidosis.       
 
The elevation in the incidence of type I diabetes does not correlate with increases in 
the frequency of the major risk genes involved in the disease, thus environmental 
factors also play a large role in the onset of type I diabetes (Knip and Siljander, 
2008;Barrett et al., 2009;Patterson et al., 2009).  Examples of environmental factors 
which have been suggested to promote the onset of type I diabetes include infectious 
agents such as viral infections, and dietary factors such as wheat (Hettiarachchi et al., 
2008). 
 
5.2.2 Type II diabetes 
 
Type II diabetes is the prevalent form of the disease with 2.8 million people currently 
diagnosed in the UK, furthermore the type II diabetes epidemic is escalating with an 
annual increase in sufferers of 8% (UK Prospective Diabetes study, 1998).  Type II 
diabetes is the insulin-independent form of the disease which is associated with 
insulin resistance and hyperglycaemia, in addition to the classical phenotype; 
polyuria, polydipsia, polyphagia, fatigue and weight loss.  
 
Insulin resistance in type II diabetes arises from impaired insulin action in skeletal 
muscle, liver and adipose tissue, and defective β-cell function (Bonadonna et al., 
1990;Tripathy et al., 2004;DeFronzo, 2009;Karastergiou and Mohamed-Ali, 2010).  
Impaired insulin sensitivity in these tissues results in reduced insulin-dependent 
glucose uptake which therefore raises plasma glucose concentration (Mari et al., 
1994).  Reduced insulin receptor sensitivity results in decreased insulin action but 
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elevated circulating insulin levels culminating in insulin resistance (Alberti et al., 
1992).  As type II diabetes progresses, β-cell function declines, due to the action of 
high extracellular glucose load on β-cells, causing impaired insulin secretion 
(Lencioni et al., 2008).  In early hyperglycaemia, the correction of high plasma 
glucose stimulus can restore β-cell function (Abdul-Ghani et al., 2006).  Additionally, 
the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory 
polypeptide (GIP) influence insulin secretion and glucose homeostasis postprandially; 
in type II diabetic patients, a reduction in GIP responsiveness of β-cells and lowered 
plasma levels of GLP-1 occur (Thorens and Waeber, 1993;Nauck et al., 1993;Elahi et 
al., 1994;Vilsboll et al., 2002;Kjems et al., 2003).     
 
5.2.2.1 Genetic and environmental factors in the onset of type II diabetes 
 
Type II diabetes, like type I diabetes, is caused by a combination of genetic and 
environmental factors.  Although the latter influences the onset of type II diabetes 
more than genetic factors, it has been shown that genes affecting insulin secretion are 
closely associated with increased risk of developing the disease (Sladek et al., 
2007;Lyssenko et al., 2007;Saxena et al., 2010).  Environmental factors which effect 
the development of type II diabetes are well-established with diet and nutrition being 
the predominant causes, although aging, sedentary lifestyle and intrauterine 
development are also risk factors.  The influences of nutrition, obesity and metabolic 
syndrome on type II diabetes are discussed in section 5.3.  Aging has been shown to 
correlate with insulin-resistance, for example Bluher et al found an 18% increase in 
the life span of mice which had selective insulin-receptor knockout in adipocytes 
(Bluher et al., 2003).  Physical inactivity, although strongly linked with the obesity 
risk factor, has been shown to affect the onset of type II diabetes independently of 
weight gain (Hamilton et al., 2007).  Furthermore, studies in rodent models and man 
observed that low birth-weight elevates the risk of onset of type II diabetes in later 
life, demonstrating a role for intrauterine nutrient restriction in the predisposition of 
the disease (Ozanne et al., 2005;Breant et al., 2006).      
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5.2.2.2 Incretins in type II diabetes 
 
In recent years, the association of incretins, gut-derived hormones, with type II 
diabetes has been hypothesised.  GLP-1 is a potent stimulator of insulin secretion and 
can thus exert significant effects on the regulation of glucose metabolism (Scrocchi 
and Drucker, 1998).  GLP-1 regulates mature β-cell function as well as β-cell 
differentiation, proliferation and survival whereas the dysregulation of β-cell growth 
and function are central in the pathology of type II diabetes (Solcia et al., 
1985;Stoffers, 2004).  GLP-1 increases postprandial insulin secretion in a dose-
dependent manner and reduces plasma glucagon levels, an effect which is preserved 
in type II diabetes (Nauck et al., 1993).  Furthermore low treatment quantities of 
GLP-1 normalises the β-cell response to glucose, however the concentration-
dependent relationship between β-cell responsiveness to glucose and GLP-1 is 
severely impaired in type II diabetes (Kjems et al., 2003). 
 
5.2.3 Potential Type III diabetes 
 
Interestingly, Alzheimer’s disease has been postulated to represent type III diabetes 
since impaired insulin signalling is a feature of the disease (de la Monte and Wands, 
2008).  Although largely confined to the brain, the chronic insulin resistance and 
insulin deficient state of Alzheimer’s disease coupled with the improvement of 
cognitive performance following insulin treatment suggests a strong relationship 
between Alzheimer’s disease and the diabetic state (Steen et al., 2005;Rivera et al., 
2005;Craft, 2006;Haan, 2006).  Furthermore the increased risk of Alzheimer’s-like 
dementia in type II diabetic patients may be linked to the chronic hyperglycaemia, 
peripheral insulin resistance and oxidative stress seen in diabetes (Whitmer, 2007).  
Therefore Alzheimer’s disease represents a form of diabetes mellitus that selectively 
affects the brain, although it should be emphasised that type II diabetes alone is not 
sufficient to cause Alzheimer’s disease. 
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5.2.4 Diabetic nephropathy 
5.2.4.1 Classification of diabetic nephropathy 
 
Hyperglycaemia is associated with the development of diabetic complications such as 
neuropathy, retinopathy and cardiovascular disease (Laakso, 1999;Gerstein et al., 
2005;Fox et al., 2007).  Diabetic nephropathy is another major complication in 
diabetes and a major cause of end-stage renal disease (ESRD), accounting for over a 
third of patients on kidney dialysis treatment (Ruggenenti and Remuzzi, 2000;Molitch 
et al., 2004;Gerstein et al., 2005).  The criteria for validating mouse models of 
progressive diabetic nephropathy include a greater than 50% decline in glomerular 
filtration rate (GFR), a greater than 10-fold increase in albuminuria, a greater than 
50% thickening of glomerular basement membrane and advanced mesangial matrix 
expansion (Brosius, III et al., 2009).  In man, diabetic nephropathy is characterised by 
early renal hypertrophy, glomerular damage and proteinuria with decreased GFR in 
later stages (Keen H. and Chlouverakis C., 1964;Rasch, 1979;Boot-Handford and 
Heath, 1981;Rasch, 1984).    
 
Hyperglycaemia results in a high intracellular glucose concentration resulting from an 
increase in cellular glucose uptake from the glomerular filtrate and directly from the 
blood at the brush-border and basolateral membrane respectively.  Elevated glucose 
uptake int the proximal tubule activates several pathways, outlined below, related to 
the production of advanced glycation end-products (AGE’s), cytokines, chemokines, 
growth factors and reactive oxidative species (ROS), all of which are mediators of 
renal damage and are associated with the polyol and hexosamine pathways (Figure 
5.2).  However, studies have yet to ascertain whether the elevated intracellular glucose 
concentration during hyperglycaemia is a result of glucose from the glomerular filtrate 
or blood.   
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Figure 5.2 – The development of diabetic nephropathy in glomerular cells following high extracellular glucose stimulation.  Glucose entry into the mesangial cell 
is mediated by GLUT1, resulting in up-regulated glucose metabolism via the polyol and hexosamine pathway; thus elevated intracellular glucose-6-phosphate (G-
6-P) and thus sorbitol, fructose and diacylglycerol (DAG) are produced which activate protein kinase C (PKC) and result in advanced glycation end-product 
(AGE) and reactive oxygen species (ROS) synthesis.  The subsequent stimulation and generation of cell signalling molecules, transcription factors and cytokines, 
such as vascular endothelial growth factor (VEGF), JAK/STAT and transforming growth factor-β (TGF-β), produces the aberrant cell growth and survival 
associated with symptoms of diabetic nephropathy such as excess extracellular matrix (ECM) production, proteinuria and hyperfiltration (modified from (Kanwar 
et al., 2008)) 
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5.2.4.2 Glomerular signalling pathway in the onset of diabetic nephropathy 
 
The facilitative glucose transporter GLUT1 is expressed on the glomerular cell membrane 
and GLUT1-mediated glucose entry into glomerular cells is up-regulated during 
hyperglycaemia; furthermore GLUT1-overexpressing mesangial cells display excessive 
extracellular matrix (ECM) production (Brosius and Heilig, 2005).   
 
High ambient glucose conditions result in the promotion of the polyol and hexosamine 
pathway, the latter results in the production of glucose-6-phosphate (G-6-P) which generates 
pyruvate.  G-6-P, in addition to the high intracellular glucose, promotes the polyol pathway; 
this results in the reduction of glucose to sorbitol, utilising aldose reductase, and the oxidation 
of sorbitol to fructose, via sorbitol dehydrogenase.  The polyol pathway, in addition to 
elevating cellular fructose levels, depletes the cell of NADPH and thus alters the cellular 
redox state and also leads to oxidant stress and elevated ROS levels (Xu et al., 2003).  
Furthermore, sorbitol and G-6-P up-regulate the production of diacylglyerol (DAG) 
production which is an intermediate in the activation of ECM and protein kinase C (PKC) 
(Quest et al., 1997;Mason and Wahab, 2003). 
 
Under high ambient glucose conditions, via Amadori rearrangement, dehydration and 
polymerisation, AGE’s activate PKC, mitogen-activated protein kinase (MAPK) and 
transcription factors such as NF-ΚB; these signalling events result in increased activity of 
growth factors, such as TGF-β which alter the expression of ECM proteins (Jakus and 
Rietbrock, 2004).  Elevated ECM increases the synthesis of type I and IV collagens, reduces 
proteoglycan expression and ECM polymerisation and expansion (Li and Gobe, 2006;Tan et 
al., 2007).  In addition, AGE’s cause the formation of ROS which also contributes to the 
pathology of ECM (Thallas-Bonke et al., 2004).  
 
PKC activation, along with ROS’s, AGE’s and DAG, all activate TGF-β signalling (Leask 
and Abraham, 2004), with TGF-β being the major cytokine responsible for ECM 
pathophysiology in diabetic nephropathy (Ziyadeh, 2004).  Indeed sufferers of diabetic 
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nephropathy exhibit elevated TGF-β expression and urinary excretion of the cytokine (Wolf, 
2006).  Other cell signalling molecules, transcription factors and cytokines involved in the 
development of diabetic nephropathy include VEGF, JAK/STAT, AP1, SP1 and MCP-1 
(Brosius et al., 2010).  
 
5.2.4.3 Tubular injury in diabetic nephropathy 
 
The effects of high glucose on mesangial cells outlined above are well-established and there 
is also evidence for similar pathways being involved in tubular injury in diabetic 
nephropathy.  Mechanisms of tubulointerstitial injury involve increased glycation of 
structural and regulatory cell proteins and extracellular proteins such as albumin.  The 
response of tubular cells to glycaemic injury include the elaboration of chemokines such as 
macrophage inflammatory protein 3 (MIP3-α) and cytokines such as transforming growth 
factor-β (TGF-β) (Qi et al., 2007) and platelet-derived growth factor (PDGF) (Deuther-
Conrad et al., 2001) which activate the immune response and initiate pro-fibrotic gene 
expression respectively.  The infiltration of macrophages and their products is involved in the 
initiation of the pathological changes of human diabetic nephropathy (Furuta et al., 
1993;Young et al., 1995;Sassy-Prigent et al., 2000).  In tubular cells, hypertrophy and 
associated basement membrane alterations precede the tubulointerstitial fibrosis which 
accompanies progressive renal dysfunction (Brito et al., 1998).  There is a direct effect of 
hyperglycaemia on the turnover of tubular basement membrane matrix components such as 
collagen and fibronectin accumulation (Ziyadeh et al., 1990;Ziyadeh et al., 1991;Phillips et 
al., 1997;Phillips et al., 1997;Phillips et al., 1997).  Furthermore, Phillips et al have shown 
that proximal tubule cells contribute to renal fibrosis via the production of profibrotic growth 
factors such as TGF-β1 and cytokines such as PDGF (Phillips et al., 1995;Phillips et al., 
1996;Phillips et al., 1997).   Thus it has been postulated that, in addition to glucose influx 
from the basolateral membrane of the proximal tubule cell, elevated glucose uptake from the 
tubular lumen in diabetes may also be a major player in the onset of diabetic nephropathy. 
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5.2.5 Current treatment for diabetes 
5.2.5.1 Treatment for type I diabetes 
 
The principle treatment for type I diabetes is currently insulin-replacement therapy, 
administered via subcutaneous injection or an insulin pump, which is effective when used in 
conjunction with vigilant blood glucose monitoring and dietary management (Cardella, 
2005;McIntyre, 2006).  Over the last
 
two decades, there have been major advances in the 
development of new types
 
of insulin and different delivery methods to mimic insulin release 
by β-cells; more user-friendly modes of glucose monitoring and islet transplantation have 
resulted
 
in substantial improvements in morbidity and mortality as well
 
as the quality of life 
of patients with type I diabetes (Benhamou et al., 2009). 
 
5.2.5.2 Treatment for type II diabetes 
 
The worldwide prevalence of type II diabetes has led to the development of many different 
treatments and therapies for the disease, however the complex nature of type II diabetes 
means that a combination-drug approach is often required.  Diet and exercise are central in 
the treatment of type II diabetes due to the efficacy of weight loss in reducing 
hyperglycaemia as well as ameliorating cardiovascular risk factors in this condition (Tinker et 
al., 1994;Macfarlane and Jeffcoate, 1997).  Furthermore, recent studies have shown that 
gastric bypass surgery in morbidly obese patients strongly improves in glucose homeostasis.  
Thus this surgical procedure may provide insights into the treatment of diabetes. 
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5.2.5.2.1 Pharmaceutical treatments of type II diabetes 
 
There are a variety of therapeutic options in the treatment of hyperglycaemia in type II 
diabetes although most patients require combination therapy to achieve effective glycemic 
control.  
 
Metformin, a member of the biguanides class of drugs, is one of the most common treatments 
for type II diabetics presenting with obesity and normal renal function (Inzucchi, 2002).  The 
efficacy of metformin is mediated by its ability to stimulate insulin binding to its receptor and  
thus the drug increases glucose uptake and utilisation (Johansen, 1999;Fonseca and Kulkarni, 
2008).  However metformin treatment is strongly associated with gastrointestinal side-effects 
such as nausea and diarrhea, which occurs in up to 50% of type II diabetics prescribed 
metformin (Bailey and Turner, 1996). 
 
Another class of drugs in the treatment of type II diabetes is the sulfonylureas which includes 
glyburide and glipizide.  These drugs bind to their receptor on the surface of pancreatic β-
cells and facilitate cell membrane depolarisation which stimulates insulin secretion and thus 
lowers circulating glucose levels (Zimmerman, 1997).  However, sulfonylureas cannot be 
used by type II diabetics with hepatic or renal impairment and are associated with insulin-
induced hypoglycaemia and weight gain (Stenman et al., 1993).  Meglitinides, the group of 
type II diabetic drugs including repaglinide and nateglitinide, mirrors the action of 
sulfoylureas to stimulate the release of insulin from pancreatic β-cells via a different receptor 
from sulfonylurea (Luna et al., 1999).  However these agents exhibit a shorter onset time for 
action and shorter half life, therefore they display a faster response than sulfoylureas. 
 
The α-glucosidase inhibitors, acarbose and miglitol, target the small intestinal brush-border 
membrane (BBM) enzyme, α-glycosidase; this enzyme breaks down dissacharides and more 
complex carbohydrates into monosaccharides (Balfour and McTavish, 1993;Takenaka and 
Uchiyama, 2001).  Therefore the drugs delay intestinal carbohydrate absorption and mitigate 
postprandial glucose excursions; however side effects of these drugs include malabsorptive 
symptoms such as diarrhoea (Goke and Herrmann-Rinke, 1998;Mochizuki et al., 2010). 
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Rosiglitazone and pioglitazone are two members of the thiazolidinediones family of type II 
diabetic treatments.  These pharmacological ligands bind to and activate the nuclear receptor 
peroxisome-proliferator-activated receptor gamma (PPARγ) which binds to responsive 
elements in DNA to alter the transcription of genes involved in carbohydrate and lipid 
metabolism (Mudaliar and Henry, 2001).  The main outcome of these drugs is the increase in 
insulin-stimulated glucose uptake by skeletal muscle cells, resulting in reduced peripheral 
insulin resistance (Chao et al., 2000).  However, side-effects associated with 
thiazolidinediones include weight gain and oedema, as well as potential hepatic impairment 
(Kelly et al., 1999). 
 
Another class of drugs are dipeptidyl peptidase-IV (DPP-IV) inhibitors which are based on 
the ability of DPP-IV to degrade GLP-1.  DPP-IV inhibitors suppress the degradation of 
GLP-1 and extend the activity period for GLP-1 action; with examples including vildagliptin 
and stialiptin (Weber, 2004;Augeri et al., 2005).  DPP-IV inhibitors evoke a reduction in 
glucose excursion following an oral glucose challenge (Pospisilik et al., 2002) and chronic 
DPP-IV inhibition can preserve islet function resulting in elevated glucose-mediated insulin 
response which is accompanied by increased glucose uptake via GLUT2 in β-cells (Reimer et 
al., 2002).  This potential for the preservation and improved function of β-cells implies a role 
for these inhibitors in the later stages of diabetes.   
 
5.2.5.2.2 Newer treatments for type II diabetes 
 
In type II diabetes, low postprandial GLP-1 levels are found in the small intestine (Toft-
Nielsen et al., 2001;Vilsboll et al., 2001;Lugari et al., 2002).  Incretin mimetics are a newer 
class of drugs in the treatment of type II diabetes; these pharmacological agents mirror the 
ability of GLP-1 to regulate glucose activity except their actions are not solely regulated by 
the pancreatic GLP-1 receptor.  Examples of GLP-1 analogues include Liraglutide and CJC-
1131.  Another incretin mimetic which is commonly prescribed is Exenatide-4, although this 
is not a GLP-1 analogue, it shares the ability of GLP-1 for glucose-dependent actions such as 
  
  37 
enhancement of insulin secretion, suppression of high glucagon secretion, slowing of gastric 
emptying and reduction of food intake (Edwards et al., 2001;Kolterman et al., 2003;Holst 
and Gromada, 2004;Fineman et al., 2004;Buse et al., 2004;DeFronzo et al., 2005).  
Furthermore, Exenatide-4 is resistant to degradation by DPP-IV and thus the drug has a 
longer physiological half-life than GLP-1 (Egan and Margolskee, 2008).  However, 
Exenatide-4 is associated with gastrointestinal effects such as nausea, vomiting and diarrhoea 
(Kolterman et al., 2003;Yoon et al., 2009). 
 
Selective inhibitors of SGLT2 target the high-capacity sodium-dependent glucose transporter 
at the brush-border of cells in the early region of the proximal tubule.  SGLT2 inhibitors have 
been found to reduce the transport maximum for glucose and thus effectively lower 
hyperglycaemia in diabetes (Katsuno et al., 2007;Han et al., 2008;Meng et al., 2008).  These 
inhibitors have been further described in section 5.6.2.2.2.  
 
5.2.5.2.3 Drug-combination treatment in type II diabetes 
 
The progressive, polymorphic nature of type II diabetes means that combination oral anti-
diabetic therapy is most often prescribed for patients (Inzucchi, 2002); the UK Prospective 
Diabetes Study (UKPDS) found that 3 years after treatment with only one drug, only 50% 
patients were adequately controlled whereas after 9 years, only 25% were controlled by 
monotherapy (Turner et al., 1999). 
 
However, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study showed 
that there was an increase in mortality when attempts at normalising hyperglycaemia were 
made with multiple combinations of the drugs outlined above (Gerstein et al., 2008).  
Therefore there are still limitations and controversy regarding the effectiveness of current 
drug treatments for diabetes and the search continues for novel therapy for the disease. 
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5.3 Metabolic models related to diabetes 
 
The rising prevalence of type II diabetes is strongly related to obesity caused by the 
consumption of a Western diet, which has become considerably enriched in saturated fat and 
high-glycaemic index sugars such as high-fructose corn syrup.  Furthermore obesity is one of 
five major risk factors in the development of metabolic syndrome, a multi-faceted disease and 
precursor to type II diabetes (Figure 5.3).   
 
Figure 5.3 – The complex interplay between the onset of obesity, metabolic syndrome and 
type II diabetes; including the environmental factors associated with elevated or reduced risk 
of disease and the common symptoms in both obesity and metabolic syndrome.  Red bars 
 for inhibitory effect and black arrows  for stimulatory effect, HDL – high-density 
lipoproteins. 
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5.3.1 Obesity 
 
 In 2010, 24.5% of the population in England were classified as obese, with a body mass 
index (BMI) greater than 30 kg/m
2
 (The National Obesity Observatory, 2010).  The obesity 
epidemic has developed in the last 20 years and is largely diet-related, although there are 
many studies showing that inherited factors profoundly influence fat mass (Farooqi and 
O'Rahilly, 2008). 
 
Excess calorie intake has a marked influence on insulin resistance in adipocytes, β-cells, 
skeletal muscle and hepatocytes; thus in obesity, both hyperinsulinaemia and insulin 
resistance are seen.  Obesity results in continuously elevated circulating levels of free fatty 
acid (FFA) levels, and this causes hypertrophy in adipocytes (Cinti et al., 2005).  In 
comparison to lean individuals, macrophages in adipose tissue of obese patients expressed 
augmented levels of proinflammatory hormones such as tumour-necrosis factor-α (TNF-α) 
and interleukin-6 (IL-6) (Weisberg et al., 2003;Hotamisligil et al., 2008).  The inflammatory 
response of the adipocyte is mediated via several signalling pathways including c-jun-N-
terminal kinase (JNK) and cAMP-responsive element binding protein (CREBH) (Hirosumi et 
al., 2002;Zhang et al., 2002;Qi et al., 2009).  Therefore, metabolic stress causes adipocytes to 
secrete cytokines, which induce macrophage accumulation and stimulates muscle and hepatic 
insulin resistance (Hotamisligil et al., 2008).  Obesity exacerbates insulin resistance in the 
adipocyte, however weight-loss has been shown to reverse these insulin-resistance effects 
(Gregor et al., 2009).  Insulin-mediated glucose uptake in skeletal muscle is very sensitive to 
excess lipid exposure, with the induction of insulin resistance occurring within 4 hours of 
FFA exposure in subjects with no predisposition to type II diabetes (Belfort et al., 2005).  In 
hepatocytes, elevated circulating FFA results in insulin resistance, impaired insulin signalling 
and the stimulation of hepatic glucose production via gluconeogenesis and glycogenolysis 
(Roden et al., 2000;Boden et al., 2002).  The adaptation of circulating FFA-induced hepatic 
insulin resistance in obesity involves an increase in insulin secretion and reduced hepatic 
insulin clearance, which causes peripheral hyperinsulinaemia (Kashyap et al., 2003).  
Therefore there is complex interplay between the physiological effects of obesity and insulin-
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resistance, which strongly associates obesity as an important factor in the development of 
type II diabetes. 
 
Obesity-induced hypertension has been strongly linked with augmented sodium reabsorption; 
a shift in renal pressure natriuresis is observed to maintain sodium balance in response to the 
rise in arterial pressure in obesity (Granger et al., 1994;Hall et al., 1998;Hakam and Hussain, 
2005).  The increased renal tubular reabsorption is also a result of the elevated intra-renal 
pressure caused by the excess of visceral adipose tissue in obesity which physically 
compresses the kidneys (Hall, 1997;Hall et al., 2002).   
 
Obesity-dependent renal damage is likely to be mediated by hormonal changes, for example, 
levels of adipokines are higher in chronic kidney disease, low-grade inflammation and 
oxidative stress (Axelsson et al., 2006;Knight and Imig, 2007;Foster et al., 2008).  There is a 
significant relationship between the excretion rate of albumin and obesity, for example, in 
subjects with the same percentage body fat, those with central fat distribution have an 
increased likelihood of exhibiting elevated albumin excretion rate (Mulyadi et al., 2001).  
Insulin resistance in sustained obesity causes hyperinsulinaemia which may result in 
hyperfiltration and glomerular hypertrophy; interestingly, only weight loss, in the early stages 
of disease development, has been shown to reduce proteinuria (Adelman, 2002).  
Furthermore, subjects with a high BMI are at increased risk of developing urolithiasis and 
recurrent stone formation due to a deficiency in ammonia production and elevation in urinary 
excretion of stone-forming substances such as calcium and uric acid (Curhan et al., 
1998;Siener et al., 2004;Taylor et al., 2005;Lee et al., 2008).  Therefore obesity predisposes 
sufferers to type II diabetes via an effect on insulin resistance, as well as resulting in early 
diabetic-like conditions such as elevated glomerular filtration rate (GFR) and an activated 
renin-angiotensin system (RAS) in the kidney. 
 
The onset of insulin resistance and hyperglycaemia occurs within one month of increased 
consumption of dietary fats; thus dietary fats are closely linked with diabetes, as well as their 
obvious correlation with obesity (Surwit et al., 1988;Surwit et al., 1997;Marshall et al., 
1997;Vessby et al., 2001).  
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Schutz et al showed that moderate consumption of dietary fat mainly induces stimulation of 
fat storage with little or no stimulation of fat oxidation (Schutz et al., 1989).  In contrast, 
ingestion of dietary carbohydrates stimulates insulin release which promotes glucose uptake 
in insulin-sensitive tissues, inhibits endogenous glucose production and reduces the release of 
FFA from adipose tissue and thus results in the relative increase of carbohydrate oxidation 
and relative decrease in lipid oxidation (Flatt et al., 1985;Aarsland et al., 1997). 
 
5.3.2 The treatment of obesity with gastric bypass surgery 
 
Interestingly, bariatric surgery, a treatment for morbid obesity, has also been shown to 
alleviate many symptoms of type II diabetes.  Gastric bypass surgery was developed in the 
1950’s with the jejuno-ileal bypass, which was superseded in the 1970’s by procedures such 
as Roux-en-Y gastric bypass (RYGB), gastroplasty (also known as ‘stomach stapling’), and 
biliopancreatic diversion (BPD).  In recent years, the application of laparoscopy to gastric 
bypass surgery has led to elevated interest and research in the field.  Gastric bypass surgery 
has been associated with an 89% reduction in the relative risk of death, as well as an 82% 
reduction of cardiovascular events among morbidly obese patients (Christou et al., 2004).  
Bariatric surgery is the only treatment which has been shown to achieve substantial and 
durable weight loss and there are suggestions to explain the weight loss following bariatric 
surgery including: 1) the resulting reduced appetite and increased satiety due to elevations in 
peptide YY (PYY) and GLP-1 as well as reductions in leptin and ghrelin (Borg et al., 
2006;Le Roux et al., 2006); 2) alterations in taste perception with a reduced preference for 
carbohydrate-rich foods (Brown et al., 1982;Brolin et al., 1994;Borg et al., 2006;Olbers et 
al., 2006); 3) the restricted intake of food due to the resectioning of the stomach into a small 
pouch with limited food capacity (Olbers et al., 2003;Borg et al., 2006); 4) nutrient exclusion 
from the duodenum thus either suppressing proximal small intestinal signalling in the 
secretion of anti-incretin hormones or delivery immediately to the distal small intestine 
enhancing the release of incretins (Mingrone and Castagneto-Gissey, 2009); 5) malabsorption 
of nutrients due to limited absorption surface (Olbers et al., 2003); 6) increased energy 
expenditure, since fat loss following gastric bypass surgery occurs concomitantly with diet-
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induced thermogenesis (Bueter et al., 2010); and 7) aversion effects such as vomiting and 
steatorrhoea (O'Brien, 2010).   
 
Gastric bypass surgery can be classed as either malabsorptive or restrictive; the former 
consists of surgery such as jejunoileal bypass and the latter includes sleeve gastroectomy 
however both these forms of surgery provide limitations with regard to patient safety, 
invasiveness and reversibility (Organ, Jr. et al., 1980;Daskalakis and Weiner, 2009).  RYGB 
surgery is considered a hybrid between restrictive and malabsorptive gastric bypass and has 
become one of the most popular forms of surgery.  As well as providing effective weight loss, 
with 60-70% of excess weight lost in the initial 12 months following surgery, RYGB also 
offers few long-term problems, with mortality rates of below 1% (Flum and Dellinger, 
2004;Flum et al., 2009).   
 
5.3.2.1 Gastric bypass surgery in type II diabetics  
 
One of the most startling and fascinating effects of gastric bypass surgery is the resolution of 
hyperglycaemia in very obese diabetic patients post-surgery, before significant weight loss 
occurred (Mingrone et al., 1997).  Although gastric banding has been shown to improve 
metabolic syndrome and type II diabetes, these effects are seen 6-12 months after banding, 
when maximal weight loss has occured (Parikh et al., 2006;Dixon et al., 2008).  At this stage, 
there is a close correlation between weight loss and reduced circulating glucose (Parikh et al., 
2006).   
 
Chai et al observed a significant reduction in hyperglycaemia in type II diabetic Goto-
Kakizaki (GK) rats 30 days after RYGB surgery (Chai et al., 2011).  In man, changes 
following gastric bypass surgery, after 6-8 months, have been attributed to improved glucose 
homeostasis with an increase in muscle insulin receptor density (Houmard et al., 2002;Gray 
et al., 2003).  Furthermore, a reduction in moieties causing insulin-resistance, such as hepatic 
lipid and long-chain fatty acyl-CoA molecules, also results in the elevation in glucose 
transport and insulin sensitivity noted following gastric bypass surgery (Friedman et al., 
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1992;Pender et al., 2004).  However, gastric bypass surgery also results in 97–100% 
improvement and remission of diabetes within 1 month post-operation, before significant 
weight loss can occur and with allowances for dietary intake taken into consideration (Pories 
et al., 1987;Mingrone et al., 1997;Rubino et al., 2004;Guidone et al., 2006;Mari et al., 
2006;Laferrere et al., 2007;Briatore et al., 2008;Chiellini et al., 2009).  Following bariatric 
surgery, diabetic patients with normal weight also exhibited abolishment of the disease 
(Mingrone et al., 1999).  There are two theories for these effects on diabetes, the foregut and 
hindgut hypothesis.   
 
5.3.2.1.1 Foregut hypothesis 
 
The foregut hypothesis is based on the exclusion of the proximal small intestine from the 
transit of nutrients, resulting in a secondary alteration in incretin signals with consequent 
improvements in blood glucose levels observed following RYGB surgery (Pories et al., 
1995;Pories and Albrecht, 2001;Clements et al., 2004).  This is supported by studies with the 
duodenal-jejunal bypass, which simulates the bypass portion of RYGB surgery without any 
reduction in gastric size.  The duodenal-jejunal bypass results in decreased food intake, 
elevated insulin levels and improved hepatic insulin sensitivity due to an increase in intestinal 
gluconeogenesis (Troy et al., 2008).  Using GK rats, Rubino et al noted the abolishment of 
type II diabetes following stomach-preserving surgery which bypasses the proximal intestine 
(Rubino, 2008).  Furthermore, on implantation of a sleeve inside the duodenum, thus 
preventing nutrient absorption by the proximal small intestine, a 55% improvement in 
peripheral insulin resistance was observed (Aguirre et al., 2008). 
 
5.3.2.1.2 Hindgut hypothesis 
 
The hindgut hypothesis, developed by Mason, suggests that a more rapid delivery of nutrients 
to the distal small intestine results in enhanced release of incretins, such as GLP-1 and GIP 
from ileal enterocytes, which is reported to improve glucose homeostasis (Mason, 1999).  
  
  44 
Indeed the elevated levels of GLP-1, a nutrient-stimulated, glucose-lowering, incretin is 
secreted from L-cells primarily in the ileum and colon, seen following RYGB surgery have 
been shown to stimulate insulin secretion and thus reduce hyperglycaemia (Mason, 
1999;Drucker, 2002;Rubino et al., 2004;Cummings and Overduin, 2007).  This theory is 
supported by the understanding that GLP-1 accentuates glucose-dependent insulin secretion, 
increasing β-cell mass as well as potentially heightening insulin sensitivity (Zander et al., 
2002;Drucker, 2007).  Furthermore, studies show that ileal transposition chronically 
stimulates the terminal ileum with nutrient-rich chyme without affecting the transit of food in 
the gastrointestinal tract (Koopmans et al., 1984).  This procedure is associated with insulin-
resistant improvements in glucose tolerance in the early post-operative time period (Patriti et 
al., 2007).   
 
However, DiGiorgi et al observed a significant incidence of recurrence or worsening of type 
II diabetes in patients 3 years after RYGB surgery, therefore further studies are necessary to 
understand the long-term connotations of gastric bypass on diabetes (DiGiorgi et al., 2010).  
 
5.3.3 Metabolic syndrome  
 
The abundance of calorie-rich, low-fibre foods with a high-glycaemic index in the Western 
diet is the main reason for the obesity epidemic seen in recent years and this condition leads 
to the onset of metabolic syndrome and diabetes.  A diet high in fat, carbohydrates and empty 
calories has been shown to increase the risk of metabolic syndrome (Ford et al., 2002;Freire 
et al., 2005;Sonnenberg et al., 2005).   
 
In addition, an increase in the consumption of a high-fibre diet has been shown to be 
inversely correlated with the onset and progression of metabolic syndrome (McKeown et al., 
2004;Sahyoun et al., 2006).  Other preventative measures include a low-fat diet which can 
result in up to 50% reduced risk in the incidence of diabetes (Tuomilehto et al., 
2001;Charatan, 2001). 
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Obesity is a central component of metabolic syndrome and thus the increasing prevalence of 
obesity is paralleled by similar increases in metabolic syndrome sufferers.  The prevalence of 
metabolic syndrome, in young adults worldwide, is 23% with higher levels seen in aging 
(Scuteri et al., 2005;Cameron et al., 2007;Zuliani et al., 2009).  Metabolic syndrome can be 
viewed as a cluster of disorders and is defined by the presentation of central obesity as well 
as two out of the four following: raised blood pressure, raised triglycerides, lowered high-
density lipoprotein (HDL) cholesterol and fasting hyperglycaemia (The National Obesity 
Observatory 2010).  This latter parameter is representative of the glucose intolerance seen in 
metabolic syndrome and, along with the ubiquitous presentation of obesity in metabolic 
syndrome, links the disease with type II diabetes; thus metabolic syndrome is a well-
established precursor to type II diabetes.  The fasting hyperglycaemia in metabolic syndrome 
is due to insulin-resistance in obesity, outlined in section 5.3.1, which predisposes obesity 
sufferers to develop metabolic syndrome.   
 
A core component of metabolic syndrome is dyslipidaemia which occurs due to obesity and 
is characterised by low HDL cholesterol and elevated triglycerides, both parameters which 
are noted in metabolic syndrome (IDF 2001).  Furthermore, metabolic syndrome sufferers 
exhibit a prothrombotic and inflammatory profile synonymous with obesity.  Abdominal 
obesity, especially elevations in visceral fat, are more highly associated with risk of 
metabolic syndrome (Despres et al., 1987;Despres et al., 2000;Despres et al., 2001;Miyazaki 
et al., 2002). 
 
The cardiometabolic abnormalities exhibited in patients with metabolic syndrome increases 
their risk of developing cardiovascular disease; in 2003, 19.2% of adults over 50 years of age 
who had cardiovascular disease also suffered from metabolic syndrome (Alexander et al., 
2003).  Metabolic syndrome patients without type II diabetes exhibit a 13.9% prevalence of 
cardiovascular disease; in comparison 7.5% type II diabetics without metabolic syndrome, 
suffered from cardiovascular disease (Alexander et al., 2003).  Thus a tight correlation exists 
between cardiovascular disease and the onset of metabolic syndrome.  
 
Genetic determinants of metabolic syndrome have been studied, for example although insulin 
resistance clusters in families, the probability of inheriting problems with insulin secretion is 
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low; therefore environmental factors are far more influential in the progression of insulin 
resistance (Groop et al., 1996;Hong et al., 1997).  Another example is hypertension, a risk 
factor in development of metabolic syndrome, and strongly associated with insulin resistance 
(Ferrannini et al., 1987); there was stronger hereditability of HDL cholesterol with insulin 
resistance than triglycerides (Hong et al., 1997).    
 
5.3.4 Pre-diabetes 
 
Pre-diabetes is a common condition characterized by either impaired fasting glucose levels, 
between 6-7 mM, or defective glucose tolerance, between 8-12 mM after an oral glucose load 
(Standards of Medical Care in Diabetes 2007). Many pre-diabetics exhibit microvascular 
hyperglycaemia-associated diseases such as blindness, similar to that seen in diabetes (Jaap et 
al., 1997).  The impaired fasting plasma glucose levels exhibited in pre-diabetes is also a 
component of metabolic syndrome and thus the common progression occurs from the onset 
of metabolic syndrome and pre-diabetes to type II diabetes.         
 
5.4 Sweeteners in the Western diet 
5.4.1 Fructose 
 
The simple sugar, fructose, is consumed in vast quantities in the Western diet, often in the 
form of the acutely sweet high-fructose corn syrup (HFCS), also defined as inverted sugars, 
in many processed foods.  In addition, the natural form of the sugar fructose is found in fruits 
and honey.  Much controversy surrounds the use of sweeteners in the Western diet with 
sugar-sweetened soda identified as the major culprit in elevating the consumption of HFCS.  
Although studies in man have identified a strong causal link between the intake of sugar-
sweetened beverages and metabolic syndrome, the relationship has been attributed to the 
increased consumption of an energy-rich diet in this population rather than a negative 
response elicited by the intake of HFCS.   
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Fructose is absorbed and metabolised by the small intestine where it moves into the portal 
vein to be metabolised by the liver, into glucose, glycogen, lactate or lipids (Mayes, 1993).  
In hepatocytes, fructose is rapidly converted into fructose-1-phosphate and triose-phsophates 
via the sequential action of fructokinase, aldolase B and triokinase; the first two enzymes are 
not regulated by cellular energy status and therefore fructose is rapidly converted into hepatic 
triose-phosphates, following ingestion (Heinz et al., 1968).  Fructose metabolism occurs 
independently of insulin and plasma glucose (Tappy et al., 1986), therefore fructose was 
thought to be a potential, natural glucose-replacement for diabetics.  However, increased 
fructose intake in both man and animal has been shown to result in features of metabolic 
syndrome such as dyslipidaemia, insulin resistance, impaired glucose homeostasis, excess 
body fat and raised blood pressure (Zavaroni et al., 1980;Bjorkman et al., 1982;Reaven et al., 
1990;Donnelly et al., 1994;Reed et al., 1994;Jurgens et al., 2005).     
 
Hyperlipidaemia is a major consequence of high-fructose feeding with increased dietary 
fructose rapidly elevating plasma triglyceride levels and lowering very low-density 
lipoprotein (VLDL) triglycerides (Park et al., 1992).  High-fructose fed rats are also 
associated with the development of hypertension and visceral fat accumulation, as well as 
exhibiting impaired insulin-mediated suppression of plasma FFA, thus insulin-resistance is 
likely to occur in adipose tissue (Hwang et al., 1987;Reaven et al., 1996;Faeh et al., 2005).  
Indeed, Bray et al have extensively described the role of high-fructose feeding in insulin 
resistance (Bray et al., 2004).  Additionally, fructose-fed rats display other changes observed 
in metabolic syndrome such as NADPH oxidase and RAS activation, both precursors in the 
development of hyperlipidaemia and insulin resistance (Delbosc et al., 2005;Nakagawa et al., 
2006;Hsieh et al., 2006;Nyby et al., 2007;Figlewicz et al., 2009).  Glucose also causes a 
more pronounced increase in circulating leptin and a greater reduction in gherlin levels than 
fructose and therefore fructose has a less overall satiating effect than glucose (Tappy et al., 
2010). 
 
Many human studies support the effects of HFCS consumption on weight gain (DiMeglio and 
Mattes, 2000;Ludwig et al., 2001;Raben et al., 2002).  In particular, epidemiological studies 
have confirmed the effect of sugar-sweetened, HFCS-enriched beverages on the development 
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of metabolic syndrome; predominantly elevated weight gain, inflammation, insulin 
resistance, impaired β-cell function and elevated blood pressure are all strongly linked with 
increased metabolism of fructose following excess consumption of HFCS-sweetened 
beverages (Malik et al., 2006;Fung et al., 2009;Malik et al., 2010;Hu and Malik, 2010).  Due 
to the extensive evidence that elevated consumption of HFCS in the Western diet leads to the 
onset of type II diabetes, artificial sweeteners have been developed in recent years as 
synthetic sugar substitutes. 
  
5.4.2 Artificial sweeteners 
 
Artificial sweeteners are intensely sweet synthetic compounds which are able to elicit a sweet 
taste response but have no calorific value.  The use and thus consumption of artificial 
sweeteners is widespread and their most common uses are as a sugar-substitute to prevent 
tooth decay, as an aid in weight loss in obesity and as a non-nutritive sweetener for diabetics.  
Examples of artificial sweeteners most commonly used are sucralose, acesulfame k, 
aspartame and saccharin, all of which are 200-600-fold sweeter than sucrose; these 
sweeteners are often used in sugar-free soft drinks, low-fat foods and as a sweetener in tea 
and coffee.    
 
Interestingly studies in man show conflicting data on the consumption of artificial 
sweeteners.  There is evidence that the intake of artificial sweeteners can increase hunger, 
food intake and body weight compared to control groups maintained on a diet of glucose 
(Blundell and Hill, 1986; Fowler et al., 2008; Swithers et al., 2010).  The positive effect of 
artificial sweeteners was also seen by Bailey et al where chronic consumption of saccharin 
was found to defer the development of hyperglycaemia and improve glucose homeostasis in 
insulin resistant ob/ob mice via an insulin-dependent mechanism (Bailey et al., 1997).  
However, other groups have shown a positive correlation between artificially-sweetened soft 
drink consumption and the prevalence of metabolic syndrome; this correlation was stronger 
and more significant than the same relationship with sugar-sweetened soft drinks (Dhingra et 
al., 2007).  Horwitz et al found that plasma insulin, but not plasma glucose, was elevated in 
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response to the consumption of artificial sweeteners; hyperinsulinaemia may therefore 
explain the relationship between non-nutritive sweeteners and the onset of metabolic 
syndrome and type II diabetes (Horwitz et al., 1988; Montonen et al., 2007).  Thus further 
studies are necessary to fully understand the impact of a diet high in artificial sweeteners, 
regularly consumed as diet soda, on glucose tolerance and the development of associated 
metabolic diseases.  
 
5.5 Animal models of metabolic dysregulation 
 
There are many different rodent models for type I and II diabetes, as well as for obesity and 
metabolic syndrome, with each model having both advantages and limitations.  The use of 
these models provides insight into the pathophysiological basis of the disease. 
 
5.5.1 Models of type I diabetes 
Table 5.1 identifies some different rodent models of type I diabetes, which can be induced by 
the damage of pancreatic β-cells, either via chemical or surgical induction, or spontaneously 
developed in genetically-bred rodents. 
 
There are limitations in animal models of type I diabetes compared with human aetiology of 
the disease; models do not represent the polygenic heterogeneous nature of type I diabetes in 
man (Polychronakos, 2004). For example, the non-obese diabetic (NOD) mice and 
BioBreeding (BB) rat are genetically homogenous, whereas humans are genetically diverse 
and although the end-point of overt diabetes is the same in rodents and humans, the pathways 
in the development of the disease are different.  
 
 
  
  50 
 
 
Table 5.1- Table of rodent models of type I diabetes induced by chemicals, surgical treatment 
or spontaneous genetic models  
 
 Model References 
Chemical 
Streptozotocin (STZ) (VAVRA et al., 1959) 
Alloxan (Ridout et al., 1944) 
Vacor (Taniguchi et al., 1989) 
Dithizone (KADOTA, 1950) 
8-hydroxyquinolone (Root M.A. and Chen, 1952) 
Surgical 
Thymectomy (Stumbles and Penhale, 1993) 
Radiation (Stumbles et al., 1993) 
Spontaneous 
Non-obese diabetic (NOD) mouse (Makino et al., 1980) 
BioBreeding (BB) rat (Nakhooda et al., 1977) 
Long Evans Tokushima Lean 
(LETL) rat 
(Kawano et al., 1991) 
 
 
5.5.2 Models of metabolic syndrome and type II diabetes 
 
The complex, multifactorial nature of metabolic syndrome means no one single animal model 
is the most appropriate to use, furthermore there is overlap of phenotype in different rodent 
models of obesity, metabolic syndrome and type II diabetes.  Central obesity and alterations 
of adipokine secretion, together
 
with a concomitant fat accumulation in different 
metabolically-active tissues such as liver, muscle and pancreas, build the
 
pathophysiologic 
basis of the metabolic syndrome (McPherson and Jones, 2003;Unger, 2003;Carr et al., 2004).  
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5.5.2.1 Rat models of metabolic syndrome 
 
Established models of metabolic syndrome include the spontaneously hypertensive obese 
(SHROB) rat, with the fa
k
/fa
k
 mutation, which exhibits obesity, hypertension and insulin 
resistance; however studies on metabolic syndrome-associated tubule reabsorption may be 
compromised as the model is associated with hypertension-induced progressive renal disease 
(Koletsky, 1973;Abramowsky et al., 1984;Koletsky et al., 1995).    The Wistar Ottawa 
Karlsburg W (WOKW) rat, a euglycaemic inbred strain, provides a useful model of 
metabolic syndrome due to the polygenic nature of disorders, such as glucose intolerance and 
obesity, in these animals, however renal studies are limited and only proteinuria at 64 weeks 
has been established (Kovacs et al., 2000;Grisk et al., 2007).  Furthermore the Nile grass rat 
has recently been identified as a novel spontaneously occurring disease model of metabolic 
syndrome which exhibits obesity, hyperglycaemia and hypertension and thus develop 
diabetes at 11 months of age when fed a standard laboratory chow with renal and hepatic 
hypertrophy (Noda et al., 2010).   
 
5.5.2.2 Mouse models of metabolic syndrome 
 
There are a myriad of mouse models of metabolic syndrome including the leptin-deficient 
Lep
ob/ob
 (or ob/ob) and leptin receptor-deficient LepR
 db/db
 (or db/db) mouse (Ingalls et al., 
1950;Hummel et al., 1966;Coleman and Hummel, 1973).  More recently, the polygenic New 
Zealand obese mouse has been identified as a suitable model of metabolic syndrome which 
exhibits high plasma glucose and cholesterol as well as hypertension and hypoinsulinaemia 
(Ortlepp et al., 2000;Joost, 2010).  Metabolic syndrome can be induced by high-fat or high-
calorie diets in mice, for example, the C57BL/6J mouse fed a high-fat diet develop obesity, 
hyperinsulinaemia and hyperglycaemia within 1 month and continuation of the diet 
exacerbates adiposity (Surwit et al., 1988;Surwit et al., 1997;Black et al., 1998).   
 
In view of the polygenic character
 
of this disorder, monogenic models of obesity and 
diabetes,
 
such as the ob/ob mouse or the obese Zucker (fa/fa) rat, do
 
not reflect the human 
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disease sufficiently. The first description of a ‘high-fat diet’ to induce obesity by a nutritional 
intervention was in 1959 (Masek and Fabry, 1959).
 
Subsequent studies have revealed that 
high-fat diets promote
 
hyperglycemia and whole-body insulin resistance.  It is generally 
accepted that high-fat diets can
 
be used to generate a valid rodent model for the metabolic 
syndrome
 
with insulin resistance and compromised β-cell function (Oakes et al., 1997;Ahren 
et al., 1999;Lingohr et al., 2002).  To adequately induce metabolic syndrome, between 30-
60% fat-as-calories diet is necessary although strain and gender affects the outcome of a 
high-fat diets (Levin et al., 1997;Ghibaudi et al., 2002).  In addition, the component of fat in 
the diet affects the manifestation of metabolic syndrome with lard exhibiting the most 
pronounced influence on obesity and insulin resistance (Yaspelkis, III et al., 2001;Buettner et 
al., 2004).  
 
In addition to high-fat feeding studies, metabolic syndrome can also be induced by high-
fructose or -sucrose diets, with rats displaying insulin resistance, elevated triglycerides and 
increased body weight, although not excessive obesity (Daly et al., 1997).  Indeed, a high-
fat/high-fructose diet, consisting of 45% fructose and 20% lard, results in elevated mesenteric 
fat and insulin resistance, both strongly associated with metabolic syndrome (Medina-Gomez 
and Vidal-Puig, 2005). 
 
5.5.2.3 Rodent models of type II diabetes  
 
Type II diabetic rodent models are defined as glucose intolerant and hyperglycaemic with 
impaired secretion and response of insulin, as well as exhibiting other diabetic-like symptoms 
for example, retinopathy, nephropathy and weight loss seen in human patients of the disease 
(Laakso, 1999;Gerstein et al., 2005).  Table 5.2 displays some of the myriad of rodent models 
which represent the metabolic syndrome and type II diabetes.  It is worth noting however that 
there are also transgenic/knock out models of type II diabetes, as well as surgically-induced 
diabetes following partial pancreatectomy (Bonner-Weir et al., 1983).   
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Interestingly, the administration of STZ 15 minutes after nicotinamide has been found to 
induce a rodent model closely resembling type II diabetes (Masiello et al., 1998).  STZ 
induces hyperglycaemia whilst nicotinamide protects β-cells from the cytotoxic effect of 
streptozotocin (Gunnarsson et al., 1974;Hoorens and Pipeleers, 1999).  The Zucker diabetic 
and GK rat represent two of the most commonly used models of metabolic syndrome and 
type II diabetes 
 
Table 5.2 - Table of obese and non-obese rodent models for spontaneous or genetically-
derived type II diabetes 
 
 Model References 
Non-obese rat 
models 
Goto-kakizaki (GK) (Goto et al., 1976) 
Cohen diabetic (Weksler-Zangen et al., 2001) 
Brattleboro (VALTIN and Schroeter, 1964) 
Torri (Shafrir, 1992) 
Non-obese 
mouse models 
Akita C57BL/6 (Mathews et al., 2002) 
Alloxan-susceptible (ALS)/Lt (Mathews et al., 2004) 
Horio-Niki diabetic (Horio et al., 2005) 
Obese rat 
models 
UC Davis type II diabetic (Cummings et al., 2008) 
Spontaneously hypertensive / NIH-corpulent (Michaelis et al., 1984) 
Otuska Long Evans Tokushima fatty (OLETF) (Kawano et al., 1994) 
James C. Russell/LA corpulent (Koletsky, 1975) 
Zucker diabetic fatty (ZDF) (Zucker, 1965;Etgen and Oldham, 2000) 
Obese mouse 
models 
ob/ob (Shafrir, 1992) 
db/db (Hummel et al., 1966) 
Kuo Kondo (Velasquez et al., 1990) 
New Zealand obese (Ortlepp et al., 2000) 
BTBR ob/ob (Hudkins et al., 2010) 
M16 (Allan et al., 2004) 
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5.5.2.3.1 Zucker rat model of obesity and type II diabetes 
 
The obese Zucker fatty rat, produced from mutations in the fa/fa leptin receptor, is one of the 
most well-established models for metabolic syndrome since rats exhibit obesity, insulin-
resistance, hyperleptinaemia and mild glucose intolerance with circulating triglycerides 10-
fold higher than in the lean Zucker animals (Zucker, 1965;Witztum and Schonfeld, 1979;Pico 
et al., 2002).   
 
Zucker obese animals exhibit proteinuria at a young age, which is related to increased 
glomerular size and glomerulosclerosis (Kasiske et al., 1985).  Blood pressure is slightly 
elevated in the obese Zucker fatty rat, however this is likely to be in response to insulin-
mediated increases in renal sodium reabsorption (DeFronzo et al., 1976;DeFronzo, 1981).  
Bickel et al observed significant proximal tubule atrophy in Zucker fatty rats at 6 weeks of 
age; furthermore sodium-dependent brush-border transporters such as NaPiIIa and NHE3 
exhibited a down-regulation in expression which correlated with GFR measurements (Bickel 
et al., 2002).  There is a selectively inbred sub-strain of Zucker fatty rats, called Zucker 
Diabetic Fatty (ZDF) rats, which develop overt type II diabetes at 7-10 weeks of age with 
hyperglycaemia and low insulin levels (Etgen et al., 2000).  In later stages of the disease, 
over 40 weeks of age, ZDF rats exhibit signs of diabetic nephropathy such as renal 
hypertrophy and renal fibronectin, collagen and ECM accumulation (Coimbra et al., 
2000;Hoshi et al., 2002).   
 
5.5.2.3.2 Goto-Kakizaki rat model of type II diabetes 
 
The Goto-Kakizaki rat is another well-established model of type II diabetes although, unlike 
the Zucker rat, it is a non-obese, normotensive model of the disease which is produced by the 
repeated inbreeding of glucose intolerant non-diabetic Wistar rats; at least 42 generations are 
necessary (Goto et al., 1976;Abdel-Halim et al., 1993).  In the breeding of the GK rat, Goto 
et al indicated that the development of diabetes is not due to a specific gene mutation but, like 
metabolic syndrome, influenced by many genes involved in carbohydrate metabolism (Goto 
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et al., 1976).  Unlike obese models of type II diabetes, the GK rat exhibits no change in 
serum cholesterol, triacylglycerol or free fatty acids (Nolte et al., 1995).  The impairment in 
the ability of the pancreatic β-cell to release insulin in response to a glucose stimulus was 
found in association with a down-regulation in β-cell expression of the facilitative glucose 
transporter, GLUT2 (Ohneda et al., 1993;Abdel-Halim et al., 1993).   The defect in insulin 
secretion in GK rats is likely to be due to low levels of islet cell glycogen and impaired 
movement of glucose through the glycerol phosphate shuttle (pathway where glycolysis-
produced NADH contributes to ATP generation) (Abdel-Halim et al., 1993;Sener et al., 
1993).  Ghannat-Pour et al used genome-wide RNA profiling to identify several glucose-
regulated islet genes which were altered in GK rats; for example serum-glucocorticoid 
kinase-1 (SGK-1) and GLUT3 were up-regulated whilst GLUT1 was down-regulated 
(Ghanaat-Pour et al., 2007).   
 
In addition to defects in pancreatic β-cell mass and function, GK rats also exhibit impaired 
hepatic glucose production and this causes the hepatic insulin resistance which defines type II 
diabetes (Picarel-Blanchot et al., 1996).  In GK rats, skeletal and cardiac muscle and 
adipocytes exhibit reduced glucose transport which may be due, in the heart, to reduced 
GLUT4 expression (Villar-Palasi and Farese, 1994;Nolte et al., 1995;Krook et al., 
1997;Desrois et al., 2004).  Furthermore skeletal muscle from GK rats also demonstrates 
defective glucose conversion to glycogen which may contribute to the mild but consistent 
hyperglycaemia in the GK rat (Villar-Palasi et al., 1994).   
 
GK rats exhibit functional and structural renal alterations such as renal hypertrophy and 
increased glomerular volume, total mesangial volume and thickening of glomerular and 
tubular basement membrane (Phillips et al., 2001;Schrijvers et al., 2004).  Kohler et al 
attributed these changes to increased nuclear transport in GK rats (Kohler et al., 2001).  
Interestingly, the accompanying albuminuria and reduced creatinine clearance in this type II 
diabetic model, in the absence of alterations in mitochondrial oxidative phosphorylation, 
make the GK rat a good experimental model for patients who suffer prolonged type II 
diabetes but have not developed overt renal disease (Phillips et al., 2001;Schrijvers et al., 
2004;Seica et al., 2005). 
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5.6 Glucose transporters 
 
Plasma glucose homeostasis is influenced by specific transporter proteins which enable the 
movement of glucose across cell membranes.  The expression of glucose transporters in 
different cell types varies depending on the specific needs of these cells.  However 
membranes are hydrophilic and therefore glucose must traverse the lipid bilayer via 
facilitative or active transport mechanisms.   
 
5.6.1 Facilitative glucose transporters  
 
The facilitative glucose transporters, GLUT’s, mediate the movement of glucose down its 
concentration gradient, thus transport is dependent on the glucose concentrations across the 
membrane.  The family of closely related (~40% overall conservation) GLUT proteins 
contain tweleve transmembrane domains which generate internal and external ligand binding 
sites, N- and C-terminal cytoplasmic domains and a single glycosylation site on one of the 
extracellular loops associated with glucose transport and are believed to form a hydrophilic 
tunnel containing a glucose-binding site (Mueckler et al., 1985;Wilson-O'Brien et al., 2010).  
There are currently fouteen members of the human SLC2A (GLUT) family which are divided 
up into three classifications (class I, II, III).  
 
5.6.1.1 Class I GLUT transporters 
 
Class I consists of the ‘classical’ transporters and these have been well described; the class is 
made up of GLUT1-4 and the GLUT3 gene duplicon, GLUT14 (Joost and Thorens, 
2001;Joost et al., 2002).  GLUT2 is of relevance in this class of GLUT’s due to its ability for 
high-capacity glucose transport.  GLUT2 is a vital component of glucose absorption across 
the small intestine and kidney brush-border, and its expression in these locations has been 
noted in metabolic dysregulation such as in diabetes and Fanconi syndrome.   
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5.6.1.1.1 GLUT1 
 
GLUT1 was first proposed to be involved in placental glucose transport by Widdas et al but 
GLUT1 has since been located at the plasma membrane of erythrocytes, hepatocytes and in 
endothelial cells in the microvasculature of the brain, as well as the BLM of the late S3 
segments of proximal tubules (Widdas, 1952;Mueckler et al., 1985;Birnbaum et al., 
1986;Widdas, 1988).  Interestingly, GLUT1 is also found in adipocytes where it has been 
shown to detect glucose via its C-terminal domain activating the ERK pathway, independent 
of any glucose transport or metabolic activity of the transporter (Bandyopadhyay et al., 
2000). GLUT1 has been shown to have a KT for glucose of 5-10 mM using the Xenopus 
oocyte expression system however the transporter also has substrate-specificity for galactose 
(Gould et al., 1989;Gould et al., 1991;Nishimura et al., 1993).  Furthermore GLUT1-related 
disorders are based on the role of the transporter in glucose transport across the blood-brain 
barrier and include infantile seizures and developmental delay, as well as a link between 
GLUT1 and the early stages of Alzheimer’s disease (Simpson et al., 1994;Klepper et al., 
1999). 
 
5.6.1.1.2 GLUT2 
 
GLUT2 is a high-capacity, low-affinity glucose transporter with a KT of 15-25 mM which 
can also transport galactose, glucosamine, mannose and fructose with KT values of 92 mM, 
0.8 mM, 125 mM and 76 mM respectively (Johnson et al., 1990;Dominguez et al., 
1992;Colville et al., 1993;Uldry et al., 2002).  GLUT2 is expressed in various tissues since it 
is involved in metabolic glucose sensing (described in section 5.6.1.1.2.1); this role in 
glucose homeostasis is mediated by the ability of GLUT2 to transport glucose bi-directionally 
and thus it can modulate intracellular glucose concentrations.  GLUT2 is highly expressed in 
pancreatic β-cells and hepatocytes as well as at the BLM of small intestinal and renal 
epithelial cells; interestingly, in response to high luminal glucose, GLUT2 is also expressed 
at the BBM at these locations (Fukumoto et al., 1988;Orci et al., 1989;Johnson et al., 
1990;Thorens, 1992;Kellett and Helliwell, 2000;Marks et al., 2003;Marks, 2004).   
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5.6.1.1.2.1 GLUT2 as a glucose sensor 
 
GLUT2 has been proposed to be a glucose sensor as it is primarily responsible for glucose 
homeostasis through its role in glucose absorption in the intestine, glucose reabsorption in the 
kidney, glucose sensing in the pancreatic β-cell and glucose uptake and release by the liver 
(Stolarczyk et al., 2010).  In pancreatic β-cells, GLUT2 is coupled with the glucokinase 
enzyme to form a glucose sensory mechanism; indeed GLUT2 mediates the initial phase of 
insulin secretion in mice in order to correct plasma glucose fluctuations (Unger, 
1991;Guillam et al., 1997).  In hepatocytes, GLUT2 can sense glucose and activate a 
signalling pathway via its large cytoplasmic domain which causes glucose-induced 
transcription, via a signalling pathway independent of glucose metabolism (Guillemain et al., 
2000;Guillemain et al., 2002).  In enterocytes, the polar nature of GLUT2 glucose sensing is 
from the BLM where GLUT2 senses alterations in glycaemia which leads to changes in 
enterocyte glucose absorption (Le et al., 2007).  Furthermore, GLUT2-loop transgenic mice 
continue to express GLUT2 in renal cells therefore the phenotype of the GLUT2-loop mice 
may not be caused by defective glucose entry but the inability of the kidney to sense sugars 
(Stolarczyk et al., 2007).  This suggests that the involvement of GLUT2 in glucose detection 
may also influence renal glucose reabsorption (Stolarczyk et al., 2007). 
 
5.6.1.1.2.2 Genetic regulation of GLUT2 
 
The transcriptional regulators of the GLUT2 gene include HNF-1α, -3β and PDX-1 
(Pontoglio et al., 2000;Shen et al., 2001;Parrizas et al., 2001;Freitas et al., 2009).  In the rat 
GLUT2 gene, the peroxisomal-proliferator-response element (PPRE) is functional and 
promoter activity of the gene was elevated by PPARγ-ligand binding (Kim et al., 2000).  
Special regions of the GLUT2 promoter have been characterised as containing glucose- and 
cAMP-responsive element therefore these substrates are enhancers and suppressors, 
respectively, of GLUT2 gene expression (Rencurel et al., 1997). 
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Homozygous or compound heterozygous mutations in the GLUT2 gene cause Fanconi-Bickel 
syndrome, the rare autosomal-recessive congenital disease which is characterised by 
glycogen accumulation in the kidney and liver, and nephropathy (Santer et al., 1997;Santer et 
al., 2002;Taha et al., 2008).  GLUT2 mutations can also result in the abolition of the 
transporter resulting in the inability of patients to tolerate simple sugars in the diet (Santer et 
al., 2002).  One outcome of Fanconi-Bickel syndrome is impaired glucose tolerance with 
hypoinsulinaemia and severe glycosuria; this is also seen with GLUT2 KO mice where the 
disease causes a lethal diabetic phenotype following weaning which is likely to be due to the 
inability to handle excess glucose and thus sugar entry and detection by the pancreas are 
impaired (Guillam et al., 1997;Guillam et al., 2000).  Interestingly, a clinical study with a 
newborn exhibiting symptoms of Fanconi-Bickel who exhibited severe renal tubular 
dysfunction, rickets and increased serum galactose levels showed a positive response to a 
lactose-free diet supplemented with fructose and corn starch; and the disorder was abolished 
within 6 months (Kentrup et al., 1999).  However no mutational hotspots have been identified 
within the GLUT2 gene; there are 33 different mutations detected in 49 sufferers of Fanconi-
Bickel syndrome, making gene localisation difficult (Santer et al., 2002). 
 
The genetic variation of the GLUT2 promoter has also been associated with the onset of type 
II diabetes, for example, the Val-197-Ile missense mutation results in abolition of the 
transport activity of GLUT2 and has been postulated to influence the pathogenesis of type II 
diabetes (Mueckler et al., 1994).  Interestingly, renal damage in patients with GLUT2 
deficiency, such as renal hyperfiltration, microalbuminuria, and glomerular mesangial 
expansion, closely matches diabetic nephropathy (Berry et al., 2005).   
 
The role of GLUT2 in renal and jejunal glucose transport is covered in sections 5.7 and 5.8. 
 
 
 
 
  
  60 
5.6.1.1.3 GLUT3 
 
GLUT3 has been located in sperm, embryo and both dendrites and axons in neurons as well 
as pancreatic β-cells (Mantych et al., 1992;Sato et al., 1996).  The transporter has also been 
found in lymphocytes, platelets, monocytes and macrophages; thus GLUT3 may have a role 
in immune and inflammatory cell activation (Estrada et al., 1994;Maratou et al., 2007).  The 
transporter has a high-affinity for glucose with Xenopus oocyte data showing a KT of 1 mM; 
furthermore GLUT3 has a high-turnover number and therefore can ensure efficient glucose 
uptake by neurons (Sato et al., 1996;Maher et al., 1996).  The GLUT14 gene, SLC2A14, is a 
duplicon of GLUT3 which exhibits 95% homology to GLUT3; it has been located in the 
testis, of man, as two alternative splice forms (Wu and Freeze, 2002). 
 
5.6.1.1.4 GLUT4 
 
GLUT4 is located in skeletal and cardiac muscle and adipose tissue and has a high-affinity 
for glucose, with a KT of 5 mM when expressed in Xenopus oocytes (James et al., 
1989;Nishimura et al., 1993).  Under normal conditions, GLUT4 is expressed at low levels in 
cell membranes but upon insulin stimulation, GLUT4 translocates to the membrane and, as a 
result, glucose uptake is elevated (Simpson et al., 2001).  The insulin-sensitivity of GLUT4 
suggests a role in diabetes; indeed disruption of the GLUT4 gene, by homologous 
recombination, results in the development of a type II diabetic-like phenotype including 
reduced muscle glucose uptake and elevated circulating levels of insulin (Stenbit et al., 
1997;Rossetti et al., 1997).  Furthermore, in other models of insulin-resistance such as in 
response to a high-fat diet, GLUT4 is down-regulated in adipose tissue and skeletal muscle 
and this has been associated with reduced glucose utilization by these tissues (Petersen et al., 
1991;Kim et al., 1994).   
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5.6.1.2 Class II and III GLUT transporters 
 
Class II of GLUT transporters consists of GLUT5, GLUT7, GLUT9 and GLUT11, all of 
which transport fructose as well as glucose, and, with the exception of GLUT5 they all have a 
KT of less than 1 mM for glucose (Kane et al., 1997;Manolescu et al., 2005;Scheepers et al., 
2005).  Class III comprises of the more obscure GLUT6, GLUT8, GLUT10, GLUT12 and 
GLUT13 (HMIT).  This class of the GLUT family contains members sharing an intracellular 
localisation signal and large extracellular loop 9, which carries their glycosylation site 
(Scheepers et al., 2001;Uldry et al., 2001;Rogers et al., 2002;Wood et al., 2003).  However, 
GLUT5 is the only transporter to be reported here due to its association with fructose-related 
metabolic diseases and its location at both the renal and small intestinal brush-border 
epithelia. 
 
5.6.1.2.1 GLUT5 
 
The rate of glucose transport by GLUT5, when assessed using the Xenopus oocyte expression 
system, is low and is inhibited by cytochalasin B (Kayano et al., 1990).  However using in 
vivo studies GLUT5 has not been shown to transport glucose (Burant et al., 1992;Rand et al., 
1993;Miyamoto et al., 1994).  GLUT5 is a major fructose transporter having a KT of 6 mM 
for cytochalasin B-sensitive, fructose transport when expressed in Xenopus oocytes (Burant et 
al., 1992;Mate et al., 2001;Douard and Ferraris, 2008).  Interestingly, the expression of 
GLUT5 in the central nervous system (CNS), where fructose is not used as a metabolic 
substrate, suggests an important role for GLUT5 in glucose transport despite the low affinity 
for glucose (Mantych et al., 1993).  GLUT5 is also located at the BBM of the small intestine 
where it is important in absorption of fructose from any sources in the diet, as well as at the 
BLM of human small intestine, implying a role of GLUT5 in transport from enterocyte to the 
circulation (Blakemore et al., 1995).  In intact small intestine, GLUT5 is so specific for 
fructose that GLUT5-mediated fructose transport is not inhibited by a 100-fold excess of 
glucose (Burant et al., 1992).  Furthermore, fructose is rapidly cleared from the blood thus 
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circulating fructose levels are low and fructose transport can be mediated by the facilitative 
transporter GLUT5.  In addition, GLUT5 is abundant in other fructose-utilising tissues such 
as the testes, erythrocytes, adipose tissue and skeletal muscle, and cells in the S3 segment of 
proximal tubules (Burant et al., 1992;Miyamoto et al., 1992;Rand et al., 1993e;Corpe et al., 
2002).   
 
Differences have been documented for GLUT5 tissue distribution in the rat and mouse (Rand 
et al., 1993).  However Inukai et al found that rat GLUT5 mRNA exhibits tissue distribution 
very similar to that in man with the jejunum presenting the highest expression of the 
transporter (Inukai et al., 1993).  In this location, levels of GLUT5 mRNA and protein are 
elevated in response to fructose-enriched, but not starch-enriched, diets (Inukai et al., 1993).  
In rats, immediately after weaning, intestinal fructose transport and GLUT5 mRNA 
expression, is up-regulated; these changes occur irrespective of dietary intake of fructose 
(Rand et al., 1993;Castello et al., 1995;Shu et al., 1997).  Barone et al used a GLUT5 KO 
mouse to show that the transporter mediates fructose metabolism and physiological effects 
mediated by high-fructose diets, such as hypertension (Barone et al., 2009); these are 
elaborated on in section 5.4.   
 
GLUT5 KO mice present with a 75% reduction in fructose absorption across the jejunum and 
a 90% decline in serum fructose levels (Barone et al., 2009).  These GLUT5-null mice also 
exhibit normal blood pressure and weight gain in response to high-fructose feeding, although 
dietary glucose handling was unaffected in this KO model (Barone et al., 2009).  Indeed 
Mesonero et al showed that Caco-2 cells, incubated with fructose, resulted in 3-fold higher 
GLUT5 protein and mRNA expression when compared with incubation with the same 
concentration of glucose (Mesonero et al., 1995).  Furthermore GLUT5 protein and mRNA, 
and GLUT5-mediated fructose uptake, was elevated in Caco-2 cells by forskolin, the 
adenylate cyclase activator which elevates intracellular cAMP (Mahraoui et al., 1994).  In 
addition, fructose has been shown to be involved in a positive regulatory loop with gastric 
leptin; fructose triggers the release of gastric leptin which up-regulates GLUT5 levels and 
modulates metabolic function in the liver, this offers a likely explanation of the damaging 
effects of fructose on lipidaemia as outlined in section 5.4.       
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5.6.1.3 Inhibitors of GLUT-mediated transport 
 
Both cytochalasin B, a major metabolite of the fungus Helminthosporium mastoideum, and 
phloretin are potent inhibitors of the GLUT family, with some exceptions (Ebstensen and 
Plagemann, 1972;Graff et al., 1973).  For example, cytochalasin B and phloretin bind to 
GLUT5 in a different location to the fructose-binding site, and therefore GLUT5-mediated 
fructose transport is unaffected by these inhibitors (Ebstensen et al., 1972;Doege et al., 
2001).  The anti-retroviral therapies, indinavir and fasentin, inhibit glucose uptake of cells 
which preferentially express GLUT1 and GLUT4, as does the flavonoid apigenin (Ebstensen 
et al., 1972;Murata et al., 2002;Wood et al., 2008;Melstrom et al., 2008).   
 
5.6.2 Active glucose transporters  
 
Secondary active transporters are energy-requiring symporters which move specific nutrient 
substrates against their concentration gradient.  The energy required for this transport is 
harnessed from electrochemical gradient-coupling of nutrient transport to the translocation of 
specific ions.   
 
5.6.2.1 SGLT family 
 
There are currently 6 members of the sodium-dependent glucose transporter (SGLT) family: 
SGLT1, SGLT2 and SGLT3 (SAAT-pSGLT2) have been well-characterised whereas 
SGLT4, SGLT5 and SGLT6 still need to be fully characterised (Wright et al., 2004;Wright 
and Turk, 2004;Wright et al., 2007).  Interestingly SGLT4, SGLT5 and SGLT6 have been 
located in the kidney, as well as other tissues, where glucose and galactose are known to be 
substrates (Nishimura and Naito, 2005). 
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SGLT transporters comprise twelve transmembrane segments and a leucine zipper domain on 
one extracellular loop; furthermore SGLT1 and SGLT2 have 60% identity homology with 
closely-related amino acid sequences (Wright et al., 1994;Turk et al., 1994).  SGLT1 and 
SGLT2, mediate reversible glucose transport across epithelial membranes by using free 
energy from an electrochemical Na
+
-gradient into a glucose concentration gradient across the 
membrane (Hummel et al., 2011).   
 
The sodium gradient is maintained by the Na
+
/K
+
-ATPase at the basolateral membrane of 
small intestinal and renal epithelial cells; the pump exports three sodium (Na
+
) from the cell 
to maintain a sodium gradient across the BBM and transports two potassium (K
+
) ions into 
the cell (Gloor, 1997;Scheiner-Bobis, 2002;Faller, 2008). 
 
5.6.2.1.1 SGLT1 
 
SGLT1 co-transports two Na
+
 ions into the cell with one glucose molecule and has a high-
affinity for glucose and galactose with a KT of 0.2 – 0.5 mM; however, SGLT1 has a low-
capacity for glucose transport (Hirayama et al., 1996;Brown, 2000;Wright, 2001).  SGLT1 
has been located at the BBM of absorptive enterocytes, but is also expressed in lower 
abundance in proximal straight tubule cells, as well as intracerebral capillaries, mammary 
glands, liver and alveolar cells in the lung (Hwang et al., 1991;Takata et al., 1991;Cramer et 
al., 1992;Takata et al., 1992;Elfeber et al., 2004;Zhao et al., 2005;Sabino-Silva et al., 2010).  
A single missense mutation in the SGLT1 gene causes a rare glucose/galactose malabsorption 
condition; this autosomal recessive disorder results in severe watery diarrhoea and 
dehydration in the newborn period which can be treated by replacing glucose and galactose in 
the diet with fructose (Turk et al., 1991;Carbonnel et al., 1995;Martin et al., 1997).   
 
Interestingly, a wide aqueous cavity in SGLT1 structure was found within the substrate-
binding conformation (Choe et al., 2010).  Rabbit SGLT1 expressed in Xenopus oocytes has 
been shown to co-transport 424 water molecules across epithelia for every 2 Na
+
 ions and 1 
glucose molecule; furthermore this water transport is not osmotic (Zeuthen et al., 2001).  This 
  
  65 
phlorizin-sensitive, isotonic water transport has been postulated to serve the role of directly 
co-transporting water across epithelia and to generate the osmotic driving force for other 
pathways such as aquaporin-mediated water transport (Loo et al., 1999;Zeuthen et al., 2001).  
Water transport via SGLT1 is gated with no release of water molecules from the transporter 
until the glucose molecule is released (Watanabe et al., 2010).  Recent studies have shown 
that SGLT1 is able to co-transport a more modest 70 molecules of water per 1 molecule of 
galactose (Watanabe et al., 2010). 
 
5.6.2.1.2 SGLT2 
 
SGLT2 co-transports one glucose molecule with one Na
+
 ion and is highly specific for 
glucose, but not galactose, and has a lower affinity than SGLT1 with a KT of 2-10 mM 
(Wright, 2001).  Furthermore SGLT2 has a higher capacity for glucose transport than SGLT1 
and is predominantly expressed in the kidney, at the BBM of proximal convoluted tubule 
cells (Wells et al., 1992;Kanai et al., 1994;Brown, 2000).  A missense mutation in the SGLT2 
gene, of which there are approximately 21 different gene mutation sites, causes the autosomal 
recessive condition familial renal glycosuria; this benign genetic defect of renal glucose 
reabsorption causes persistent glycosuria, with glucose excretion of up to 160 g/day, in the 
absence of hyperglycaemia, or any other clinical phenotype (Santer et al., 2003;Francis et al., 
2004;Scholl-Burgi et al., 2004). Interestingly this disorder does not affect renal transport of 
other sugars and the uptake and utilisation of glucose by other tissues is normal (Carbonnel et 
al., 1995).  
 
5.6.2.1.3 SGLT3 
 
SGLT3 is found in the small intestine, kidney and skeletal muscle with a KT of 2 mM for 
glucose however rather than being a sugar transporter like SGLT1 and SGLT2, SGLT3 is a 
glucose-activated Na
+
-channel found in the plasma membrane of cholinergic neurons (Zhao 
and Keating, 2007).  Interestingly, in enteric neurons, glucose sensing by SGLT3 triggers 
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specific phlorizin-sensitive, Na
+
-dependent depolarisation of the membrane potential.  
However, unlike the enterocyte BBM, the glucose-induced inward currents in the cells are 
not accompanied by glucose transport (Diez-Sampedro et al., 2003).  Recently, Bianchi et al 
identified that the mutation of SGLT3 from glutamate to glutamine, in position 457, changes 
the sugar sensor into a glucose transporter with the same stoichiometry as SGLT1 (Bianchi 
and Diez-Sampedro, 2010).  
 
5.6.2.2 SGLT inhibitors 
5.6.2.2.1 Phlorizin  
 
Phlorizin, a β-glucopyranoside first isolated from the root bark of apple trees, is a potent 
competitive and non-competitive inhibitor of SGLT1 and SGLT2 with no effect on the 
GLUT family of glucose transporters (Brazy and Dennis, 1978;Bell et al., 1990;Petersen et 
al., 1991).  The administration of phlorizin to diabetic rats results in the development of 
glycosuria accompanied by the normalisation of blood glucose levels (Rossetti et al., 
1987;Kahn et al., 1991;Zhao et al., 2004;Masumoto et al., 2009).  Phlorizin treatment has 
also been shown to prevent proteinuria, hyperfiltration and kidney hypertrophy exhibited by 
type I diabetic rats (Malatiali et al., 2008).  Freitas et al compared the efficacy of phlorizin 
with insulin treatment and found the SGLT inhibitor to be useful for reducing blood glucose 
levels in type II diabetes; although both treatments significantly reduced the plasma glucose 
levels in diabetic rats, phlorizin had no effect on body weight or plasma insulin levels 
whereas insulin treatment increased both parameters (Freitas et al., 2008).  However 
phlorizin is not selective for renal SGLT transporters but also targets SGLT1 in the small 
intestine (Pajor et al., 1992;Tyagi et al., 2007).  Phlorizin is rapidly degraded by β-
glucosidases in the gastrointestinal tract which results in low bioavailability as well as the 
production of phloretin, a GLUT inhibitor (Miyamoto et al., 1994;Crespy et al., 2001).  
However Masumoto et al found a 3-fold rise in plasma phlorizin levels in STZ-induced 
diabetic mice fed a diet containing 0.5% phlorizin, for 14 days, when compared to 0.1 % 
phlorizin, suggesting the inhibitor may be absorbed across the enterocyte (Masumoto et al., 
2009).  
  
  67 
 
5.6.2.2.2 SGLT2 inhibitors in type II diabetes treatment 
 
Despite the multitude of type II diabetic drugs currently available (outlined in 5.2.5.2) these 
treatments have their limitations, therefore SGLT2 inhibitors present a novel and potentially 
effective method in the treatment of type II diabetes.  Subsequently alternatives for phlorizin 
have been studied for their use in managing glucose reabsorption in the kidney by targeting 
SGLT2, without exerting an effect on SGLT1-mediated glucose transport.  The first example 
of this was the oral pro-drug T-1095, which is metabolised into T-1095A in the liver and 
therefore T-1095A, but not T-1095, was detected in plasma following oral administration of 
T-1095 (Tsujihara et al., 1999;Arakawa et al., 2001).  T-1095A exerts a hypoglycaemic 
effect in animal models of diabetes, such as the ZDF rat, db/db mice and STZ-induced type I 
diabetic animals, with concomitant glycosuria (Nawano et al., 2000;Oku et al., 
2000;Arakawa et al., 2001).  Furthermore, T-1095 prevented the age-related decrease in 
plasma insulin levels and loss of pancreatic insulin seen in db/db mice, as well as improving 
symptoms of diabetic nephropathy such as urinary albumin excretion (Arakawa et al., 2001).   
 
5.6.2.2.2.1 Potential treatment of diabetes by SGLT2 inhibitors 
 
Subsequently there are currently over 21 SGLT2 inhibitors being developed for treatment in 
diabetes, with examples including the C-aryl glucoside, dapagliflozin and the O-glucoside, 
sergliflozin (Katsuno et al., 2007;Han et al., 2008;Meng et al., 2008).   
 
Dapagliflozin is a selective inhibitor of SGLT2 and reduces plasma glucose levels between 
50—60%, within 2 hours of a single oral dose in STZ-induced type I diabetic rats; 
dapagliflozin exerts a dose-dependent decrease in glycaemia with a concomitant increase in 
glycosuria (Han et al., 2008;Meng et al., 2008;Komoroski et al., 2009).  Furthermore, this 
SGLT2 inhibitor does not influence body weight or glucose transport in other tissues, nor 
does it induce hypoglycaemia (Han et al., 2008).   
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Sergliflozin is the pro-drug for the potent and selective SGLT2 inhibitor sergliflozin-A; like 
dapagliflozin, it exhibits a dose-dependent decrease in glycaemia with an increase in 
glycosuria (Katsuno et al., 2007;Hussey et al., 2010).  Despite the inhibition of renal glucose 
reabsorption, sergliflozin has no effect on GLUT1 activity at the BLM of proximal tubules, 
nor does it cause hypoglycaemia (Katsuno et al., 2007).  Interestingly, when used at 
supraphysiological doses, it causes transient osmotic diuresis and a reduction in body weight 
(Katsuno et al., 2007;Hussey et al., 2010).   
 
The safety and efficacy of SGLT2 inhibitors as a treatment for diabetes requires further 
clinical testing.  However, in the rare genetic disease, Familial Renal Glycosuria (FRG), 
sufferers exhibit extensive glycosuria with no other complications or adverse effects (Santer 
et al., 2003).  This implicates the use of SGLT2 inhibitors as a powerful and safe tool in the 
treatment of diabetes.  However, Ly et al have recently developed the Sweet Pee mouse 
model which carries a nonsense mutation in the SGLT2 gene, resulting in the loss of protein 
function (Ly et al., 2011).  On induction of diabetes with STZ, these mice display glycosuria 
with accompanying euglycaemia however no change in insulin sensitivity is observed.  
Furthermore, although there are no changes in GFR in the Sweet Pee mouse, the diabetic 
animals develop multiple urinary tract infections and kidneys from older animals exhibit 
massive white blood cell infiltration; furthermore, an earlier age of mortality was noted in 
type I diabetic Sweet Pee mice compared with diabetic wild-type mice (Ly et al., 2011).  
Therefore the long-term effects of SGLT2 inhibition in diabetes requires further investigation 
to characterise the efficacy of SGLT2 inhibitors as treatment in the disease. 
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5.7 Glucose handling in the kidney 
 
The kidneys are vital for glucose homeostasis due to their role in the filtration and 
reabsorption of glucose; thus is it important to understand the regulation of these processes in 
order to understand the pathology of diseases in glucose transport.  Studies show that the 
kidneys are able to generate glucose and potentially act as a storage pool for glucose, thus the 
control of glucose handling by the kidney plays a major role in maintaining whole body 
glucose status.   
 
5.7.1 Renal glucose filtration and reabsorption 
5.7.1.1 Glucose filtration 
 
Under normal conditions, when glycaemia is approximately 5.5 mM, since 180 L of plasma 
is filtered by the kidneys per day, 180 g of glucose is filtered by the kidney over this time 
period.  Circulating glucose moves from the glomerular capillaries into the Bowman’s 
capsule, together with low molecular weight constituents such as amino acids and 
electrolytes.  The filtrate moves through the proximal tubule, along the loop of Henle, into the 
distal convoluted tubule and through a series of collecting ducts to form urine for excretion.  
As plasma glucose levels increase, the amount of glucose in the filtrate increases in a linear 
manner, assuming no change in glomerular filtration rate (GFR).  The reabsorption of glucose 
is saturable and increases in a linear manner until the maximal reabsorptive capacity is 
exceeded, after which the glucose is excreted in increasing amounts (Deetjen and Boylan, 
1968;Zelikovic and Przekwas, 1995;Hall et al., 1996).   
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5.7.1.2 Glucose reabsorption 
 
Normally, over 99% of glucose filtered from the plasma is reabsorbed along the nephron, 
with very low glucose excretion in the range of 0.03 to 0.3 g per day (Wright, 2001).  The 
glucose transporters SGLT1 and SGLT2, and GLUT1 and GLUT2, are vital for glucose 
reabsorption by the kidney (Figure 5.4).   
 
Free-flow micropuncture studies in the rat show that 90% of the filtered glucose is reabsorbed 
in the early proximal convoluted tubule, S1/S2 segment, by SGLT2 at the BBM of the 
proximal tubule cell, the remaining fraction of glucose in the filtrate is absorbed in the late 
proximal straight tubule, S3 segment (Cramer et al., 1992;Brown, 2000;Lee et al., 2007;Chen 
et al., 2008).  This is reinforced by studies using the isolated perfused tubule technique; it has 
been shown that the maximal rate of active glucose transport decreases considerably from the 
proximal convoluted tubule to the proximal straight tubule.  This reduced rate of uptake is 
accompanied by increased affinity of transporters at the BBM for glucose (Barfuss and 
Schafer, 1981).  Thus in the early proximal tubule a low-affinity, high-capacity glucose 
transport system has been established which is attributed to SGLT2 whereas SGLT1, a high-
affinity but low-capacity glucose transport system was identified in the later proximal tubule, 
which reabsorbs most of the remaining glucose from the tubular fluid (Turner and Silverman, 
1977;Turner and Moran, 1982;Turner and Moran, 1982).  Sodium ions co-transported with 
glucose by SGLT1 (2 Na
+
) and SGLT2 (1 Na
+
) are pumped out of the proximal tubule cell 
via the basolateral Na
+
/K
+
-ATPase, which is responsible for maintaining the sodium 
electrochemical potential gradient at the BBM, for SGLT-mediated glucose transport.     
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Figure 5.4 – Schematic diagram of the specific regions of the proximal tubule associated with glucose reabsorption from tubular fluid, across the cell, via the 
sodium gradient maintained by the basolateral Na
+
/K
+
-ATPase.  A: cell diagram for glucose transporters involved in glucose reabsorption across the early S1/S2 
region of the proximal tubule, where the luminal glucose load is high following glucose filtration by the glomerulus  B: cell diagram from glucose transporters 
involved in glucose reabsorption across the late S3 region of the proximal tubule, where the luminal glucose load is considerably reduced following glucose 
reabsorption in the early proximal convoluted tubule (Figure adapted from (Marks, 2004)).      Glucose molecule      sodium ion        potassium ion. 
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A recent study by Hummel et al indicates that SGLT1 contributes a greater proportion 
of glucose transport than originally believed, with a KT for glucose of 1.8 mM 
compared to a value of 4.9 mM for SGLT2 (Hummel et al., 2011).  As well as 
confirming the 2:1 Na
+
-glucose coupling for SGLT1 and 1:1 Na
+
-glucose coupling for 
SGLT2, the study also found that the KT of SGLT1 for galactose transport was 6.1 
mM whereas galactose is a poor substrate for SGLT2 with a KT of more than 100 mM 
(Hummel et al., 2011).  Interestingly, the contribution of SGLT1 to glucose 
reabsorption has been shown in SGLT2 KO mice which, despite the concomitant 40% 
reduction in SGLT1 mRNA and protein, still reabsorb 30-40% glucose from the 
glomerular filtrate (Vallon et al., 2010).  In the Sweet Pee mouse model with loss of 
SGLT2 protein function, mice exhibited a significant elevation in SGLT2 mRNA in 
the kidney with no change in SGLT1, GLUT1 or GLUT2 mRNA (Ly et al., 2011).  
However it is worth noting that, although in vitro studies with dapagliflozin show 
complete inhibition of SGLT2 activity, in vivo the drug only blocks glucose 
reabsorption by 50% (Meng et al., 2008;Komoroski et al., 2009).  Although 
dapagliflozin is still an effective drug in the reduction of hyperglycaemia and 
treatment of type II diabetes, this data provides evidence for a larger role of renal 
SGLT1 in glucose reabsorption then has hitherto been recognised (Hummel et al., 
2011). 
 
Glucose efflux from the proximal tubule cell across the BLM is driven by the 
outwardly-directed glucose gradient, mediated through the facilitative glucose 
transporters GLUT1 and GLUT2, like SGLT transporters, there is an axial distribution 
of GLUT transporters along the proximal tubule.  The high-affinity GLUT1 is found 
at the BLM of proximal convoluted and straight tubule cells whereas the low-affinity 
GLUT2 is confined to the proximal convoluted tubule BLM (Thorens et al., 
1990;Cramer et al., 1992;Dominguez et al., 1992). 
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5.7.1.3 Renal glucose production and storage 
 
In humans, glucose is released into the circulation by both the liver and kidney which, 
as the only tissues containing significant amounts of the enzyme glucose-6-
phosphatase, are the only two organs able to perform gluconeogenesis (Ekberg et al., 
1999).  The renal contribution to systemic glucose is between 20-42% following 
ingestion of a meal (Stumvoll et al., 1995).  Glucose production by the kidney is not 
mediated by glycogenolysis as, under normal conditions, the kidney stores low levels 
glycogen (Biava et al., 1966).  Thus the kidney relies on gluconeogenesis, from 
alanine, lactate or glutamine, to release glucose into the circulation (Stumvoll et al., 
1998;Cersosimo et al., 1999;Meyer et al., 2002).  Gluconeogenesis is up-regulated in 
response to adrenalin; the hormone elevates renal uptake of precursors lactate and 
alanine, and increases renal gluconeogenic efficiency (Meyer et al., 2003).  
Interestingly, Meyer et al showed that, unlike the down-regulation seen in the liver, 
renal gluconeogenesis is up-regulated by two-fold in the postprandial state (Meyer et 
al., 1999).   
 
5.7.2 Regulation of renal glucose handling 
 
There are many factors which influence renal glucose handling including the diabetic 
disease state, feeding, fasting as well as severe inflammation and hepatocyte nuclear 
factors.  
 
5.7.2.1 Renal glucose filtration, production and storage in diabetes 
5.7.2.1.1 Filtration and tubuloglomerular feedback 
 
One of the earliest indicators of altered kidney function in diabetes is an elevation in 
GFR; GFR and tubular function are closely interlinked via the tubular composition of 
the tubular fluid (O'Donnell et al., 1988).  However, the diabetes-mediated effects on 
GFR are unrelated to renal tubule glucose transport or plasma osmolality (Skott et al., 
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1991).  Diabetic hyperglycaemic elevates the tubular glucose load and, provided the 
transport maximum for glucose has not been exceeded, this leads to elevated proximal 
tubule reabsorption.  The fractional reabsorption of fluid and electrolytes in the 
proximal tubule is elevated in response to STZ-induced diabetes; furthermore in long-
term type I diabetic patients, the rise in reabsorption occurs irrespective of the 
presence of diabetic nephropathy (Skott et al., 1989;Bank and Aynedjian, 
1990;Vallon et al., 1995;Vallon et al., 1999).  These changes result in glomerular 
hyperfiltration and oxidative stress, and culminate in inactivated tubuloglomerular 
feedback mechanisms (Tucker et al., 1978;Tucker and Blantz, 1978;Skott et al., 
1989).   
 
5.7.2.1.2 Renal glucose production and release 
 
One of the main factors causing fasting hyperglycaemia in type II diabetic patients is 
the elevated release of glucose by the kidney and liver (Bearn et al., 1951;Dinneen et 
al., 1992).  Although there is a rise in both renal and hepatic gluconeogenesis; the 
kidney contributes a greater amount to the whole body glucose pool than the liver, 
with renal glucose release in type II diabetic patients elevated by nearly 300% (Meyer 
et al., 1998).  The increase in renal gluconeogenesis is also seen in obese patients who 
undergo prolonger fasting (Owen et al., 1969).  Postprandially, type II diabetes in man 
also leads to elevated renal glucose release, which is not unexpected with regards to 
the reduced postprandial increase in insulin release and the effects of insulin on renal 
glucose release (Meyer et al., 2004).  Diabetic Zucker rats, an established model of 
type II diabetes, showed a high rate of renal gluconeogenesis which correlated with 
the increased activity of key gluconeogenic enzymes (Eid et al., 2006).   
 
5.7.2.1.3 Renal glucose storage 
 
Raised renal glucose uptake and gluconeogenesis in diabetes increases glucose levels 
in tubular cells and provides a likely explanation for the elevated glycogen levels 
found in both type I and II diabetes (Rasch, 1984;Williams and Airey, 2002;Bamri-
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Ezzine et al., 2003;Ohta et al., 2007).  The accumulation of glycogen, seen in human 
and rodent models of diabetes, has been proposed to be a result of impaired AMPK-
mediated reduction by glycogen synthase and can result in tubular cell apoptosis 
(Bamri-Ezzine et al., 2003;Londono et al., 2004;Cammisotto et al., 2008).   
 
Thus in addition to the contribution of renal glucose handling to the hyperglycaemia 
of diabetes, knowledge of changes in renal glucose handling has increased out 
understanding of the pathology of diabetes-induced renal complications. 
 
5.7.2.1.4 Renal glucose reabsorption  
 
In diabetic patients, glycosuria does not occur at plasma glucose concentrations that 
would normally produce glycosuria in non-diabetics (Mogensen, 1971).  This 
tolerance is likely to be due to increased glucose reabsorption in diabetes implying a 
raised transport maximum for glucose. 
 
Uncontrolled diabetes, by increasing blood and interstitial glucose concentrations, 
influences the glucose gradient across the proximal tubule cell via impairment of 
glucose efflux from epithelial cells and thus glucose reabsorption.  To this end, 
increased gene expression of renal glucose transporters could be viewed as being 
important in the maintenance of glucose reabsorption in diabetes (Dominguez et al., 
1992;Dominguez et al., 1994a;Dominguez et al., 1994b).   
 
The increase in renal glucose reabsorption during hyperglycaemia implies an 
augmentation of glucose movement across both the BBM and BLM of the proximal 
tubule cell.  Bank et al hypothesised that the higher rate of glucose reabsorption seen 
in diabetes is a result of elevated sodium-dependent glucose uptake from the luminal 
fluid with basolateral glucose transport increasing concomitantly to maintain steady-
state transcellular glucose efflux (Bank et al., 1990).   
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5.7.2.1.4.1 Renal glucose transporters involved in glucose reabsorption 
 
There are a plethora of changes in glucose transporters in proximal tubule cells in 
response to diabetes.  An elevation in renal GLUT2 expression has been reported in 
diabetes while GLUT1 is suppressed (Dominguez et al., 1994a;Chin et al., 
1997;Kamran et al., 1997;Vestri et al., 2001).  Marks et al found augmented GLUT2 
protein levels at the BBM of proximal tubule cells prepared from STZ-induced 
diabetic rats, along with elevated GLUT5 protein, which was matched by augmented 
GLUT-mediated glucose transport activity; however, no change in GLUT1 expression 
at the BBM was noted (Marks et al., 2003).  Interestingly, the study also reported that 
GLUT2 at the proximal tubule BBM, and GLUT-mediated glucose uptake was down-
regulated by an overnight fast, whereas GLUT5 was unaffected.  These data 
suggested a relationship between glycaemic status and GLUT2 expression (Marks et 
al., 2003).  Indeed, Goestemeyer et al used nicotinamide to modulate the extent of 
hyperglycaemia in STZ-induced diabetes and showed that GLUT2 expression at the 
BBM exhibited a strong positive correlation with plasma glucose (Goestemeyer et al., 
2007).  The relationship between plasma glucose level and GLUT2 protein expression 
in type I diabetes was also seen by Freitas et al.  The group found that both acute and 
short-term insulin treatment induced an early elevation in the already raised levels of 
GLUT2 in the renal cortex, seen in type I diabetes (Freitas et al., 2005).  Despite this 
early increase in GLUT2 being transitory, acute insulin treatment may exacerbate 
diabetes-induced renal dysfunction by increasing intracellular glucose concentrations 
(Freitas et al., 2005).  Interestingly, the normalisation of renal GLUT2 expression in 
the proximal tubule cell seen with long-term insulin treatment, is also seen following 
the treatment of control rats with the structurally similar hormone, insulin-like growth 
factor 1, IGF-1 (Asada et al., 1997). 
 
Type II diabetic patients and Zucker diabetic rats exhibit tubular overexpression of 
GLUT2, although the contribution of GLUT-mediated glucose transport in these 
models has not yet been established (Kamran et al., 1997;Rahmoune et al., 2005).  
Interestingly, Kamran et al postulated that an interaction between tubular glucose 
levels with SGLT at the BBM is necessary for GLUT2 activation (Kamran et al., 
1997).  Thus it is possible that SGLT signals to GLUT2 via elevating intracellular 
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glucose concentration; a mechanism which has been identified to regulate GLUT2 
expression at the enterocyte BBM (see section 5.8.2.3) (Kellett and Helliwell, 2000).  
In agreement with this is the down-regulation in renal expression of GLUT2 in 
response to phlorizin treatment of type I diabetic rats, suggesting interplay between 
the regulation of renal SGLT’s and GLUT2 expression (Freitas et al., 2007). 
 
In contrast to GLUT2, the effects of diabetes on SGLT-mediated glucose transport at 
the proximal tubule BBM are less clear.  STZ-induced type I diabetes of 2-7 weeks 
duration has been shown to have no effect on SGLT1 expression or SGLT-mediated 
glucose transport at the proximal tubule BBM; however an increase in SGLT1 
expression was evident after 8-week diabetes and also in 12-week alloxan-induced 
diabetes (Vestri et al., 2001;Marks et al., 2003;Vidotti et al., 2008).  Furthermore in 
studies using cultured proximal tubule cells, SGLT-mediated glucose uptake was 
found to be inhibited by high glucose levels; this is a likely consequence of high-
glucose-mediated PKC activation in proximal tubule cells, which has been shown to 
inhibit rodent but not human SGLT1 (Ohta et al., 1990;Hediger and Rhoads, 
1994;Ishii et al., 1998).  Additionally, a high glucose concentration in tubular fluid 
induces oxidative stress which inhibits SGLT activity in renal proximal tubule cells 
(Han et al., 2005). 
 
Albertoni Borghese et al found a decrease in SGLT2 protein and α-methylglucose 
uptake in short-term 3 and 7 day, but not 2 week, type I diabetic animals (Albertoni 
Borghese et al., 2009).  Although the early elevation in glucose transport may mediate 
protection of renal proximal tubules against glucose-induced cell damage, this 
contradicts data showing an increase in SGLT2 mRNA in alloxan-induced type I 
diabetes which is normalised after insulin treatment (Vestri et al., 2001;Freitas et al., 
2008).  Both SGLT1 and SGLT2 are up-regulated in proximal tubule cells from type 
II diabetic patients and Zucker diabetic rats (Rahmoune et al., 2005;Tabatabai et al., 
2009).  Increased sodium-dependent renal glucose transport was noted in 
experimental hypertension (Ikari et al., 2001); this raises the possibility that the 
transport response to diabetes may be a side-effect of the disease and not a direct 
effect of raised plasma glucose levels.   
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5.7.2.1.4.2 Involvement of PKC in glucose transporter expression 
 
Five of the twelve known protein kinase C (PKC) isoforms, PKC-α, -βI, -βII, -δ and -
ε, are detected in the proximal tubule; PKC-α and -βI are both expressed at high levels 
at the BBM of the S2/S3 segment of the proximal tubule (Dong et al., 1991;Pfaff et 
al., 1999;Kang et al., 1999) where, interestingly, PKC-α, -βI and -ε are up-regulated 
in proximal tubule cells from STZ-induced type I diabetic rats (Kang et al., 
1999;Hsieh et al., 2006).  In 1988, Hise et al suggested a role for PKC in the control 
of nutrient transport across the proximal tubule BBM (Hise and Mehta, 1988).  An 
elevation in PKC activity at the proximal tubule BBM in rats was seen during growth 
accompanied by a decrease in cytoplasmic PKC activity, implying a movement of the 
enzyme from an intracellular to BBM location; furthermore PKC activity at the 
proximal tubule BBM has been shown to be elevated in STZ-induced type I diabetes 
(Hise et al., 1988;Hise and Mehta, 1988).  PKC activity has been found to affect 
proline transport and the Na
+
/H
+
-exchanger at the proximal tubule BBM, as well as 
glucose transport (Weinman et al., 1989;Pahlavan et al., 1993;Zelikovic et al., 
1995;Goestemeyer et al., 2007).  Type I diabetes is associated with raised cytoplasmic 
levels of calcium (Ca
2+
) in proximal tubule cells due to the increased expression of L-
type Ca
2+
 channels at the proximal tubule BBM which may be due to high luminal 
glucose concentrations (Marcinkowski et al., 1997;Park et al., 2001). 
 
Goestemeyer et al have comprehensively shown the relationship between glucose 
transport and PKC-βI at the proximal tubule BBM (Goestemeyer et al., 2007).  In 
response to either the stimulation of PKC by phorbol myristate acetate (PMA), or the 
release of Ca
2+
 from intracellular stores, via thapsigargin, the rate of GLUT-mediated 
glucose transport, at the proximal tubule BBM, was elevated whereas no effect was 
seen on SGLT-mediated glucose transport.  Furthermore, the study shows that PKC-
βI was the only PKC isoform to be significantly up-regulated at the proximal tubule 
BBM in response to STZ-induced type I diabetes, an effect which was reversed by 
reducing blood glucose levels to normal by overnight fasting or administration of 
nicotinamide.  Thus, PKC-βI showed a strong positive correlation with both plasma 
glucose levels and GLUT2 expression at the proximal tubule BBM.  Therefore, in 
diabetes-induced hyperglycaemia, elevated tubular fluid glucose concentrations might 
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result in recruitment of the high-capacity GLUT2 to the proximal tubule BBM, in a 
PKC-βI-dependent manner, leading to increased glucose entry into the cell (Figure 
5.5) (Goestemeyer et al., 2007). 
 
Figure 5.5 – Schematic diagram of the sugar transporters involved in glucose 
reabsorption across the proximal tubule cell during diabetes.  The high plasma glucose 
concentration, occurring in diabetes, results in an elevated tubular fluid glucose load, 
thus SGLT-mediated glucose transport is saturated and GLUT2 is recruited to the 
proximal tubule BBM, likely due to PKC-βI-mediated signalling. (Figure adapted 
from (Marks et al., 2003;Goestemeyer et al., 2007)).     Glucose molecule      sodium 
ion       potassium ion. 
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5.7.2.2 Other factors affecting renal glucose transport 
 
Many other factors apart from hyperglycaemia and diabetes have been shown to 
influence expression of GLUT2 and SGLT in the kidney cortex, some of which are 
outlined below.  Renal denervation, to cause sympathetic hypoactivity, induced a 
reduction in renal sympathetic nervous activity which caused a decrease in renal 
cortical GLUT2 expression (Schaan et al., 2005).  Conversely, the same study 
observed an elevation in GLUT2 expression in the renal cortex in spontaneously 
hypertensive rats, a model to assess sympathetic hyperactivity.   
 
Another disease model which influences expression of GLUT2 is the X-linked renal 
tubular disorder, Dent’s disease; mice lacking the gene for the chloride channel ClC5, 
developed glycosuria as a result of depressed renal GLUT2 expression (Souza-
Menezes et al., 2007). 
 
Renal expression of GLUT2 can also be modulated by severe inflammation with a 
reduction in transporter expression after the injection of lipopolysaccharides (LPS), an 
effect which is abolished by glucocorticoid treatment (Schmidt et al., 2007).  Indeed 
transcription of the serum and glucocorticoid-inducible kinase 1 (SGK1) is stimulated 
by both high glucose concentrations and diabetes (Lang et al., 2000;Saad et al., 2005).  
SGK1 stimulates proximal tubule glucose reabsorption in type I diabetic mice via an 
increase in SGLT1 activity (Ackermann et al., 2009). 
 
PKC signaling strongly influences SGLT activity, which is likely to be mediated by 
the PKC-binding site in rabbit renal SGLT1 (Chalumeau et al., 1999).  The 
vasoconstrictor angiotensin II inhibits SGLT1 and SGLT2 expression and glucose 
transport activity via a PKC-MAPK-cPLA2 signal cascade whereas adenosine binding 
to its receptor causes a PKC-dependent stimulation of sodium-dependent glucose 
transport in opossum kidney (OK) cells (Coulson et al., 1991;Han et al., 2004).   
 
The transcription factor hepatocyte nuclear factor 1α (HNF1α) has been shown to 
influence levels of glucose transporters in the proximal tubule; HNF1α KO mice 
exhibit impaired proximal tubule reabsorption of glucose (Pontoglio et al., 1996).  
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Freitas et al found that HNF1α and 3β transcription factors were important in the 
modulation of renal GLUT2 gene expression (Freitas et al., 2009).  The group noted 
that increases in GLUT2 mRNA in diabetes were mirrored by elevations in HNF1α 
and 3β whereas the reduction in GLUT2 gene expression in response to insulin 
therapy resulted in a down-regulation of the HNF transcription factors.  Interestingly, 
HNF1α has also been shown to affect renal SGLT2 by binding DNA that encodes the 
sodium-dependent glucose transporter (Freitas et al., 2008).  In diabetes, increased 
levels of both SGLT2 and HNF1α mRNA expression has been attributed to raised 
binding of nuclear proteins to the HNF1α consensus site; this response is likely to be 
mediated by plasma glucose since modulation of glycaemia by either phlorizin or 
insulin, resulted in normalised expression of SGLT2 and HNF1α mRNA (Freitas et 
al., 2008). 
 
5.8 Glucose absorption across the small intestine 
 
There are many similarities between glucose reabsorption across the proximal tubule 
and glucose absorption in the small intestine, for example the same GLUT and SGLT 
glucose transporter families mediate glucose uptake in both tissues. However in 
contrast to the kidney, intestinal glucose transport is influenced by dietary 
carbohydrate intake; indeed, dietary sugars provide a large proportion of the daily 
energy requirement of the body and therefore contribute strongly to glucose 
homeostasis.  Intestinal glucose absorption has been studied to a greater degree then 
renal glucose reabsorption.  Furthermore, the regulation of glucose absorption in the 
small intestine is important as dysregulation can occur in metabolic diseases such as 
diabetes.   
 
The majority of studies on glucose transport in the small intestine are centred on the 
jejunum; this region is the principal site of absorption of carbohydrate digestion 
products.  Furthermore, the jejunum is also involved in the terminal stages of 
digestion, for example dissacharidases such as maltase are present at the BBM of the 
jejunum (Ferraris and Diamond, 1992;Jang et al., 2000).  
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5.8.1 Before a meal 
 
Figure 5.6 shows the classical model of glucose absorption across the enterocyte.  
Before a meal, when luminal glucose concentration is low, the sodium-dependent 
glucose transporter SGLT1 found at the jejunal BBM is responsible for glucose 
uptake (Kellett and Brot-Laroche, 2005).  The high-affinity SGLT1 scavenges glucose 
from the lumen and cotransports sugar, against its concentration gradient, into the 
enterocyte with two Na
+
.  Glucose exit from the enterocyte, across the BLM, is 
mediated by the facilitative glucose transporter GLUT2 (Thorens et al., 
1990;Cheeseman, 1993).  Under conditions of low luminal glucose concentrations, 
GLUT2 is also present at the jejunal BBM but in very low levels, furthermore, 
GLUT2 expression is abolished following an overnight fast (Gouyon et al., 2003).  
The intrinsic activity of GLUT2 at the jejunal BBM, under basal conditions, is low 
and therefore any glucose transported by the facilitative glucose transporter is rapidly 
utilised via the enterocyte glycolytic pathway (Levine et al., 1982). 
 
5.8.2 Following a meal  
 
There is an elevation in glucose uptake following either short-term luminal exposure 
to glucose or the feeding of a high-carbohydrate diet.  Early studies by Windmueller 
& Spaeth showed that the jejunum of fed rats absorbed 97% of glucose perfused 
through the lumen (Windmueller and Spaeth, 1980).  Transport studies showed that an 
increase in luminal glucose in vivo for 30 minutes caused an enhanced SGLT1-
mediated glucose uptake, implying a dynamic response of the jejunum to manage 
dietary carbohydrates (Sharp et al., 1996).  Karasov & Debnam found a 60% increase 
in carrier-mediated glucose absorption in the jejunum following exposure to luminal 
glucose, an effect not seen in other segments of the small intestine (Karasov and 
Debnam, 1987).  Furthermore high-carbohydrate feeding over several days has been 
shown to stimulate intestinal glucose uptake (Figure 5.6) (Diamond et al., 
1984;Solberg and Diamond, 1987). 
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Figure 5.6 – Schematic diagram of the sugar transporters involved in glucose absorption across the enterocyte before and after a meal.  A: Before a 
meal, where little or no dietary carbohydrate is present in the jejnual lumen, SGLT1 scavenges glucose from the lumen into the cell whilst GLUT2 and 
PKC-βII are expressed at very low levels at the BBM.  At the BLM, GLUT2 balances glucose levels between the enterocyte and the blood.  B: After a 
meal, raised luminal carbohydrates lead to increased glucose concentration at the BBM.  This saturates SGLT1 and results in trafficking of GLUT2 to 
the BBM; in this position, GLUT2 transports the high load of glucose from the lumen into the cell (Figure adapted from (Kellett and Brot-Laroche, 
2005)).        Glucose molecule                  carbohydrate molecule       sodium ion         potassium ion           BBM hydrolase. 
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5.8.2.1 Breakdown of carbohydrates at the enterocyte BBM 
 
Before they can be absorbed by the enterocyte, dietary carbohydrates are broken down by the 
action of luminal followed by membrane-bound hydrolytic enzymes, such as the intestinal 
BBM dissacharidases, isomaltase and sucrase, into the monosaccharides D-glucose, D-
galactose and D-fructose (Goda et al., 1999;Kishi et al., 1999).  Dietary fructose has been 
shown to modulate activity of dissacharidases; Goda et al found that ingestion of a high-
starch diet elevates sucrase and lactase activity in the lower jejunum (Goda and Takase, 
1994).  Early studies showed that, following feeding, glucose concentration in the jejunal 
lumen reaches 50 mM in the rat and 75 mM in humans (Borgstrom et al., 1957;Murakami et 
al., 1977).  However more recent studies by Ferraris et al have found more conservative 
concentrations of free glucose in the jejunal lumen of the rat, with ranges from 16-28 mM 
with peak postprandial concentrations reaching 48 mM (Ferraris et al., 1990). 
 
5.8.2.2 Sodium-dependent glucose absorption into the enterocyte 
 
The KT for the phlorizin-sensitive component of intestinal glucose transport, indicative of 
SGLT1-mediated transport, has been reported to be 4 mM measured in vitro (Debnam et al., 
1988).  However, in vivo studies have found the value to be 20 mM; thus SGLT1-mediated 
glucose transport becomes saturated at levels lower than the postprandial glucose 
concentration in the lumen (Debnam et al., 1988).  At these concentrations, a diffusive 
component of glucose transport has been identified which, unlike SGLT-mediated transport, 
is non-saturable, phlorizin-insensitive and non-electrogenic, and was originally believed to 
represent paracellular movement (Kimmich, 1973;Murer and Hopfer, 1974;Debnam and 
Levin, 1975;Pappenheimer and Reiss, 1987;Pappenheimer, 1993).  However the localisation 
of the facilitative glucose transporter GLUT2 and the elucidation that it was present at the 
intestinal BBM of STZ-induced type I diabetic rats led to the understanding that the diffusive 
component of glucose transport was GLUT2-mediated (Chowrimootoo et al., 1992;Corpe et 
al., 1996;Kellett, 2001).        
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5.8.2.3 GLUT2-mediated glucose absorption and its regulation 
 
Following perfusion of jejunal loops with 75 mM glucose, GLUT2-mediated glucose 
absorption reaches a steady-state within 15 minutes; in fact, GLUT2 trafficking to and from 
the jejunal BBM can occur with a half-life time of 3.5 minutes (Kellett and Helliwell, 
2000;Helliwell et al., 2003).  Furthermore an elevation in GLUT2 transporter levels, at the 
jejunal BBM was seen with increasing luminal glucose concentrations (Kellett and Helliwell, 
2000).  At high glucose concentrations, approximately 75% of absorption was GLUT2-
mediated (Kellett et al., 2008).  Interestingly, the inhibition of SGLT1, with phlorizin, has 
been shown to down-regulate jejunal GLUT2-mediated transport (Kellett and Helliwell, 
2000).  As the luminal glucose concentration decreases, GLUT2 is trafficked away from the 
BBM to restore basal low levels of the transporter (Kellett and Brot-Laroche, 2005).   
 
The insertion of GLUT2 into the BBM is regulated not only in the short-term, by high 
luminal glucose, but also by long-term dietary changes.  Wild type mice receiving a complex 
diet of low-glycaemic index carbohydrates were found to have reduced GLUT2 expression at 
the BBM (Gouyon et al, 2003).  In the same study, mice given a diet that was rich in high-
glycaemic index carbohydrates were shown to have increased expression of GLUT2 at the 
intestinal BBM and augmented plasma glucose levels, thus indicating the role of the 
facilitative transporter in glucose absorption from lumen to circulation. 
 
5.8.2.4 PKC-βII and calcium signalling 
 
The influence of SGLT-mediated glucose transport on expression of GLUT2 at the jejunal 
BBM has been well-established; studies have shown that PKC-βII modulates this effect. 
 
PKC-βII is regulated by SGLT-mediated glucose transport and the recruitment of GLUT2 to 
the jejunal BBM correlates with PKC-βII activation (Helliwell et al., 2000;Kellett and 
Helliwell, 2000).  PKC-βII is activated by increased levels of intracellular Ca2+, which cross 
the BBM via Cav1.3, the L-type calcium channel at the jejunal BBM (Morgan et al., 
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2003;Morgan et al., 2007).  In addition to PKC-βII activation, Ca2+ absorption depolarises the 
BBM causing the recruitment of GLUT2 to the membrane where it up-regulates glucose 
absorption (Hug and Sarre, 1993;Morgan et al., 2007).  Thus after a meal, the large 
transepithelial gradient causes Ca
2+
 transport across the BBM, via Cav1.3, leading to elevated 
glucose absorption.  In addition, high cellular Ca
2+
 levels activate the myosin light chain 
kinase (MLCK); MLCK mediates phosphorylation of the regulatory light chain (RLC20) of 
myosin II within the perijunctional actomysin ring and results in cytoskeletal rearrangement 
(Turner et al., 1999;Berglund et al., 2001;Clayburgh et al., 2004).  The movements in the 
cytoskeleton assists the translocation of GLUT2 from intracellular vesicles to the intestinal 
BBM (Figure 5.7) (Mace et al., 2007). 
 
Figure 5.7 – Original model of the regulation of GLUT2 recruitment to the enterocyte BBM:  
SGLT1-mediated glucose transport at the enterocyte BBM causes membrane depolarisation; 
as a result, the calcium channel Cav1.3 is activated and an elevation in uni-directional calcium 
influx occurs.  The rise in intracellular calcium stimulates the myosin light chain kinase 
(MLCK) which stimulates rearrangement of the terminal web and cytoskeleton; these events 
are known to stimulate the movement of GLUT2-containing vesicles to the enterocyte BBM 
via PKC-II activation (Figure adapted from (Morgan et al., 2007;Mace et al., 2007)).   
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5.8.3 Sweet taste receptors in the enterocyte 
 
The absorption of Ca
2+ 
across the BBM reaches maximal levels at 20 mM glucose, when 
GLUT2 levels are unchanged at the BBM, whereas at glucose levels above 20 mM, GLUT2-
mediated absorption is unaffected by increasing luminal calcium levels (Morgan et al., 
2003;Mace et al., 2007).  Therefore, although luminal calcium is a necessary signal, there is a 
second downstream signal required for GLUT2 insertion at the jejunal BBM which operates 
at higher glucose concentrations than those influencing Ca
2+
 movement.  
 
Studies to elucidate the second signal required to recruit GLUT2 to the jejunal BBM 
implicate sweet taste receptors, members of the G-protein-coupled receptor family.  These 
taste sensors T1R2 and T1R3 form a sweet taste heterodimer T1R2/3, that detects simple 
sugars, sweet proteins and artificial sweeteners (Nelson et al., 2001;Li, 2009).  The glucose 
concentration range of the second pathway for GLUT2 expression at the enterocyte BBM 
matches that for T1R2/3 activation in response to simple sugars (Li et al., 2002;Mace et al., 
2007).  Furthermore, studies indicate the presence of a luminal sugar sensor located at the 
BBM which is able to initiate a signalling pathway, independent of glucose metabolism, to 
cause enhanced SGLT1 expression in the small intestine (Dyer et al., 2003). 
 
The components of the sweet taste heterodimer, and its major signalling molecule, the 
gustducin α-subunit, have been located along the length of the mouse and rat small intestine 
(Hofer et al., 1999;Dyer et al., 2005).  However there remains some controversy over the 
location of sweet taste receptors in the small intestine; Mace et al identified the clear 
distribution of receptors on the enterocytes, brush cells and Paneth cells whereas Margolskee 
et al noted expression solely on enteroendocrine cells (Mace et al, 2007; Margolskee et al, 
2007). These discrepancies may be due to the differing artificial sweeteners used to elicit a 
response and the varying antibodies used to study localisation.  Margolskee et al found that 
both sugars and non-metabolisable artificial sweeteners promoted SGLT1 expression and 
caused a cAMP-dependent rise in glucose absorption across the BBM which was absent in 
T1R3 or Gα-gustducin KO mice (Dyer et al., 2003;Margolskee et al., 2007).  Stearns et al 
found that both fructose and glucose were able to stimulate SGLT1 expression, despite the 
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transporter being unable to transport fructose (Stearns et al., 2010).  Furthermore this effect 
was also seen using artificial sweetener saccharin, with the response occurring after 3 hours, 
similar to the time needed for SGLT1 synthesis (Stearns et al., 2010).   
 
In contrast, up-regulation of GLUT2 at the jejunal BBM, at low glucose concentration 
required only 15 minutes exposure to 1 mM sucralose; this was similar to that seen following 
a high luminal glucose load (Mace et al., 2007).  Within this short time frame, SGLT1 
expression was unaffected by exposure to the artificial sweetener (Mace et al., 2009;Stearns 
et al., 2010).  The artificial sweeteners saccharin and acesulfame K are also able to increase 
GLUT2 recruitment to the BBM, as well as GLUT2-mediated glucose absorption, in parallel 
with elevated levels of cellular calcium (Li et al., 2002;Mace et al., 2007).      
 
Although the effects of T1R2/3 activation on SGLT1 need further studies, the effect on 
GLUT2 recruitment to the jejunal BBM has already been hypothesised.  Mace et al propose 
that the activation of T1R2/3 by high glucose concentrations or low artificial sweetener plus 
low glucose concentration, results in the conversion of GDP to GTP and thus the dissociation 
and release of α-gustducin from its G-protein heterodimer and into the cytoplasm (Figure 5.8) 
(Mace et al., 2009).  The remaining BBM-bound βγ-subunits of the G-protein activate 
PLCβ2, resulting in movement of inactive PLCβ2 to the BBM; this results in the IP3-
dependent production of DAG, a messenger molecule which activates PKC-βII (Stehno-Bittel 
et al., 1995;Huang et al., 1999;Rhee, 2001).  Although intracellular calcium is able to 
promote PKC-βII insertion at the BBM, the generation of DAG, via PLCβ2 activation, results 
in complete activation of PKC-βII which stimulates GLUT2 insertion at the jejunal BBM 
(Helliwell et al., 2000;Helliwell et al., 2000;Wright et al., 2003;Helliwell et al., 2003).   
 
Another consequence of T1R2/3 activation is the release of cAMP.  Cytosolic α-gustducin, 
released from the G-protein heterodimer, activates adenylyl cyclase causing an elevation in 
cAMP (Gilbertson et al., 2000;Bezencon et al., 2007).  This may explain the longer term 
cAMP-mediated synthesis of SGLT1 (Stearns et al., 2010).  Thus it is likely that the rapid 
induction of GLUT2 in response to stimulation by artificial sweeteners is PLCβ2-mediated, 
unlike the longer-term alterations in SGLT1 synthesis which are cAMP-mediated.             
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Figure 5.8 – The signalling cascade activated by the stimulation of the sweet taste 
heterodimer; on binding of simple sugars or artificial sweeteners to T1R2/3, the gustducin 
heterodimer converts GDP to GTP and the α-gustducin subunit is released into the cytoplasm 
whereas the βγ-subunits remain membrane-bound.  The dissociation of the gustducin 
heterodimer activates phospholipase β2 (PLCβ2) which stimulates the activation of PKC-βII 
at the enterocyte BBM (Figure adapted from (Stehno-Bittel et al., 1995;Rhee, 2001;Mace et 
al., 2009)) 
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5.8.4 Revised model of glucose absorption across the enterocyte 
 
Therefore the original model for regulation of glucose absorption across the enterocyte BBM 
has been updated and is shown in Figure 5.9.  In addition to causing cytoskeletal 
rearrangement, which results in the release of GLUT2 from the terminal web, Ca
2+
 
accumulation within the enterocyte also stimulates a common cellular pool of PKC-βII to 
translocate to the BBM.  In this location, PKC-βII needs to be activated; sweet taste receptor 
agonists such as artificial sweeteners or simple sugars, at critical concentrations are able to 
activate T1R2/3.  This causes an α-gustducin-mediated signalling pathway resulting in 
PLCβ2-dependent DAG generation, which phosphorylates PKC-βII.  In this active state, the 
protein kinase isoform is able to recruit GLUT2 from cellular vesicles to the BBM.  This 
signalling pathway enables the enterocyte to rapidly modulate the process of glucose 
absorption in response to changes in dietary carbohydrate load.   
 
The implications of the involvement of sweet taste receptors are vast, especially in light of 
the widespread use of artificial sweeteners and HFCS in the western diet, outlined in section 
5.4.1 and 5.4.2.  The consumption of a high-fructose meal results, within minutes, in the 
trafficking of GLUT2 to the enterocyte BBM and is a far more effective stimulant than 
sucrose or glucose (Gouyon et al., 2003).  Thus the rapid elevation in a high-capacity process 
for glucose absorption, following stimulation of the intestinal sweet taste receptor 
heterodimer, provides an explanation for the excess weight gain and onset of type II diabetes 
noted in response to consumption of HFCS and artificial sweeteners (Stellman and Garfinkel, 
1986;Fowler et al., 2008;Swithers et al., 2010;Bocarsly et al., 2010;Hu et al., 2010).   
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Figure 5.9 – Revised model of the regulation of GLUT2 recruitment to the enterocyte BBM, mediated by sweet taste receptors and intracellular calcium.  Diagram 
on the left shows the recruitment of PKC-βII to the enterocyte BBM via calcium influx into the cell, however the activation of PKC-βII requires a secondary 
stimulus from sweet taste receptor activation.  Diagram on the right shows, on stimulation, the PLCβ2-dependent activation of PKC-βII causes the recruitment of 
GLUT2 to the enterocyte BBM (Figure adapted from (Mace et al., 2009)) 
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5.8.5 Glucose transport at the small intestine in diabetes 
 
Abnormal regulation of intestinal glucose transporters occurs in response to metabolic 
diseases such as insulin-dependent and non insulin-independent diabetes, as well as 
insulin-resistant models such as obesity and metabolic syndrome.  These conditions 
can result in elevated glucose delivery to the blood which will exacerbate 
hyperglycaemic conditions. 
 
Both type I and type II diabetes increase the rate of glucose absorption; this correlates 
with the increased activity of the dissacharidases and α-glucosidases as well as 
hyperplasia and hypertrophy of the intestinal epithelium (Stenling et al., 
1984;Debnam et al., 1990;Zoubi et al., 1995;Fujita et al., 1998;Adachi et al., 2003).  
Thus the small intestine adapts to diabetes via increased hydrolysis of carbohydrates, 
as well as elevated recruitment of brush-border glucose carriers, which has been 
shown to occur in the enterocytes in the midvillus-to-tip region (Fedorak et al., 1991).  
In fact, the trafficking of glucose transporters has been shown in both type I diabetes 
and hyperglycaemia induced by IV glucose infusion (Maenz et al, 1986). 
  
BBM hyperpolarisation, as a result of decreased Na
+
 permeability, occurs in early 
type I diabetes and increases the driving force for SGLT1-mediated glucose transport 
(Debnam et al., 1988;Sharp et al., 1997).  In agreement with this data, up-regulation 
of SGLT1 mRNA, protein and capacity for glucose transport has been established at 
the enterocyte BBM in type I diabetes (Debnam et al., 1990;Fedorak et al., 
1991;Ferraris et al., 1993;Burant et al., 1994;Sharp et al., 1997).  A possible signal 
for this up-regulation has been presented by Wong et al, who suggested that a down-
regulation of the RAS in type I diabetes reduces the inhibitory effect of angiotensin II 
on SGLT1, culminating in an increase in SGLT-mediated glucose transport (Wong et 
al., 2009).   
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The elevated SGLT1 expression is paralleled by augmented GLUT2 levels at both the 
BBM and BLM in type I diabetes and hyperglycaemia induced by IV infusion of 
glucose (Csaky and Fischer, 1981;Corpe et al., 1996;Le et al., 2007;Wong et al., 
2009).  However, prolonged type I diabetes is associated with decreased GLUT2 
expression at the BLM (Burant et al., 1994;Wong et al., 2009).  In addition, 
expression of both GLUT1 and GLUT5 at the BBM are up-regulated in diabetes, with 
levels of GLUT5 at the BLM also elevated (Burant et al., 1994;Boyer et al., 
1996;Corpe et al., 1996).  Corpe et al found a reduction in intestinal fructose uptake 
measured in vivo in type I diabetes (Corpe et al., 1996); this discrepancy between 
GLUT5 expression and fructose uptake studies during diabetes requires further 
investigation.   
 
In contrast to type I diabetes, far fewer studies have been performed on insulin-
independent diabetes.  However, it is known that type II diabetic patients exhibit 
increased expression of SGLT1 and GLUT5 transporters at the enterocyte BBM and 
up-regulated GLUT2 mRNA expression (Dyer et al., 2002). 
 
In response to insulin secretion following a meal, the insulin receptor at the enterocyte 
BLM is activated; this signals the internalisation GLUT2 from both the BBM and 
BLM of the enterocyte and thus limits glucose absorption from the diet (Buts et al., 
1997;Tobin et al., 2008).  However, in diabetes, this protection mechanism to prevent 
excess glucose absorption following a carbohydrate-rich meal is overridden by 
elevated expression of GLUT2 at the BBM, resulting in hyperglycaemia.  Insulin 
resistance, induced via high-fructose feeding, results in the loss of control of GLUT2 
trafficking and therefore GLUT2 is permanently expressed at the BBM, an effect 
which was unchanged by overnight fasting or IV infusion of insulin (Tobin et al., 
2008).   
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5.8.5.1 Other regulators of intestinal glucose absorption  
 
In addition to the effects of hyperglycaemia on glucose absorption specific regulators 
of glucose transporters at the BBM and BLM of the enterocyte have been postulated.   
 
5.8.5.1.1 Flavonoids 
 
The flavonoid quercetin has been shown to abolish GLUT2 overexpression at the 
BBM and non-competitively inhibit GLUT2-mediated glucose and fructose transport 
(Kwon et al., 2007).  Additionally, the administration of quercetin and glucose to 
Zucker diabetic rats significantly blunted postprandial hyperglycaemia (Song et al., 
2002).  Thus quercetin could represent a therapeutic method for reducing sugar 
absorption in metabolic syndrome and type II diabetes (Mooradian and Thurman, 
1999).      
  
5.8.5.1.2 Stages of development 
 
During the first 24-30 days of age, until the completion of weaning, a low abundance 
of GLUT5 has been noted in rat enterocytes; however if fed a high-fructose diet, 
animals show increased GLUT5-mediated fructose absorption at a younger age 
(Davidson et al., 1992;Castello et al., 1995;David et al., 1995;Shu et al., 1997;Reimer 
et al., 1997).  In contrast, SGLT1 levels at the BBM remain constant from birth with 
no early postnatal developmental changes (Buddington and Diamond, 1989;Shu et al., 
1997;Jiang et al., 2001).  Intestinal GLUT2 mRNA is expressed on day 16 after 
conception and expression remains constant in the neonatal and adult rat with the 
transporter induced by both luminal glucose and fructose (Cui et al., 2003). 
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5.8.5.1.3 Stress 
 
Environmental stress on rats has been found to reduce GLUT2-mediated glucose 
absorption across the enterocyte BBM, without influencing SGLT1 expression or 
SGLT-mediated glucose transport (Shepherd et al., 2004).  In addition, the technique 
employed to study glucose absorption can influence GLUT2-mediated glucose 
transport.  Helliwell et al found that high-perfusion rates during experimentation can 
alter GLUT2-mediated glucose absorption (Helliwell and Kellett, 2002).  This may be 
an explanation of why the GLUT2 component of glucose uptake is more readily 
detected using in vivo rather than in vitro techniques.  Interestingly, water avoidance 
stress, inflicted by placing rats on a platform surrounded by water for 1 hour a day, 
resulted in elevated GLUT2 abundance and glucose transport across the enterocyte 
BBM (Boudry et al., 2007).  However, in this model of psychological stress, SGLT-
dependent glucose absorption at the enterocyte BBM was down-regulated (Boudry et 
al., 2007).  
 
Chronic starvation in rats caused an increase in SGLT-mediated glucose absorption 
across the BBM, to enable more efficient uptake of glucose from low levels of 
glucose within the lumen (Habold et al., 2005).  Upon refeeding, GLUT2 levels at the 
BBM increased rapidly to enable efficient glucose absorption from higher levels 
within the lumen. 
 
5.8.5.1.4 AMPK 
 
Under metabolic stress, such as energy depletion in long-term starvation, the AMP-
activated protein kinase (AMPK) is activated by AMP-binding, as well as via ATP-
independent signalling pathways (Stein et al., 2000;Kemp et al., 2003).  The 
activation of AMPK resulted in an elevation in net glucose transport, across the 
jejunum, which was GLUT2-mediated (Walker et al., 2003).  A recent study by 
Sopjani et al showed that AMPK-stimulated Na
+
-coupled glucose transport occurred 
in Xenopus oocytes and elevated SGLT1 expression at the BBM of Caco-2 cells 
(Sopjani et al., 2010).  The augmentation of SGLT1-mediated glucose transport 
  
  96 
occurred despite the low cellular ATP levels available to drive the basolateral Na
+
/K
+
-
ATPase (Woollhead et al., 2007;Vadasz et al., 2008).   
 
Interestingly, the activation of AMPK also maintains glucose homeostasis in many 
tissues; therefore, AMPK activators, such as amino imidazole carboxamide 
ribonucloetide (AICAR), have been proposed as effective treatment in metabolic 
disorders.  Indeed PPARγ activators rosiglitazone and pioglitazone, which activate 
AMPK by elevating the intracellular AMP:ATP ratio, are current drugs in the 
treatment of type II diabetes (section 5.2.5.2.1) (Fryer et al., 2002;Saha et al., 2004).   
 
5.8.5.1.5 RELMβ 
 
Resistin-like molecule β (RELMβ) is released from adipocytes to impair insulin 
signalling via MAPK activation and influences lipidaemia and inflammation; thus the 
regulation of RELMβ has been indicated in obesity, metabolic syndrome and type II 
diabetes (Steppan et al., 2001;Kushiyama et al., 2005;Kusminski et al., 2005).  
RELMβ is also expressed in the small intestine where it effects goblet cell secretion 
and is strongly influenced by nutrient intake (Gerstmayer et al., 2003).  In response to 
a high-carbohydrate diet, RELMβ expression is down-regulated whereas RELMβ 
expression is up-regulated by insulin treatment (Fujio et al., 2008).  Interestingly, 
RELMβ is also up-regulated in high-fat fed or type II diabetic rat models (Shojima et 
al., 2005).   
 
Krimi et al reported that oral administration of RELMβ resulted in hyperglycaemia 
caused by augmented GLUT2-mediated glucose absorption across the jejunal BBM; 
interestingly, the accompanying elevation in GLUT2 expression at the BBM was 
associated with PKC-βII activation and AMPK phsophorylation (Krimi et al., 2009).  
In contrast, the study also showed a reduction in SGLT1 abundance and SGLT-
mediated glucose transport at the jejunal BBM in response to luminal exposure to 
RELMβ (Krimi et al., 2009).  Thus RELMβ in the lumen of the small intestine 
elevates glucose absorption, whereas high-glucose in the lumen down-regulates 
intestinal expression of RELMβ.    
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5.8.5.1.6 Hormones 
5.8.5.1.6.1 Incretin hormones 
 
Incretins are gut-derived hormones which have been found to exhibit regulation of 
glucose absorption.  Nutrient intake and delivery are the primary stimulators of 
incretin secretion, with glucose being one of the most potent stimulators in the release 
of the enteric hormones GLP-1 and GIP (Roberge and Brubaker, 1991;Elliott et al., 
1993;Rocca and Brubaker, 1999;Holst, 2007;Tolhurst et al., 2009).    
 
In response to an oral glucose load, GIP and GLP-1 levels are elevated but not in 
response to plasma glucose stimulus, therefore there is a luminal sensor for glucose 
which triggers incretin secretion (Unger et al., 1968).  SGLT1-dependent glucose 
transport stimulates the release of GLP-1 and GIP (Cheeseman, 1997). 
 
GLP-2, another incretin, promotes SGLT1 expression at the small intestinal BBM 
within an hour (Cheeseman, 1997).  Circulating GLP-2 also increases GLUT2-
mediated transport at the BLM (Cheeseman and Tsang, 1996;Cheeseman and O'Neill, 
1998).  Au et al showed that levels of GLUT2 at the jejunal BBM are augmented in 
response to circulating GLP-2 (Au et al., 2002).  GLP-1 and GLP-2 release from L-
cells in the ileum is promoted by GIP, which is released from K cells, promoted by 
luminal glucose in the duodenum and jejunum (Crouzoulon and Korieh, 1991;Inukai 
et al., 1995;Limb et al., 1997).  Therefore GLP-2 release may require the presence of 
glucose in the intestinal lumen and thus elevated GLUT2-mediated glucose absorption 
occurs in response to secretion of the incretin. 
 
In addition, the effect of incretins on glucose absorption across the BBM may be 
mediated by sweet taste signalling, which has already been described in association 
with jejunal glucose transport (section 5.8.3).  Jang et al found that the taste signalling 
elements involved in sweet taste, such as T1R2, T1R3 and PLC-β2, are co-expressed 
with GLP-1 in duodenal cells (Jang et al., 2007).  Furthermore, the study also showed 
that α-gustducin KO mice display impaired GLP-1 secretion in response to luminal 
glucose with reduced α-gustducin expression causing a decrease in glucose-mediated 
GLP-1 secretion; interestingly, the artificial sweetener sucralose has  been shown to 
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induce GLP-1 secretion from L-cells in a concentration-dependent manner (Jang et 
al., 2007).  Thus the regulation of GLUT2 and SGLT1 expression involves a complex 
feedback pathway with incretin secretion to modulate glucose absorption across the 
enterocyte.  
 
5.8.5.1.6.2 Leptin 
 
Following food consumption, leptin is released from both adipocytes and the stomach, 
into the circulation and small intestine respectively (Zhang et al., 1994;Ahima and 
Flier, 2000;Cammisotto et al., 2007).  The leptin receptor (Ob-R) is expressed at both 
the BBM and the BLM of enterocytes in the small intestine and, on binding with 
luminal leptin, SGLT-1 mediated absorption is rapidly inhibited (Hoggard et al., 
1997;Lostao et al., 1998;Bado et al., 1998).  This response has been suggested to 
delay the entry of sugars into the enterocyte, thus enabling the cell to process glucose 
(Barrenetxe et al., 2004).  In contrast, in vitro studies by Sakar et al showed that 
luminal leptin, acting on the jejunal BBM, elevates the transport activity of GLUT2 
and GLUT5, via Ob-R-coupled activation of PKC-βII (Sakar et al., 2009).  
Furthermore, the group found that consumption of a high-fructose diet triggers the 
release of gastric leptin which up-regulates GLUT2 and GLUT5-mediated fructose 
absorption (Sakar et al., 2009).  Thus further studies are necessary to elucidate the 
physiological relevance of postprandial leptin release on elevated GLUT-mediated 
absorption and down-regulated SGLT-mediated transport across the enterocyte.    
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5.9 Aims of thesis 
 
Diabetic nephropathy occurs as a consequence of hyperglycaemia-induced renal cell 
damage with tubular injury in the disease postulated to be the result of elevated 
GLUT-mediated glucose entry into proximal tubule cells, in a manner similar to that 
seen in mesangial cells (Brosius and Heilig, 2005).  Previous studies have established 
that in type I diabetes PKC-βI-dependent GLUT2 recruitment to the proximal tubule 
BBM occurs as a direct result of hyperglycaemia, resulting in up-regulated glucose 
transport across this membrane (Marks et al., 2003;Goestemeyer et al., 2007).  
However type II diabetes is the prevalent form of the disease in which sufferers 
develop insulin-resistance; therefore type II diabetes presents an interesting model to 
characterise the factors moduliating glucose reabsorption across the proximal tubule 
cell in the presence of a basolateral insulin stimulus.  The development of type II 
diabetes is strongly linked to the current epidemic of obesity and metabolic syndrome; 
consequently, it was important to characterise glucose transport across the proximal 
tubule BBM in rodent models of metabolic dysregulation.  In addition, the novel 
modulation of renal glucose transport across the BBM, by sweet taste receptors, was 
studied using recently characterised mediators of jejunal glucose transport as a model, 
with the aim of identifying targets in the treatment for diabetes. 
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6 Materials and Methods 
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6.1 Short-term intravenous (IV) infusions  
 
Male Sprague-Dawley rats (250-300 g) were anaesthetised with 60 mg.kg
-1
 
intraperitoneal (IP) pentobarbitone sodium (Pentoject, Animalcare Ltd, York, UK) 
and maintained at 37
o
C with a thermostatically-maintained heat blanket (Harvard 
Apparatus Ltd, Kent, UK).  A catheter was placed in the bladder and the jugular vein 
was cannulated for administration of anaesthetic and infusate.  The femoral artery was 
cannulated for blood sample removal, which was assessed for plasma glucose 
concentration. Animals were infused with saline (154 mM NaCl), at a rate of 5.5 
ml.hr
-1
, for 1 hour after cannulations.  After the ‘rest’ period, animals were infused 
with saline or saline with 0.08 M mannitol, 1.09 M mannitol, 1.1 M glucose or 1.37 
mM saccharin for 1 or 2 hours.  2 hour infusions were begun with a 3 ml.min
-1
 bolus 
into the jugular vein.  Blood glucose concentration was measured every 15 minutes 
with Accucheck Active (Roche Diagnostics, West Sussex, UK) and urine was 
collected every 15 minutes to assess urine flow rate and glucose concentration.  At the 
end of the experiment, 2 ml blood was collected from the femoral cannulae, the 
kidneys were harvested, sliced into 2 mm sections and the cortex was dissected away 
for brush border membrane (BBM) vesicle preparation. All procedures were carried 
out in accordance with the Animals (Scientific Procedures) Act 1986. 
 
6.2 Animal models 
6.2.1 Insulin-dependent diabetes mellitus (IDDM) 
 
Type I diabetes was induced in male Sprague-Dawley rats (250-300 g) by 
administering a single tail vein injection of 55 mg.kg
-1
 streptozotocin (STZ) (Sigma, 
Dorset, UK) under halothane anaesthesia (2% halothane in 100% oxygen).  STZ was 
prepared in 0.05 M citrate buffer (pH 4.5) and control animals were administered with 
citrate buffer only.  Animals were allowed ad libitum access to a standard rat chow 
(diet RM1, SDS Ltd, Witham, Essex, UK) and water, until time of experimentation 
(between 2-30 days). For all experimental procedures, animals were terminally 
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anaesthetised with 60 mg.kg
-1
 IP pentobarbitone sodium (Pentoject, Animalcare Ltd, 
York, UK) before cardiac puncture, urine collection and removal of kidneys for BBM 
vesicle preparation and mRNA expression.  All procedures were carried out in 
accordance with the Animals (Scientific Procedures) Act 1986. 
 
6.2.2 Non insulin-dependent diabetes mellitus (NIDDM) 
 
Type II diabetes was studied in the non-obese, non-hypertensive Goto-Kakizaki (GK) 
rat (Goto et al., 1976).  The model was developed spontaneously by the repeated 
inbreeding of glucose-intolerant Wistar rats, over several generations (Charles River, 
USA).  Rats exhibit fasting hyperglycaemia, hepatic and peripheral insulin-resistance 
and polyuria.  
 
Lean Wistar rats and type II diabetic GK rats were used at 8-9 weeks of age and 
allowed ad libitum access to a standard rat chow (diet RM1, SDS Ltd, Witham, Essex, 
UK) and water, until time of experimentation.  For all experimental procedures, GK 
animals were terminally anaesthetised with 60 mg.kg
-1
 IP pentobarbitone sodium 
(Pentoject, Animalcare Ltd, York, UK) before cardiac puncture, urine collection, 
removal of kidneys and small intestine segments for BBM vesicle preparation.  All 
procedures were carried out in accordance with the Animals (Scientific Procedures) 
Act 1986. 
 
6.2.3 High-fat diet 
 
A lipid-rich chow was used as a model of high-fat diet-associated insulin-resistance.  
Wistar rats were allowed ad libitum access to a 60% fat-as-calories chow (Research 
Diets, New Brunswick, USA), over a 5-week period.  Control Wistar animals were 
allowed ad libitum access to a standard rat chow (Lillico, Betchworth, UK) and water, 
over a 5-week period. Animals were housed in cages of 4 and fasted overnight, prior 
to cull; they were terminally anaesthetised with CO2 and decapitated before cardiac 
puncture, urine collection, and removal of kidneys for BBM vesicle preparation.  All 
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procedures were carried out at the Royal Veterinary College with the assistance of Dr. 
M. Cleasby, in accordance with the Animals (Scientific Procedures) Act 1986. 
 
6.2.4 Junk-food diet 
 
Wistar rats were allowed ad libitium access to water and a balanced standard rat chow 
diet (RM3, SDS Ltd, Betchworth, Surrey, UK) in the case of control animals or chow 
and junk-food in the case of experimental animals (Rothwell and Stock, 1979;Bayol 
et al., 2005).  The junk-food diet consisted of an ad libitum choice of palatable, 
processed foods with a high fat and/or high sugar content including muffins, jam 
doughnuts, biscuits, cheese, marshmallows, potato crisps and chocolate bars 
(nutritional information, Table 6.1).  Chow-fed animals consumed 17.5 kcal (73.2 kJ) 
per day whereas the junk-food animals consumed 198 kcal (830.6 kJ). 
 
Table 6.1 - Nutritional Information for chow and junk-food diet given to animals over 
an 8 week period: components of the diet are expressed as a percentage of the total 
diet offered to rats  
 
  Chow Junk-food 
Protein (%)  77.4 4.4 
Carbohydrates (%)  3.7 35.9 
 Of which sugars (%) 2.1 15.4 
Fat (%)  0.8 19.6 
 Of which saturates (%) 15.7 4.6 
Fibre (%)  0.2 1.5 
Sodium (%)  0 18.6 
 
 
Animals were housed in cages of 3.  Daily food intake of both chow and junk-food 
was measured, as well as weekly body weight measurements, for the 8 week 
experimental period.  Unfasted rats were terminally anaesthetised with 60 mg.kg
-1
 IP 
pentobarbitone sodium (Pentoject, Animalcare Ltd, York, UK) before cardiac 
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puncture, urine collection, removal of kidneys for BBM vesicle preparation.  All 
procedures were carried out at the Royal Veterinary College with the assistance of Dr. 
S. Wildman, in accordance with the Animals (Scientific Procedures) Act 1986. 
 
6.2.5 Roux-en-Y Gastric Bypass (RYGB) surgery 
 
Gastric bypass surgery was studied using the RYGB model in control Wistar rats, 
performed by Dr. M Bueter at Imperial College London.  RYGB surgery was 
performed by transecting the stomach close to the junction with the oesophagus to 
create a small gastric pouch which was then anastomosed to a loop of jejunum distal 
to the pylorus in an end-to-side fashion. A small bowel anastomosis was performed 
between the biliopancreatic (duodenum) and alimentary (jejunum) limbs to create a 
common channel.  The sham operation consisted of a laparotomy on the stomach wall 
and jejunum which was subsequently closed.  Both gentamicin and carprofen were 
administered preoperatively as IP for the treatment of post-operative infection and 
pain relief (Bueter et al., 2010). 
 
Animals were maintained for 60 days with ad libitum access to chow and fasted 
overnight, prior to cull.  Rats were terminally anaesthetised with CO2 before cardiac 
puncture, urine collection, and removal of kidneys and small intestine for BBM 
vesicle preparation and analysis of mRNA expression.  All procedures were carried 
out in accordance with the Animals (Scientific Procedures) Act 1986. 
 
6.3 LLC-PK1 cell culture 
 
Porcine renal epithelial LLC-PK1 cells were cultured in Dulbecco's modified Eagle's 
medium, supplemented with 10% fetal bovine serum (FBS), 4 mM glutamine, 0.1 
mg.ml
-1
 streptomycin sulfate and 100 U.ml
-1
 penicillin G.  Cells were maintained at 
37°C in a 5% CO2 atmosphere and, at confluence, washed with ice-cold phsophate-
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buffered saline (PBS) and harvested with RIPA buffer (25 mM Tris HCl, 150 mM 
NaCl, 1% NP-40, 0.1% SDS, protease inhibitors, pH 7.4).  For harvesting, 1 ml of 
RIPA buffer, per 75 cm
2
 flask containing 5 x 10
6
 cells, was added to cells for 5 
minutes on ice.  Cells were then scraped from the flask and centrifuged for 10 minutes 
at 13 000 rpm to pellet cell debris. 
 
6.4 Membrane preparation  
6.4.1 Whole membrane preparation  
 
Whole membrane was prepared from the kidney cortex and jejunal mucosa, from 
male Sprague-Dawley rats and C57BL/6 mice.  Tissue was homogenised three times 
for 20 seconds at setting 5, with an Ultra Turrax homogeniser (Janke & Kunkel, IKA-
Labortechnik, Germany) in buffer (50 mM mannitol, 2 mM HEPES, protease 
inhibitors, pH 7.4) used at 10 ml per 1 g tissue.  Homogenate was centrifuged for 15 
minutes at 3500 rpm and the supernatant fraction was then centrifuged for 30 minutes 
at 10 500 rpm and resuspended in ~ 500 μl buffer using a 21-gauge needle and 
syringe.  All procedures were carried out at 4
o
C. 
 
6.4.2 Renal BBM vesicle preparation 
 
BBM vesicles were prepared using a double Mg
+
 chelation protocol, previously 
described by Biber et al (Biber et al., 1981).  Renal cortical fragments were pooled 
and homogenised for 2 minutes at setting 5, with an Ultra Turrax homogeniser (Janke 
& Kunkel) in 30 ml R1 buffer (300 mM mannitol, 12 mM Tris HCl, 5 mM EGTA and 
protease inhibitors, pH 7.4).  Deionised water (42 ml) was added to the homogenate 
and stirred, on ice, for 15 minutes with 12 mM MgCl2 before centrifugation for 15 
minutes at 4500 rpm.  The supernatant fraction was centrifuged for 30 minutes at 16 
000 rpm and the pellet was re-suspended in 20 ml R2 buffer (150 mM mannitol, 6 
mM Tris HCl, 2.5 mM EGTA and protease inhibitors, pH 7.4) with a hand-held 
Teflon homogeniser.  The re-suspensions were stirred for 15 minutes with 12 mM 
MgCl2 and centrifuged at the low- and high-speed spins outlined above.  The resulting 
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pellet was re-suspended in 20 ml R3 buffer (300 mM mannitol, 12 mM Tris HCl, 2.5 
mM EGTA and protease inhibitors, pH 7.4) with a hand-held Teflon homogeniser. 
The solution was centrifuged for 30 minutes at 16 000 rpm and the pellet re-
suspended in ~ 500 μl R3 buffer using a 21-gauge needle and syringe.  All procedures 
were carried out at 4
o
C. 
 
6.4.3 Small intestinal BBM vesicle preparation 
 
Intestinal segments were opened longitudinally and the mucosa was scraped off the 
small intestine walls using glass slides.  Mucosa was suspended in homogenising 
buffer (50 mM mannitol, 2 mM HEPES and protease inhibitors, pH 7.4) and 
homogenised three times for 20 seconds at setting 5, with an Ultra Turrax 
homogeniser (Janke & Kunkel).  The homogenate was then stirred, on ice, for 20 
minutes with 10 mM MgCl2 before centrifugation for 10 minutes at 6000 rpm.  The 
supernatant fraction was centrifuged for 30 minutes at 18 000 rpm and the pellet was 
suspended in re-suspension buffer (300 mM mannitol, 20 mM HEPES, 0.1 mM 
MgSO4 and protease inhibitors, pH 7.4) by passing six-times through a 21-gauge 
needle.  The re-suspension was centrifuged for 15 minutes at 8500 rpm and the 
resulting supernatant was centrifuged at 18 000 rpm for 30 minutes.  The purified 
BBM pellet was finally re-suspended in resuspension buffer using a 21-gauge needle 
and syringe.  All procedures were carried out at 4
o
C. 
 
The purity of BBM vesicles was assessed using the alkaline-phosphatase assay 
(section 6.7) for BBM enrichment and Bradford assay (section 6.6) for protein 
concentration. 
 
 
 
 
  
  107 
6.5 Renal glucose uptake studies 
6.5.1 Validation of BBM vesicles for glucose uptake studies 
 
To ensure the BBM vesicles were not ‘leaky’ and were able to transport glucose 
effectively, various methods were employed to validate the glucose uptake capacity of 
the vesicles.   
 
6.5.1.1  Intravesicular volume 
 
One such method is the assessment of the intravesicular space of the BBM vesicles. 
This can be established after vesicles have been exposed to 100 μM glucose and 
uptake buffer for 20 minutes.  At this point, the vesicles have reached equilibrium and 
the volume accumulated within the vesicle can be measured using the equation below: 
 
6.5.1.2  Time-dependent overshoot 
 
To verify the ability of BBM vesicles to accumulate glucose, sodium-dependent 
glucose transport was determined at 100 μM glucose concentration, with or without 
phlorizin.  An early peak in glucose uptake has been previously shown (Marks et al., 
2003), where there is a rapid influx in Na
+
 ions into the BBM vesicles.  This SGLT-
mediated Na
+
 uptake co-transports glucose into the vesicles and is blocked by 
phlorizin. 
 
Glucose uptakes were performed on freshly-made renal BBM vesicles, brought up to 
room temperature (20°C) for 10 minutes.  Uptake buffer (200 mM NaSCN, 12 mM 
Tris HCl, pH 7.4), with or without 1 mM phlorizin (Sigma, Dorset, UK) was prepared 
to 100 μM with 3[H] and cold glucose. Glucose uptake was measured at different time 
points from 3 seconds to 20 minutes, at glucose concentration of 100 μM, by adding 
           Glucose uptake (pmol.mg protein
-1
)  
[Glucose] (µM) 
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20 μl of uptake buffer to 20 μl BBM vesicles.  Glucose uptake at each time point was 
terminated with 2 ml ice-cold stop solution (0.5 mM phlorizin in 154 mM saline).  
The solution was then filtered, under vacuum, using 0.45 μm nitrocellulose filters 
(Sartorius, Germany), then washed with 2 ml stop solution three more times. 
Scintillation counting was performed on the filters with the addition of 2.5 ml Ultimo 
Gold (Perkin-Elmer, Cambridge, UK) scintillant, using a Beckman liquid scintillation 
counter LS2000 (Beckman-Coulter Research, Buckinghamshire, UK).   
 
6.5.2 SGLT- and GLUT-mediated glucose uptake 
 
SGLT-mediated glucose uptake was measured at lower glucose concentrations (10 
μM to 958 μM), whilst, GLUT-mediated glucose uptake was assessed at higher 
glucose concentration (20 mM).  The accumulation of these concentrations of 
glucose, by BBM vesicles, was measured in the presence and absence of phloridzin. 
 
Glucose uptakes were performed as described in section 6.5.1.2, except that uptake 
buffer was prepared containing 
3
[H]-glucose with cold glucose concentrations ranging 
from 30 μM to 20 mM, and uptake was measured at 4 seconds only.  Glucose uptake 
was terminated with 2 ml ice-cold stop solution and counted, and calculated, as 
previously described.    
 
6.5.3 Glucose uptake calculations 
 
Disintegrations per minute (DPM) of 
3
[H] in the samples represented the 
accumulation of glucose by the BBM vesicles, whereas DPM of 
3
[H] in the 
background represented non-specific retention of glucose on the filters in the absence 
of BBM vesicles (DPMbackground).  DPM of 
3
[H] in the initial uptake buffer, with 
glucose, was also measured with scintillant (DPMinitial counts). 
 
The counts were converted to uptake (pmol.mg protein
-1
) using the equation below, 
with glucose concentration measured in μM and by doubling the protein concentration 
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(mg.ml
-1
), from section 6.6, to allow for the 1:1 dilution of BBM vesicles in uptake 
buffer. 
 
The kinetic parameters for SGLT-mediated glucose transport between 30 μM to 960 
μM, Vmax (maximum transport capacity) and KT (glucose concentration at half Vmax), 
was calculated using the Lineweaver-Burk plot. 
 
6.6 Determination of protein concentration 
 
Protein concentration of whole membrane, LLC-PK1 cells and BBM vesicle 
preparations was measured using the Bradford assay (Bradford, 1976). This assay is 
based on the absorbance shift of acidic Coomassie Brilliant blue G-250 dye (BDH 
Chemicals Ltd, Poole, UK) from 465 nm, when unbound, to 595 nm, when bound as 
protein-dye complex.  The increase in absorbance, at 595 nm, is proportional to the 
amount of bound dye and therefore the concentration of protein in the sample. 
 
protein + NaOH                       bound protein-dye complex 
                   
Coomassie Brilliant Blue (brown)     
(blue) 
 
Homogenates and BBM vesicles were diluted 1:10 in 0.1 M NaOH and 100 μl of 
stock was measured with 4.5 ml Bradford reagent (0.01% (w/v) Coomassie Brilliant 
Blue G-250, 5% (w/v) ethanol and 10% orthophosphoric acid).  Bovine serum 
albumin (BSA) was used as a protein standard with a concentration range from 15 - 
90 mg.ml
-1
, increasing at 15 mg.ml
-1
 increments, in 0.1 M NaOH; 4.5 ml Bradford 
reagent was also added to measure standards.   
 
Duplicates of samples and standards were measured, in 3 ml cuvettes, at 595 nm with 
a Beckman Du 650 spectrophotometer (Beckman-Coulter Research, 
Buckinghamshire, UK).   
 
  [DPM samples – DPM background] x [glucose] 
DPM initial counts  x     2 [protein] 
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6.7 Determination of alkaline phosphatase  
 
There are many different markers to validate BBM vesicle preparations, including 
assaying for sucrase activity, or change in Na
+
/K
+
- ATPase activity (BLM marker).  
The enzyme alkaline phsophatase was used in these experiments, as a BBM marker, 
to assess the enrichment of the BBM vesicles, compared to the original homogenate.  
The alkaline phosphatase assay is based on the conversion of p-nitrophenol phosphate 
substrate, by alkaline phsophatase, into free p-nitrophenol and phosphate.  The free p-
nitrophenol can be measured spectrophotometrically at 400 nm wavelength (Forstner 
et al., 1968).  
  
p-nitrophenol phosphate                  p-nitrophenol + phosphate 
          
alkaline phosphatase  
(yellow) 
 
Homogenate samples were diluted 1:5 and BBM vesicle at 1:50, in dH2O, and 100 μl 
stock was used in the assay. 4-nitrophenol was used as a standard and prepared, in 
dH2O, at dilutions from 50 nM to 300 nM, increasing in 50 nM increments.  The 
substrate was prepared in alkaline buffer (50 μM glycine, 5 mM MgCl2 and 1 mM 
zinc acetate, pH 9.4) and 500 μl was incubated, with the samples and standards, for 15 
minutes at 37°C.  The reaction was terminated with 2.5 ml 1 mM NaOH. 
 
Duplicates of samples and standards were measured, in 3 ml cuvettes, at 400 nm with 
a Beckman Du 650 spectrophotometer (Beckman-Coulter Research, 
Buckinghamshire, UK). 
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6.7.1 BBM vesicle enrichment of alkaline phosphatase 
 
The purity of BBM vesicles was evaluated by assessing the relative specific activity 
of the membrane marker alkaline phsophatase, using the equation below: 
 
6.8 Determination of plasma and urine glucose concentration 
6.8.1 Plasma 
 
Blood from cardiac puncture, or collected via femoral artery cannulation, was placed 
into heparinised tubes, containing 7500 kallikrain inactivator units (KIU) of the broad 
range protease inhibitor Aprotonin. After centrifugation at 8000 rpm for 15 minutes, 
the resulting supernatant (plasma) was used in the glucose oxidase assay. Plasma from 
diabetic or glucose-infused rats was diluted 1:10, in dH2O, for the assay, for readings 
to remain within the standard curve. 
 
6.8.2 Urine 
 
Urine from diabetic animals or glucose-infused rats was diluted 1:100, in dH2O, for 
the glucose oxidase assay, for readings to remain within the standard curve. 
 
6.8.3 Glucose oxidase assay 
 
In the assay, glucose is oxidised, by glucose oxidase, to produce hydrogen peroxide 
which, in the presence of peroxidase, oxidises dianisidine, to produce a chromogenic 
product (oxidised o-dianisidine), which can be measured spectrophotometrically at 
450 nm. 
] [ ] X          10 
BBM vesicle alkaline phosphatase activity 
(nmol) 
BBM vesicle [protein] (mg.ml-1) 
[ Homogenate [protein] (mg.ml-1)  Homogenate alkaline phosphatase activity (nmol) 
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Glucose + H2O + O2                          gluconic acid + H2O2  
                
glucose oxidase  
                      + o-dianisidine
 
(colourless) 
 
H2O2 + o-dianisidine                               oxidised o-dianisidine (brown)
          
peroxidase    
 
Glucose oxidase reagent (GOR) was prepared with 44 mg glucose oxidase, 1.76 ml 
peroxidise (0.53 mg.ml
-1
 stock) and 2.8 ml dianisidine (2.5 mg.ml
-1
 stock) in 176 ml 
H2O.   
 
Glucose standards (25 μl) were used at 5, 10 and 15 mM, with 500 μl dH2O and 4 ml 
GOR.  Samples (25 μl) were also prepared in 500 μl dH2O with 4 ml GOR and 
incubated for 1 hour at room temperature to allow glucose to oxidise.   
 
Duplicates of samples and standards were measured at 450 nm with a Beckman Du 
650 spectrophotometer (Beckman-Coulter Research, Buckinghamshire, UK). 
 
6.9 Insulin assay 
 
Plasma insulin concentrations were established using a rat insulin sandwich ELISA 
kit (Millipore, Watford, UK).  In short, standards (0.2, 0.5, 1, 2, 5 and 10 ng.ml
-1
) or 
plasma (10 μl) was incubated in ELISA wells pre-coated with mouse anti-rat insulin 
antibody, after which insulin in the plasma samples was captured using biotinylated 
polyclonal antibody (80 μl) and incubating the ELISA for 2 hours.  Horseradish 
peroxidise (HRP)-linked secondary antibody (100 μl) binds to the immobilised 
biotinylated antibody and this complex was quantified by monitoring HRP activity in 
the presence of the substrate tetramethylbenzidine (TMB); the increase in absorbance 
at 450 nm, corrected from absorbance at 590 nm, after the acidification of TMB was 
directly proportional to the amount of captured insulin in the plasma samples.  
Absorbance of the duplicates of samples and standards were measured with a 
Beckman Du 650 spectrophotometer (Beckman-Coulter Research, Buckinghamshire, 
UK). 
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For the high-fat rat model, an intra-peritoneal insulin sensitivity test (IPIST) was 
performed (by Dr. Cleasby) on plasma, using a rat insulin ELISA kit (Crystal Chem 
Inc, Illinois, USA) and analysed statistically with a 2-way ANOVA/Holm-Sidak t test, 
for multiple comparisons. 
 
6.10 Osmolality measurements 
 
Osmolality was measured, using freezing-point depression osmometry, with a micro-
osmometer model 3M0 (Advanced Instruments Inc, Norwood, Massachusetts, US).   
A 20 μl sample of plasma or urine was frozen and the freezing point is depressed in 
direct relation to the amount of solute in solution and displayed in mOsM. 
 
6.11 Protein analysis 
6.11.1 Dot blots 
 
Whole membrane preparations (50 μg) were solubilised in Laemmli sample buffer 
(10% SDS, glycerol, Tris HCl (pH 6.8), bromophenol blue and dithiothreitol (DTT)).  
Proteins were directly applied to dampened Sequi-blot PVDF nitrocellulose 
membrane (Bio-Rad, Hemel Hempstead, UK) and left for 10 minutes to adhere.  
Membranes were then blocked in 6% milk-PBS-T (PBS with 0.1% Tween 20) and 
incubated in primary antibody, anti-T1R2 and –T1R3 (described in Table 6.2) on a 
shaker overnight at 4
o
C.   
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6.11.2 Western blotting 
 
BBM vesicles, LLC-PK1 cells and whole membrane preparations (20 – 50 μg) were 
solubilised in Laemmli sample buffer (10% SDS, glycerol, Tris HCl (pH 6.8), 
bromophenol blue and dithiothreitol (DTT)).  Samples were loaded onto 10% SDS-
PAGE (sodium dodecyl sulphate-polyacrylamide gel electrophoresis) gels with 
kaleidoscope pre-stained standards (Bio-Rad, Hemel Hempstead, UK) as a molecular 
weight marker.  Gels were electrophoresed, in running buffer (25 mM Tris, 192 mM 
glycine and 0.1% (w/v) SDS-running buffer (Sigma, Dorset, UK)) for approximately 
1 hour, or until the dye-front reached the bottom of the gel.  Proteins were transferred 
onto Sequi-blot PVDF nitrocellulose membrane (Bio-Rad) at 100 – 130 mA for 1 ½ 
hours.  Membranes were blocked in 6% milk-PBS-T (PBS with 0.1%-Tween 20) and 
incubated in primary antibody on a shaker.  Antibodies were used as described in 
Table 6.2 and were incubated overnight at 4
o
C, with the exception of anti-mouse β-
actin antibody which was incubated at room temperature for 1 hour. 
 
Blots were rinsed in PBS-T (1 x 15 minutes, 3 x 5 minutes) and incubated with the 
appropriate horseradish peroxidise-linked secondary antibody, outlined in Table 6.3 
for 1 hour on a shaker at room temperature.  After repeat rinses as above, the filters 
were visualised using ECL, prepared at a 1:1 ratio of ECL I (0.25 mM luminol (3-
aminophthalic acid hydrazide), 0.04 mM p-coumaric acid, 100 mM Tris HCl, 200 
mM NaCl, pH 8.8) and ECL II (30% H2O2).  Proteins were detected with a Fluor-S 
MultiImager system (BioRad, Hertfordshire, UK); all values were calculated relative 
to β-actin and % BBM expression was displayed as a ratio of control average. 
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Table 6.2 -Table of the primary antibodies used to detect proteins analysed in western 
blotting, including the species that the antibody was raised in and the dilution that the 
antibody was used for incubation 
 
Antibody 
Species 
raised in 
Concentration 
used at 
Epitope antibody raised 
against Company 
Species Region 
GLUT2 Rabbit 1:1000 Rat C-terminal AbD Serotec 
GLUT5 Rabbit 1:500 Rat 
C-terminal 
(cytoplasmic 
domain) 
Alpha Diagnostic 
International 
SGLT1 Rabbit 1:1000 Human N-terminal 
Gift from G. Kellett 
(University of York) 
PKC-βI Rabbit 1:1000 Human C-terminal 
Santa Cruz 
Biotechnology 
PKC-βII Rabbit 1:1000 Human C-terminal 
Santa Cruz 
Biotechnology 
T1R2 Rabbit 1:500 Mouse 
N-terminal 
(extracellular 
domain) 
Santa Cruz 
Biotechnology 
T1R3 Rabbit 1:500 Mouse 
N-terminal 
(extracellular 
domain) 
Santa Cruz 
Biotechnology 
β-actin Mouse 1:5000 
Xenopus 
laevis 
C-terminal Abcam 
 
 
Table 6.3 - Table of the secondary antibodies used to bind to and detect primary 
antibodies (outlined in Table 6.2) analysed in western blotting, including the species 
that the antibody was raised in and the dilution that the antibody was used for 
incubation 
 
Antibody 
Species 
raised in 
Concentration 
used at 
Species antibody 
raised against 
 
Company 
Anti-mouse-
HRP 
Goat 1:5000 Mouse Sigma 
Anti-rabbit-
HRP 
Donkey 1:1000 Rabbit GE Healthcare 
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6.12 Real time PCR 
6.12.1 cDNA preparation 
 
The mRNA expression profile of glucose transporters and sweet taste receptors was 
assessed with RT-PCR in kidney and small intestine tissues.  Mucosal scrapes from 
duodenum, jejunum and ileum, and kidney cortex were placed in RNAlater (Ambion, 
Texas, USA), snap frozen in liquid N2 and stored at -70°C. RNA was extracted from 
tissue, using Trizol, according to manufacturer’s instructions (Invitrogen, Paisley, 
UK).   
 
Extracted RNA samples were prepared in load buffer (Sigma, Dorset, UK) and loaded 
on a 1.2% agarose gel, containing 0.1% ethidium bromide, and run at 120 V to ensure 
RNA quality.  RNA concentration was determined using nanodrop (Bio-Rad 
Laboratories Ltd. Hemel Hempstead, UK) and RNA was diluted to 1 µg.ul
-1
. RNA 
was reverse transcribed with 0.5 µg of oligo-dT 12-18 primer and a First Strand 
cDNA synthesis kit (Superscript II RNase H-reverse transcriptase; Life Technologies, 
Paisley, UK).   
 
Transcript levels were measured on a Chromo4™ Real-Time Detector (Bio-Rad 
Laboratories Ltd. Hemel Hempstead, UK), using QuantiTech SYBR Green PCR kit 
(Invitrogen, Paisley, UK), with β-actin used as the house-keeping gene. All primers 
were run at 95°C for 15 minutes, 95°C for 15 seconds, 60°C for 20 seconds, 72°C for 
40 seconds and cycled 42 times.   
 
6.12.2 Primers 
 
Gene expression was measured, using specific intron-spanning primers designed from 
the published sequence of the gene of interest (Table 6.4).  Primers were tested with 
cDNA and QuantiTech SYBR Green PCR kit (Invitrogen, Paisley, UK) and amplified 
using Chromo4™ Real-Time Detector (Bio-Rad Laboratories Ltd. Hemel Hempstead, 
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UK).  PCR products were run on an agarose gel (as in section 6.12.1) to check there 
was no primer dimerisation. 
 
Table 6.4 – Table of intron-spanning primers designed for use in mRNA expression 
analysis 
 
Primer GenBank accession number Forward position Reverse position Product size (bp) 
GLUT2 NM_012879.2 1101-1116 1420-1405 319 
GLUT5 NM_031741.1 921-939 1280-1264 359 
SGLT1 NM_013033.2 1871-1886 2198-2183 327 
SGLT2 NM_022590.2 838-857 1088-1069 250 
T1R1 NM_053305.1 1315-1334 1473-1454 158 
T1R2 XM_00107479.1 3759-3778 3923-3904 164 
T1R3 NM_130818.1 2107-2126 2327-2308 220 
β-actin NM_031144 937-955 1223-1208 286 
 
6.13 Statistics 
 
Values were expressed as mean ± S.E.M.; n values represent numbers per 
experimental group. Differences between groups were tested by Student’s unpaired t 
test and using one-way analysis of variance (ANOVA) with post-hoc comparisons 
performed using Dunnett’s Multiple comparisons test with P considered significant at 
< 0.05. 
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7 Acute regulation of GLUT2 at the proximal 
tubule brush-border 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  119 
7.1 Introduction 
 
The ‘classical’ model for intestinal glucose absorption is that glucose, the major 
product of dietary carbohydrate digestion, traverses the brush border membrane 
(BBM) of enterocytes via the sodium-dependent transporter SGLT1, and exits 
through the basolateral membrane (BLM) using the facilitative transporter GLUT2.  
At low plasma glucose concentrations, SGLT1 is the primary route of glucose 
absorption at the BBM, however this is not the case at higher concentrations.   
 
Brush-border expression of GLUT2 in the intestine is dependent on glucose transport 
by SGLT1 and its insertion into the BBM is regulated by a short-term high glucose 
stimulus in the lumen and long-term dietary changes.  Before a meal, any glucose in 
the lumen is scavenged by the high affinity SGLT1 and transported into the cell 
against a concentration gradient.  However, after feeding there is a high luminal 
glucose concentration which saturates SGLT1 (Sharp et al., 1996) and stimulates 
PKC-βII, via the T1R family and calcium (Ca2+), to move to the enterocyte BBM 
(Morgan et al., 2007;Mace et al., 2007).  In this position, PKC-βII causes GLUT2 
recruitment from intracellular vesicles to the BBM and this insertion occurs within 15 
minutes of high glucose signal.  This enables GLUT2 to shuttle glucose from the 
lumen, along its concentration gradient, and reduce the luminal glucose concentration 
(Kellett and Helliwell, 2000).  As luminal concentration decreases, both PKC-βII and 
GLUT2 are inactivated and trafficked away from the BBM which restores resting low 
levels of the transporter (Helliwell et al., 2000).    
 
A high-carbohydrate diet causes an increase in the number of high affinity ‘glucose-
protectable’ phlorizin binding sites, suggesting an increase in phlorizin-sensitive 
SGLT1 transporters at the enterocyte BBM (Ferraris et al., 1992;Burant et al., 1994).  
It has also been shown that brush-border GLUT2 expression is reduced in mice 
receiving a complex diet of low-glycaemic index carbohydrates (Kellett and Brot-
Laroche, 2005).  In the same study, mice given a diet rich in high-glycaemic index 
carbohydrates were shown to have increased GLUT2 and augmented plasma glucose 
levels.       
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There are striking similarities between the reabsorption of glucose across the proximal 
tubule cell and glucose absorption in the jejunal enterocyte. However there are far 
fewer studies on the molecular mechanisms affecting the recruitment of GLUT2 to the 
BBM in proximal tubule cells, in response to luminal glucose stimulus. 
 
Dominguez et al found that both GLUT1 and GLUT2 coexist in the early proximal 
tubule whereas only the high affinity GLUT1 was found in the late proximal tubule 
(Dominguez et al., 1994a).  The group also established that 2-4 weeks streptozotocin 
(STZ)-induced diabetes caused a decrease in GLUT1 protein and mRNA expression 
in the proximal tubule.  The opposite was seen for GLUT2 where there was a marked 
increase in proximal tubule mRNA and protein expression, which was accompanied 
by an increase in 
3
[H]-deoxyglucose (DOG) uptake.  Up-regulation of renal GLUT2 
in type I diabetes was also seen by Chin et al, where a 5-fold increase in mRNA levels 
occurred within 1-3 months of the disease, and continued to rise after 6 months of 
diabetes (Chin et al., 1997).   
 
The expression of both SGLT1 and SGLT2 has been extensively demonstrated in the 
proximal tubule (Kanai et al., 1994;Wallner et al., 2001;Wright, 2001;Balen et al., 
2008), however, how the expression of sodium dependent glucose transporters change 
in STZ-induced diabetes is more disputed. Yasuda et al showed that diabetes caused a 
decrease in SGLT-mediated glucose uptake in renal cortex brush-border membranes, 
which was attributed to reduced SGLT expression (Yasuda et al., 1990).  After 
normalisation of blood glucose with insulin-treatment or starvation, glucose uptake 
returned to control levels therefore they postulated that SGLT-mediated glucose 
uptake is regulated by blood glucose concentrations per se (Yasuda et al., 1990).  
Although a rapid down-regulation of SGLT2 has been observed in response to early 
diabetes (Albertoni Borghese et al., 2009), Dominguez et al found no change in 
sodium-dependent glucose transporter protein or mRNA in 2-4 week type I diabetes, 
with or without insulin treatment (Dominguez et al., 1994a).  The discrepancies in 
SGLT data in renal proximal tubules during diabetes may be due to different methods 
of induction of the disease, with both alloxan and streptozotocin used, as well as 
different time points of diabetes studied (Albertoni Borghese et al., 2009).  
Furthermore, different molecular species of SGLT, possibly depending on the 
glycosylation or phosphorylation state of the transporter may result in the differences 
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seen in the data during diabetes (Stearns et al., 2009).  Also, the presence of two 
different SGLT proteins in the proximal tubule, as oppose to only SGLT1 in the 
jejunum, may explain why early studies showed such conflicting results. 
 
In contrast, studies show agreement that the inhibition of SGLT2 causes normalisation 
of the increased blood glucose seen in type I diabetes, suggesting a major role for the 
transporter in this disease (Adachi et al., 2000;Oku et al., 2000;Oku et al., 2000).  In 
the SGLT2 KO mouse, renal SGLT1 expression is also down-regulated and this could 
be a mechanism of limiting the increase in glucose reabsorption at high luminal 
glucose concentrations (Vallon et al., 2010). 
 
During STZ-induced diabetes, increases in blood glucose levels, tubular glucose 
uptake, more specifically GLUT-mediated transport, and GLUT2 protein expression 
at the BBM have all been noted; however, overnight fasting of type I diabetic rats 
revokes all these effects (Marks et al., 2003).  Thus it has been hypothesised that 
hyperglycaemia stimulates GLUT2 expression, and these elevated levels of GLUT2 
are responsible for the increased glucose uptake found in diabetes.  Additionally, this 
group established that GLUT2 is not detected at the BBM following overnight fasting 
of diabetic rats, suggesting that GLUT2 is rapidly translocated away from the 
membrane in response to normalisation of blood glucose levels (Marks et al., 2003).   
 
Freitas et al have also demonstrated the expression of renal GLUT2 in response to 
hyperglycaemia, using insulin and phlorizin as modulators of blood glucose levels.  
Despite opposing effects on plasma insulin and urinary glucose levels, both insulin 
and phlorizin reversed the increased renal GLUT2 mRNA and protein expression 
present in diabetes (Freitas et al., 2007).  This reversal of diabetes-induced GLUT2 
expression occurred over a 6-day period of treatment with insulin, suggesting the 
glucose transporter is removed from the renal BBM at a slower rate than seen after 
overnight fasting (Marks et al., 2003;Freitas et al., 2007), in response to a more 
moderate normalisation of plasma glucose levels.   
 
The link between PKC-βII signalling and GLUT2 translocation at the BBM in 
enterocytes, presented the possibility of a similar PKC-dependent effect on renal 
expression of GLUT2.  This theory was tested by exposing renal proximal tubule cells 
  
  122 
to thapsigargin, which promotes the release of intracellular stores of calcium, and 
PMA, a PKC activator (Goestemeyer et al., 2007).  In these experiments, GLUT-
mediated transport at the BBM was increased by thapsigargin and PMA.  Western 
blotting analysis revealed the expression of PKC isoforms -α, -βI, -βII, -δ and -ε, 
although only -βI was affected by STZ-induced diabetes.  This study also 
demonstrated a positive correlation (r = 0.718) between plasma glucose levels and 
GLUT2 protein levels at the BBM.  Positive correlations (r = 0.779) between plasma 
glucose levels and PKC-βI, and between PKC-βI and GLUT2 protein levels (r = 
0.648) were also noted (Goestemeyer et al., 2007). 
 
Thus, BBM expression of both jejunal and renal GLUT2 is up-regulated by high 
luminal glucose, and down-regulated by the normalisation of luminal glucose.  Also, 
in both tissues the different isoforms of PKC-β are involved in recruitment of the 
transporter to the BBM; PKC-βII in the small intestine and PKC-βI in the kidney.  It 
is known that jejunal brush-border GLUT2 responds to a glucose stimulus within 15 
minutes whereas 2-4 weeks hyperglycaemia causes recruitment of renal GLUT2 and 
overnight fasting abolishes this GLUT2 insertion.  However, despite similarities 
between GLUT2 expression in the jejunum and proximal tubule, no studies have yet 
been undertaken to assess the time required for renal GLUT2 insertion at proximal 
tubule BBM.   
 
7.2 Aims of chapter 
 
The aim of this study was therefore to establish the period of time needed for GLUT2 
expression at the proximal tubule BBM in response to changes in plasma, and 
therefore tubular luminal, glucose levels.  This was done by assessing GLUT2 
movement to the proximal tubule BBM in response to acute and chronic 
hyperglycaemia.  The effect of an acute increase in tubular glucose concentration on 
glucose transport was studied to evaluate whether short term GLUT2 insertion was 
mediated by PKC-βI, as has previously been shown for a 2-4 week period of diabetes. 
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7.3 Results 
7.3.1 Acute hyperglycaemia: time course in vivo infusion studies 
7.3.1.1 Effect of infusion studies on plasma glucose  
 
Within 15 minutes of 1.1 M glucose infusion, there was a significant increase in 
plasma glucose from 7.1 ± 0.41 mM at start of infusion, to 14.6 ± 1.4 mM after 15 
minutes (Figure 7.1).  This elevation of plasma glucose continued for up to 60 
minutes, where plasma glucose reached a value of 21.7 ± 2.49 mM.  As expected, 
when infused with saline or the osmotic control, 0.08 M mannitol, rats showed no 
change in glycaemia throughout the 1 hour infusion (7.3 ± 0.12 mM and 7.06 ± 0.34 
mM, respectively) (Figure 7.1). 
 
Similar glycaemic effects were seen in the 2 hour infusion studies.  In these 
experiments, a 3 ml bolus preceded the constant infusion protocol.  Both saline and 
mannitol infusions did not affect normal plasma glucose levels, 5.39 ± 0.2 mM and 
6.13 ± 0.54 mM respectively, during the 2 hour infusion period.  The glucose-infused 
animals exhibited a significant elevation in plasma glucose levels within the initial 15 
minutes of the experiment, increasing from a pre-bolus value of 5.8 ± 0.3 mM to 23 ± 
2.6 mM.  Hyperglycaemia continued over the experimental period, reaching values of 
32.2 ± 0.3 mM after 2 hours (Figure 7.2).  Table 7.1 shows that these effects on 
plasma glucose had no effect on body or kidney weight between those rats infused 
with saline, mannitol or glucose.  To correct for the effect that infusing glucose would 
have on plasma osmolality, 0.08 M mannitol was used as a control infusate.  This 
concentration of mannitol maintained plasma osmolality at 306 ± 2 mOsM, which 
was within the range of that occurring with the other infusates, saline and glucose 
(Table 7.2). 
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Figure 7.1– Effect of 1 hour 1.1 M glucose infusion (dotted line) on plasma glucose 
concentrations compared with 154 mM saline (broken line) and 0.08 M mannitol 
(solid line) control infusions. Values are expressed as mean ± SEM, n=4-6, 
***p<0.005, ****p<0.001 compared with both controls at each time point 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2 – Effect of 2 hour infusion of 1.1 M glucose (dotted line), with initial 
bolus, on plasma glucose concentrations, compared with 154 mM saline (broken line) 
and 0.08 M mannitol (solid line) control infusions. Values are expressed as mean ± 
SEM, n=4-6, ****p<0.001 compared with both controls at each time point 
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Table 7.1 – Body and kidney weights and renal BBM vesicle enrichment of alkaline 
phosphatase marker enzyme, in rats infused with 154 mM saline, 1.1 M glucose, 0.08 
M and 1.09 M mannitol. Values are expressed as mean ± SEM for 1 and 2 hour time 
period, n = 3-6, no significant change between infusions, p>0.5. 
 
 
 154 mM Saline 0.08 M Mannitol 1.1 M Glucose 1.09 M Mannitol 
Body weight (g) 291.4 ± 21.8 255.6 ± 3.07 301.6 ± 23 263.7 ± 12.7 
Kidney weight (g) 1.04 ± 0.05 0.99 ± 0.03 1.06 ± 0.08 1.02 ± 0.09 
BBMV enrichment 6.02 ± 0.29 5.82 ± 0.44 6.12 ± 0.36 6.19 ± 0.37 
 
 
 
Table 7.2 – Infusate osmolality and its effect on plasma osmolality for 154 mM 
saline, 0.08 M mannitol, 1.1 M glucose and 1.09 M mannitol.  Values are expressed 
as mean ± SEM, n=4-6, ****p<0.001 compared with saline infused control 
 
 
 154 mM Saline 0.08 M Mannitol 1.1 M Glucose 1.09 M Mannitol 
Infusate osmolality 312 ± 7 mOsM 388 ± 10 mOsM 1706 ± 26 mOsM 1675 ± 18 mOsM 
Plasma osmolality 310 ± 5 mOsM 306 ± 2 mOsM 319 ± 4 mOsM 617 ± 9 mOsM **** 
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7.3.1.2 Glycosuria in acute hyperglycaemia 
 
The infusion of glucose caused a significant, albeit expected, effect on glucose 
concentration in the urine in the 1 hour infusion experiments, increasing from 0.53 ± 
0.03 mM pre-infusion to 27 ± 3.21 mM in the initial 30 minutes.  This further 
increased to 136 ± 5.13 mM at the 1 hour end-point compared with both saline and 
mannitol infusions where there were negligible levels of glucose in the urine, 0.55 ± 
0.05 mM and 0.53 ± 0.09 mM, respectively.  
 
Glycosuria was significantly higher in the 2 hour glucose infusion with bolus group, 
with an increase from 0.157 ± 0.037 mM pre-infusion, to 306 ± 6 mM after 30 
minutes.  After 2 hours infusion, the glucose concentration in the urine had dropped to 
191 ± 3 mM, suggesting the initial peak was due to the bolus administered.  In both 
control infusions, there was no glycosuria with glucose concentrations in the urine 
similar to those seen after 1 hour infusion. 
 
7.3.1.3  Effect of acute hyperglycaemia on GLUT2 expression at the proximal 
tubule BBM 
 
Despite the hyperglycaemic and glycosuric effects of the glucose infusions described 
above, there was no effect on renal GLUT2 expression in BBM vesicles prepared 
from both the 1 and 2 hour infused animals (Figure 7.3).  There was also no 
significant effect on expression of the GLUT2 effector, PKC-βI or the sodium-
dependent transporter, SGLT1 (Figure 7.3).  This lack of response to short-term (1 
and 2 hour) hyperglycaemia, suggests that, unlike the jejunum, a longer period of high 
glucose stimuli is required to stimulate GLUT2 movement to the proximal tubule 
BBM.              
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Figure 7.3 – Effect of acute hyperglycaemia, induced by I.V. infusion of 1.1 M 
glucose (slatted bars) for 1 and 2 hours, on GLUT2 (1), PKC-βI (2) and SGLT1 (3) 
expression at the proximal tubule BBM (expressed as control ratio %) compared with 
expression in animals infused with 154 mM saline control (open bars) and 0.08 M 
mannitol as osmotic control for glucose (closed bars). Values are expressed as mean ± 
SEM, n=4-6, no significant change between infusions p>0.5. 
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7.3.1.4 Effect of plasma osmolality on renal GLUT2 expression 
 
As an osmotic control for the short-term infusion studies, 1.09 M mannitol was also 
used as an infusate since its osmolality is similar to 1.1 M glucose (1675 ± 18 mOsM 
compared to 1706 ± 26 mOsM, (Table 7.2).  The 1.09 M mannitol infusion had a 
dramatic effect on GLUT2 expression at the proximal tubule BBM with a 2.2-fold 
increase in expression compared with the saline infused control animals (Figure 7.4).  
This increased pattern of expression was also seen in the GLUT2 effector, PKC-βI 
(Figure 7.4).  In contrast, 1.09 M mannitol infusion was without effect on the BBM 
expression of SGLT1 (Figure 7.4).  It was noted that animals infused with 1.09 M 
mannitol had significantly augmented plasma osmolality in comparison to the saline, 
0.08 M mannitol and glucose infused animals (Table 7.2).   
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Figure 7.4 – Effect of 1.09 M mannitol infusion (closed bars) on the expression of 
GLUT2 (1), PKC-βI (2) and SGLT1 (3) at the proximal tubule BBM (expressed as 
control ratio %) compared with expression in 154 mM saline-infused animals (open 
bars).  Values are expressed as mean ± SEM, n=4-6, ***p<0.005, ****p<0.001 
compared with saline controls, (3) no significant change between infusions p>0.5. 
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7.3.2 Chronic hyperglycaemia: type I diabetes induced with streptozotocin 
 
The infusion experiments above established that a longer time-course of 
hyperglycaemia was required to stimulate GLUT2 expression at the proximal tubule 
BBM.  To study this, hyperglycaemia was induced using the STZ-induced type I 
diabetic model.   
 
7.3.2.1 Effects of short-term STZ-induced diabetes  
 
STZ treatment rapidly induced glycosuria with urine glucose levels at 5.75 ± 0.06 
mM within 5 hours of tail-vein injections, although interestingly there was no effect 
on glycaemia at this stage of diabetes.  However, 2 days after STZ, unfasted plasma 
glucose levels were significantly increased (35.7 ± 3.36 mM) compared with the 
citrate buffer controls (10.26 ± 0.88 mM).  These animals also exhibited glycosuria, 
with urine glucose concentrations reaching 316 ± 19 mM.  However, despite these 
responses to STZ, no changes in GLUT2, PKC-βI or SGLT1 expression at the 
proximal tubule BBM were observed 2 days after STZ (Figure 7.5).  
 
7.3.2.2 Effect of 7-day STZ-induced diabetes on GLUT2 expression at the 
proximal tubule BBM 
 
GLUT2 was studied in STZ-induced type I diabetes at further time points, with the 
aim to elucidate the maximum time for the hyperglycaemic stimulus to induce 
GLUT2 expression at the proximal tubule BBM.  At 7 days hyperglycaemia, GLUT2 
expression at the proximal tubule BBM was significantly increased compared with 
that of the citrate buffer-injected controls, and from expression seen at 2-6 days STZ 
(Figure 7.5).  This expression of GLUT2 at the proximal tubule BBM (744% 
increase) was mirrored by an increase in PKC-βI (496% increase), but there was no 
change in SGLT1 expression, a result similar to that previously shown at 2-4 weeks 
diabetes (Marks et al., 2003). Table 7.3 shows that there was a 23% increase in 
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kidney weight in 7-day STZ diabetic animals compared with those from control 
animals; however no difference in BBM enrichment was detected in membranes 
prepared from control and 7-day STZ diabetic animals.  There was also a decrease in 
body weight in the 7-day STZ diabetic rats compared to the controls, although this did 
not reach statistical significance (Table 7.3).  
 
Table 7.3 – Body and kidney weights and renal BBM vesicle enrichment of alkaline 
phosphatase marker enzyme in rats with 7-day STZ-induced type I diabetes.  Values 
are expressed as mean ± SEM, n = 3-6, *p<0.05 compared with control 
 
 
 Control STZ 
Body weight (g) 268.5 ± 11.3 244.4 ± 7.1 
Kidney weight (g) 0.95 ± 0.11 1.17 ± 0.04* 
BBMV enrichment 5.86 ± 0.31  5.79 ± 0.22  
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Figure 7.5 – Effects of 2 – 7 days of STZ-induced diabetes on GLUT2 (green bars), 
PKC-βI (pink bars) and SGLT1 (grey bars) expression at the proximal tubule BBM.  
1) Western blots 2) quantification of western blots (expressed as control ratio %) 
standardised to β-actin.  Values are expressed as mean ± SEM, n=3-6, ****p<0.001 
compared with citrate buffer vehicle controls by ANOVA. 
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7.3.3 Effect of STZ-induced diabetes on GLUT2 intracellular pool in proximal 
tubule cells 
 
GLUT2 mRNA in the renal cortex was studied to assess possible changes in the 
intracellular pool of GLUT2 in the early stages of STZ-induced hyperglycaemia.  It 
was important to ascertain whether hyperglycaemia induced an increase in 
intracellular GLUT2 or whether a greater proportion of the available intracellular pool 
was shuttled to the proximal tubule BBM. 
 
The baseline level of renal GLUT2 mRNA was significantly increased by 2- and 3-
fold after 10 and 30 days STZ-induced diabetes, respectively (Figure 7.6), suggesting 
raised levels of intracellular GLUT2 in renal cortical cells in response to 
hyperglycaemia seen in type I diabetes. 
 
 
Figure 7.6 – Effects of 10- and 30-day STZ-induced type I diabetes on GLUT2 
mRNA expression in renal cortex.  Values are expressed as mean ± SEM, n=9-12, 
*p<0.05, ****p<0.001 compared with control by ANOVA.  
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7.4 Discussion 
 
The aims of this study were to establish the time period for GLUT2 expression at the 
proximal tubule BBM in response to IV glucose infusion that will increase plasma 
glucose concentration and therefore proximal tubule fluid.  The methods to study the 
response to luminal glucose in the small intestine, for example, in vivo jejunual loops 
(Kellett and Helliwell, 2000) cannot be utilised in the kidney without the use of 
microperfusion studies.  The latter technique was previously used by Bank et al using 
in vivo reperfusion studies, where each tubule was perfused in the presence or absence 
of glucose (Bank et al., 1971).  Sodium absorption was assessed in the proximal 
tubule in response to increased luminal glucose concentrations and the same 
procedure could be applied to study the amount of glucose reabsorption occurring in 
the early and late proximal convoluted tubules.  As this technique was not available 
for the present study, glucose was infused into the circulation in vivo and the 
assumption made that all the glucose in the blood was freely filtered at the glomerulus 
into the proximal tubule lumen.       
 
The data obtained from the short-term glucose infusions highlights the difference 
between the regulation of renal GLUT2 compared with that previously noted at the 
small intestinal BBM.  Glucose transport in the jejunum needs to rapidly respond to 
ingested carbohydrates; therefore, within 15 minutes of a glucose stimulus, when 
jejunal luminal glucose concentrations have been estimated to be between 50 to 300 
mM (Ferraris et al., 1990;Pappenheimer, 1993), GLUT2 is recruited to the brush-
border to absorb the bulk of glucose from the luminal fluid (Kellett and Helliwell, 
2000). 
 
In contrast to the jejunum, the GLUT2 response at the renal BBM was unaffected by 
short-term (1 and 2 hour) glucose stimuli, despite blood, and therefore tubular fluid 
glucose concentrations, exceeding 30 mM.  Glycosuria under these conditions was 
noted throughout the infusion period, suggesting that the renal glucose absorptive 
mechanism was saturated.  Furthermore, there was no change in the expression of 
SGLT1 or the renal GLUT2 activator, PKC-βI, in response to 1 or 2 hour glucose 
infusion.  This implies that there was no up-regulation of upstream signals to GLUT2 
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in response to short-term hyperglycaemia.  There are several possible explanations for 
the absence of renal GLUT2 recruitment to the proximal tubule BBM following a 
short-term glucose stimulus.  The renal BBM is not usually exposed to dramatically 
and dynamically changing glucose concentrations compared to those present at the 
jejunal BBM where glucose levels may approach 50 mM after a meal (Ferraris et al., 
1990); therefore renal glucose transporters may not have the necessary signalling 
pathways to allow rapid shuttling of GLUT2 in response to high glucose 
concentrations.  It has been shown that jejunal GLUT2 responds to SGLT1-mediated 
PKC-βII activation, as well as complex calcium (Ca2+) and sweet taste receptor-
mediated PKC-βII activation (Morgan et al., 2007;Mace et al., 2007).  However, data 
on the control of GLUT2 shuttling to the renal brush-border is limited; currently it is 
known that altered expression of PKC-βI at the BBM correlates with that of GLUT2 
in 2-4 week type I diabetes (Goestemeyer et al., 2007), although the presence of a 
secondary signalling pathway, and the involvement of SGLT, in GLUT2 expression at 
the renal BBM has not been established in this model of diabetes.  However the 
studies presented here only indicate the expression of glucose transporter at the 
proximal tubule BBM and do not offer an indication of the mechanism of recruitment 
from intracellular to membrane location.  In the jejunum, GLUT2 has been 
established to translocate from intracellular vesicles to the BBM, thus to adequeately 
assess the shuttling of GLUT2 to the proximal tubule BBM, immunofluorescence 
during hyperglycaemia would be necessary (Kellett and Helliwell, 2000). 
 
STZ-induced type I diabetes was used as a model of hyperglycaemia to study the 
effect of prolonged exposure to glucose on GLUT2 expression at the proximal tubule 
BBM.  The data shows that, despite a significant increase in plasma glucose levels in 
type I diabetic animals, GLUT2, and its activator, PKC-βI, were not recruited to the 
BBM until 7
 
days after the induction of diabetes.  This suggests that, rather than a 
dose-dependent response to tubular glucose levels, there may be an ‘on/off’-switch 
mechanism acting at 6 - 7 days, which is responsible for inducing GLUT2, via PKC-
βI, to the proximal tubule BBM.  Expression of both GLUT2 and PKC-βI correlates 
positively with plasma glucose concentrations, as previously seen in 2-4 week studies 
of STZ-induced diabetes (Goestemeyer et al., 2007).  Since previous studies using the 
STZ model have shown an increase in GLUT-mediated glucose uptake (Marks et al., 
2003) and increased renal glycogen storage (Khandelwal et al., 1979), the up-
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regulation of GLUT2 expression implies an increased glucose uptake by the proximal 
tubule cell.  It is worth noting that GLUT2 expression at the renal BBM is abolished 
after normalisation of glycaemia by overnight fasting (Marks et al., 2003), and 
therefore the transporter has the capacity to shuttle away from the BBM at a more 
rapid rate than it can be inserted.  Also, GLUT2 mRNA is increased in short-term 
diabetes (10-day STZ) which implies that there is an increased intracellular pool of 
the transporter within proximal tubule cells readily available for shuttling to the 
proximal tubule BBM.  However, mRNA was prepared from the renal cortex of 
diabetic rats and thus, in addition to proximal tubule cell mRNA, the preparation will 
include a proportion of distal tubules, fibroblasts and dendritic cells (Kaissling and Le 
Hir, 1994).  The absence of any change in SGLT1 expression, in response to 
hyperglycaemia of 7-day duration, suggests that, unlike GLUT2, this transporter is 
unaffected by blood glucose levels.  The cytotoxic effect of STZ is mediated by it’s 
action as an alkylating agent on pancreatic β-cells to abolish insulin secretion; the 
drug is transported into the pancreas via GLUT2 due to a strong molecular similarity 
to glucose.  Interestingly, STZ accumulates in non-pancreatic locations including the 
liver and kidney and, in the latter, is responsible for renal toxicity and glycosuria 
(Hall-Craggs et al., 1982).  Therefore, in addition to rendering the rats diabetic, the 
drug is likely to exhibit a damaging effect on GLUT2 at the proximal tubule; this may 
offer an explanation for the absence of a rapid GLUT2 response to STZ, between 2 
and 7 days. 
 
Recent interest on the use of SGLT2 inhibitors as a treatment for hyperglycaemia in 
diabetes implies a potential relationship between SGLT-mediated increase in 
intracellular glucose and GLUT2 recruitment to the renal BBM.  The inhibitors act by 
blocking the high capacity SGLT2 transporter in the early proximal tubule, which 
causes increased glycosuria in diabetes as a result of lowered transport maximum (Tm) 
for glucose reabsorption leading to restoration of glycaemia (Bays, 2009). As GLUT2 
moves glucose along its concentration gradient, if the transporter was able to move 
independently of SGLT2, it would be recruited to the BBM of the diabetic proximal 
tubule, in response to the high tubular glucose concentration and transport glucose 
into the proximal tubule cell.  This does not appear to be the case as the inhibitor’s 
efficacy has been extensively studied and is currently in clinical trial stages (Adachi et 
  
  137 
al., 2000;Fujimori et al., 2009;Patel and Fonseca, 2010); this suggests that GLUT2 
may require a SGLT-mediated signal for its recruitment to the proximal tubule BBM. 
 
In fact, the presence of GLUT2 at the BBM exacerbates hyperglycaemia and might be 
seen as an ‘unwanted feature’ in diabetes; in the absence of GLUT2 at the renal BBM, 
SGLT-mediated uptake would become saturated at much lower tubular glucose 
concentrations.  Although the enrichment of BBM vesicles was assessed using the 
membrane marker enzyme, alkaline phosphatase, BLM contamination in the 
preparation is still possible.  To adequately assess the BLM component of the vesicles 
preparation, the presence of the Na
+
-K
+
-ATPase could be used as a marker enzyme.  
GLUT2 has been previously identified at the proximal tubule BBM by confocal 
imaging and immunohistochemistry, thus it is likely, in the experiments presented 
here, that GLUT2 expression in the vesicle preparation is from the BBM (Marks, 
2004).  Therefore it is possible that the long period required for brush-border insertion 
of the facilitative glucose transporter, GLUT2, is a mechanism of protection from 
hyperglycaemia, and a physiological short-term attempt at maintaining glucose 
homeostasis.   
 
However, there are limitations with using hyperglycaemia to simulate high tubular 
glucose levels for the study of GLUT2 expression.  When the BBM and BLM are 
exposed to high levels of glucose, the facilitative transporter could cause bi-
directional glucose flux.  In studies using LLC-PK1 proximal tubule cells, the rate of 
GLUT-mediated glucose uptake from the BLM was higher than that at the BBM 
(Miller et al., 1992).  This suggests that the BLM has a higher capacity for facilitative 
glucose transport, a likely result of a high GLUT2 expression.  Therefore in 
hyperglycaemic conditions there is a large load of glucose moving from the blood into 
the proximal tubule cell, via the BLM, thereby raising intracellular glucose levels.  
Thus, despite the data presented here showing an increase in GLUT2 protein and 
mRNA in response to 7 day STZ-induced diabetes, the net glucose flux across the 
BBM will not necessarily be in favour of a luminal to intracellular direction.      
 
Furthermore, the data observed, following 1.09 M mannitol infusion, shows that 
GLUT2 is capable of rapid expression at the proximal tubule BBM, via PKC-βI 
activation, in the absence of hyperglycaemia.  This highlights an alternative, non-
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genomic mechanism for PKC-βI-mediated GLUT2 activation in proximal tubules; 
high osmotic pressure from the mannitol infusate caused a rapid (within 1 hour) and 
sustained (maintained at 2 hour) increase in GLUT2 and PKC-βI recruitment to the 
BBM.  Although the infusate osmolality of 1.09 M mannitol matched that of 1.1 M 
glucose, previous studies have shown that glucose is absorbed and stored by tissues in 
the body, for example, skeletal muscle (Dimitrakoudis et al., 1992), adipocytes 
(Fonseca-Alaniz et al., 2008) and the liver (Fery et al., 2001); therefore the resulting 
plasma osmolality from glucose infusions was within the normal physiological range 
as the saline control (Table 7.2).  However the plasma osmolality after 1.09 M 
mannitol infusion was 2-fold higher than with 1.1 M glucose, this phenomenon of 
mannitol raising plasma osmolality has been reported with high-dose mannitol 
therapy.  Mannitol treatment is commonly administered after cardiovascular surgery 
or to patients at risk of acute renal failure, where side-effects include acute expansion 
of extracellular fluid volume, hyperosmolality, hyponatremia, and intracellular 
dehydration in the brain (Visweswaran et al., 1997).  The substantial dehydration 
which occurred in the rats in the study presented here is also likely to result in the 
rapid shrinkage of proximal tubule cells, accompanied by the activation and release of 
intracellular acid hydrolases and necrosis (Janigan and Santamaria, 1961).  Therefore 
the expression of GLUT2 noted at the proximal tubule BBM following the high 
mannitol infusion may be a consequence of the breakdown of cytoplasmic vacuoles as 
oppose to a direct response of intact proximal tubule cell GLUT2. 
 
Jejunual GLUT2 has been shown to respond to ill-defined stress, for example, strong 
inhibition of expression of the transporter was seen in animals whilst building works 
near the building that housed rats used in the study; the reduced levels of GLUT2 
were normalised rapidly after this particular stress was removed (Shepherd et al., 
2004).  However, no change was noted in jejunal SGLT1 expression, under the same 
stress conditions.  These results are in keeping with the pronounced changes in renal 
GLUT2, but not SGLT1, in response to plasma osmotic stress in the mannitol infusion 
studies observed in this chapter.   
 
In the kidney, mannitol has been shown to have many different effects on tubular 
transport, including the up-regulation of the water channel aquaporin in the proximal 
tubule cell (Bouley et al., 2009). Mannitol inhibits proximal tubular isosmotic fluid 
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reabsorption because of the presence of the non-reabsorbable solute in the tubular 
fluid.  This causes proximal tubular fluid sodium concentration to decrease below the 
plasma concentration and creates a concentration gradient that limits net sodium 
reabsorption.  This theory agrees with clinical data that patients suffer hyponatremia 
after mannitol treatment (Perez-Perez et al., 2002).  Although no link between 
restricted sodium reabsorption and increased glucose transporter expression has been 
previously elucidated, studies on glucose metabolism in other tissues suggests that the 
rapid response of GLUT transporters, to infused 1.09 M mannitol, may be stress-
induced; for example, Kuzuya et al showed that mannitol-induced hyperosmolarity 
stimulated glucose uptake and glycogen synthesis in both adipose tissue and the 
diaphragm (Kuzuya T et al., 1965).  Furthermore, it has also been shown that 
fibroblasts exposed to 600 mM sorbitol for 30 minutes had a 2.6-fold increase in 
GLUT-mediated glucose transport (Sakoda et al., 2000).  A similar phenomenon 
occurs in 3T3L1 adipocytes; Chen et al showed that sorbitol-induced osmotic shock 
caused an increase in GLUT4 translocation to the plasma membrane which was 
mirrored by an increase in glucose uptake (Chen et al., 1997).  However, this GLUT2 
response to mannitol is activated by a hyperglycaemic-independent, rapid stress-
response signalling pathway to increase renal glucose reabsorption during times of 
osmotic stress.  
 
Previous studies have shown an increase in GLUT3 protein and mRNA in the 
pituitary gland in response to 3-day water deprivation studies, an effect which is 
remedied by rehydration (Koehler-Stec et al., 2000).  Although Koehler-Stec et al 
made no plasma osmolality measurements during dehydration, it has been established 
that 48 hour water deprivation causes a significant increase in plasma osmolality 
(Gottlieb et al., 2006).  The data presented in this chapter shows a similar mediation 
of GLUT expression in response to normalised osmolality as the use of 0.08 M 
mannitol, a more accurate control for the plasma osmotic effect of glucose, did not 
influence GLUT2 levels at the proximal tubule BBM.    
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7.5 Conclusions 
 
In summary, the results presented here show that, unlike GLUT2 in the jejunum, 
levels of GLUT2 at the renal BBM are not influenced by short-term hyperglycaemia.  
A longer-term STZ-induced hyperglycaemic period of 7 days is necessary to induce 
expression at the proximal tubule BBM.  The expression of GLUT2 into the proximal 
tubule BBM correlates with PKC-βI expression, suggesting that the signals to recruit 
GLUT2 also require a 7-day hyperglycaemic period for activation. Compared with 
previous studies in type I diabetes, where renal GLUT2 is rapidly abolished after 
overnight fasting, present data indicates that the mechanism of increased GLUT2 
expression at the renal BBM is different from its removal from the membrane.  
Furthermore, the data also shows that renal PKC-βI and GLUT2 may be activated via 
a separate, rapid-response signalling pathway to increase glucose reabsorption during 
osmotic stress. 
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8 Renal glucose transport adaptations in rodent 
models associated with metabolic syndrome 
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8.1 Introduction 
 
The experiments described in Chapter 7 demonstrated that renal GLUT2 expression at 
the proximal tubule BBM, via PKC-βI, requires a 7-day streptozotocin (STZ)-induced 
hyperglycaemic stimuli, although osmotic shock results in a far more rapid response 
of GLUT2.  Studies presented here, and in the literature (Dominguez et al., 
1994a;Dominguez et al., 1994b;Chin et al., 1997;Marks et al., 2003;Goestemeyer et 
al., 2007;Albertoni Borghese et al., 2009) have been performed to understand 
proximal tubular glucose handling in type I diabetes however less is understood in the 
insulin-independent form of the disease, type II diabetes.  Studies from the small 
intestine imply that a basolateral insulin stimulus is responsible for the postprandial 
recruitment of GLUT2 to the enterocyte BBM however similar studies have yet to be 
undertaken to assess the effect of insulin on proximal tubular GLUT2 (Tobin et al., 
2008).  Renal glucose handling in response to the metabolic models associated with 
the onset of type II diabetes, such as obesity, have also been assessed in this chapter.  
In addition, further understanding of glucose reabsorption in obesity and diabetes led 
to the study in response to palliative Roux-en-Y (RYGB) gastric bypass surgery.    
 
8.1.1 Type II diabetes – the Goto-Kakizaki model 
 
Currently, type II diabetes is the prevalent form of the disease with over 285 million 
sufferers worldwide and predictions for more than 438 million by 2030 (Diabetes UK 
report 2010).  Unlike type I diabetes which can be induced in control animals using a 
single IV injection of alloxan or streptozotocin (Dunn et al., 1944;Rakieten et al., 
1963), type II diabetes can be studied in genetically, experimentally and nutritionally 
altered animal models (Table 5.2).  However, due to the complex nature of the 
disease, some models are related to an obese phenotype with leptin deficiency or 
resistance, for example, Zucker Diabetic Fatty (ZDF) rats (Pick et al., 1998), whereas 
other models also have an association with hypertension, for example the ZSF1 rat 
(Tofovic et al., 2001).  The Goto-Kakizaki (GK) rat model was considered most 
appropriate for the studies reported in this thesis due to its normotensive, non-obese 
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phenotype; this makes the GK rat one of the best characterised models for studying 
complications in type II diabetes.  The GK rat was developed in 1976 by Goto et al, 
by the selective inbreeding of non-diabetic Wistar rats with glucose intolerance used 
as a selective index over many generations (Goto et al., 1976).  As a result, GK rats 
carry a susceptibility locus for diabetes (known as Niddm1), which confers defective 
insulin secretion (Fakhrai-Rad et al., 2000).  GK rats exhibit moderate and stable non-
ketotic hyperglycaemia of around 15 mM displayed at 12 weeks of age, although 
glucose intolerance is displayed as early as 2 weeks of age with impaired insulin 
secretion (Adachi et al., 2003).   
 
GK rats do not exhibit progressive renal disease, characterised by glomerulosclerosis, 
proteinuria or end-stage renal disease (ESRD); however, at 8-10 weeks of age they 
display thickening of the glomerular basement membrane, mild mesangial matrix 
expansion and glomerular hypertrophy, which results in both increased total 
mesangial volume and glomerular capillary luminal volume (Yogihashi et al, 
1978;Phillips et al., 2001).  The introduction of a further factor, such as hypertension, 
is necessary for the GK rat to become a model for renal disease; for example, Janssen 
et al showed that deoxycorticosterone salt (DOCA)-induced hypertension in GK rats 
caused an increase in renal damage with progressive and marked podocyte injury and 
proteinuria, as well as further tubulointerstitial damage (Janssen et al., 2003).  
Therefore, since prolonged hyperglycaemia in the GK rat is not associated with 
changes in renal function, it is an appropriate model for the early pre-clinical phase of 
human diabetic nephropathy (Osterby et al., 1975). 
 
Early studies in diabetes showed an increase in carbohydrate digestion and glucose 
absorption in the small intestine, suggesting an insulin-dependent consequence of the 
disease (Stenling et al., 1984;Debnam et al., 1990;Fujita et al., 1998).  
Hyperglycaemia was believed to be the cause of the increased glucose absorption rate 
in type I and II diabetes, as a reversal was noted in response to insulin treatment 
(Caspary, 1973;Csaky et al., 1981;Thomson, 1983).  Fujita et al found an increase in 
SGLT-mediated glucose absorption in response to post-prandial glucose in type II 
diabetic Otsuka Long Evans Tokushima Fatty (OLETF) rats with an increase in 
SGLT1 mRNA (Fujita et al., 1998).  Additionally, STZ-induced type I diabetic rats 
exhibited up-regulated active glucose uptake, whereas Ferraris et al saw no change in 
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glucose absorption in STZ-induced type I diabetic mice (Debnam et al., 1990;Ferraris 
et al., 1993).  However, a complete understanding of glucose absorption and the 
transporters responsible, in different regions of the small intestine is still unresolved.  
 
8.1.2 Obesity and metabolic syndrome 
 
The imbalance between energy intake (the consumption of processed foods with high-
energy and low-fibre content) and energy expenditure (reduction in physical activity 
due to sedentary lifestyle) are strongly correlated with the prognosis for type II 
diabetes (Olefsky, 2001;Knowler et al., 2009).  Specifically, an increase in the 
consumption of saturated and trans-saturated fats has been shown to adversely 
influence glucose metabolism and insulin resistance, whereas a low-glycaemic index 
diet, high in fibre can reduce the risk of type II diabetes (Hu et al., 2001;Hu et al., 
2001).  However, the onset of type II diabetes is also linked with genetic mutations 
and most variants are associated with pancreatic β-cell function (De Silva and 
Frayling, 2010).  The junk-food-induced development of diabetes is more likely in 
OLETF rats, possessing the diabetogenic gene ODB-1, than the control rats lacking 
the ODB-1 gene (Ishida et al., 1996;De Silva et al., 2010).  Also, the excess adiposity 
in OLETF rats fed a cafeteria diet, compared with those fed a chow diet, results in 
increased risk of type II diabetes (Okauchi et al., 1995); thus suggesting that both 
genetic risk factors and feeding-induced obesity together result in the high incidence 
of type II diabetes.   
 
As well as being a cause of type II diabetes, central obesity (classified as weight 
circumference ≥ 94cm for men and ≥ 80cm for women by the 2006 IDF) is the most 
dominant risk-factor for developing metabolic syndrome (Lorenzo et al., 2003).  Both 
hypertension (classified as systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg by the 2006 
IDF) and fasting hyperglycaemia (classified as ≥ 5.6 mM by the 2006 IDF) are also 
symptoms of metabolic syndrome (Khunti and Davies, 2005;Reaven, 2005).  Indeed, 
patients who suffer from metabolic syndrome and hypertension are more at risk of 
developing type II diabetes (Cooper-DeHoff et al., 2010).  Both type I and type II 
diabetes have been associated with metabolic syndrome but a recent study found that 
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69.5% patients with type II diabetes had metabolic syndrome, whereas only 22% 
patients with type I diabetes suffered metabolic syndrome (AlSaraj et al., 2009).  
There is also considerable data to show that the increase in adipocytes in a high-fat 
diet model causes insulin resistance, which is a determining factor in the development 
of type II diabetes (Unger, 1991;Yki-Jarvinen, 2002;Despres and Lemieux, 2006).  In 
fact only 5 days of high-fat feeding in healthy humans is necessary to raise plasma 
glucose by 0.5 mM, with an accompanying increase in insulin secretion due to hepatic 
insulin resistance (Brons et al., 2009).  
 
Although the literature clearly indicates a very tight relationship between obesity and 
the onset of metabolic syndrome and type II diabetes (Figure 5.3) (Must et al., 
1999;Mokdad et al., 2001;Knowler et al., 2009), there are few studies on renal 
glucose handling in obesity or metabolic syndrome as a model of prediabetes.  To 
understand further renal glucose transport in diabetes, the factors leading to the 
disease were studied in feeding studies with both a junk-food diet, a model to reflect 
the etiology of dietary obesity in humans, and a high-fat diet, an established model of 
insulin-resistance and obesity.   
 
8.1.2.1 Junk-food diet 
 
The epidemic of type II diabetes has been attributed to an increase in obesity due to 
junk-food within the Western diet; therefore, to adequately simulate prediabetes, a 
feeding study using processed ‘human’ junk foods was established.  Feeding a 
palatable junk-food diet to rats results in obesity and glucose intolerance, but the 
underlying mechanisms leading to these symptoms have not been adequately 
elucidated (Kiens and Richter, 1996;Petry et al., 1997). 
 
In 1976, Sclafani and Springer set up a feeding study, the ‘cafeteria diet’, in control 
rats to study the effects of dietary junk-food-induced obesity, rather than overfeeding 
of chow, on feeding behavioural patterns (Sclafani and Springer, 1976).  The cafeteria 
diet comprised of supermarket-purchased palatable foods, including chocolate chip 
cookies, salami, cheese, marshmallows and peanut butter.  This diet has been used 
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more recently as a model of dietary obesity to study different facets of obesity such as 
the physiological and neurological causes and consequences of compulsive eating 
behaviour (Heyne et al., 2009), and the regulation of the leptin receptor (Milagro et 
al., 2006).   
 
Interestingly, the junk-food diet has been shown to promote elongation of the small 
intestine, due to the reduced fibre content of the diet, increased food storage capacity 
and calorie intake occurring in response to the diet (Planas et al., 1992;Scoaris et al., 
2010).  These alterations in the handling of the diet are likely due to the atrophy in the 
small intestine that occurs from a lack of food in the diet, with reduced villus height 
and crypt depth in response to a low-fibre diet (Firmansyah et al., 1989;Scoaris et al., 
2010).  Furthermore, in rodents fed a high-fat diet, both alkaline phosphatase and α-
glucosidase activities in the jejunum are increased compared with those maintained on 
a normal chow diet (Sefcikova et al., 2008), however, it has been shown that 
genetically obese mice exhibit significantly higher intestinal disaccharidase and 
alkaline phosphatase activity, which precedes the development of excess body weight 
(Flores et al., 1990).   
 
The junk-food diet model used in the work presented here was set up in normal 
Wistar rats given ad libitium access to a diet high in saturated fats, sugar and salt, and 
low in protein and fibre, including food items such as flapjacks, crisps and chocolate 
bars over an 8 week period to reflect human feeding patterns resulting in obesity. 
 
8.1.2.2 High-fat diet 
 
The relationship between insulin resistance, metabolic syndrome, and obesity, and 
type II diabetes was also studied using a high-fat diet.  Chen et al showed that a 50%-
fat diet increases the plasma concentrations of total cholesterol and triglycerides, both 
of which are heavily associated with metabolic syndrome; indeed the 2006 IDF 
classified reduced high-density lipoprotein (HDL) cholesterol < 1.03 mM in males 
and < 1.29 mM in females and raised triglycerides > 1.7 mM as symptoms of 
metabolic syndrome (Chen et al., 2010).  In the same study, chronically restricting the 
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high fat diet by 50% of baseline daily food intake caused a reduction in both HDL 
cholesterol and triglycerides. 
 
The few renal studies using a high-fat model show conflicting data with regards to 
kidney function: a high-fat diet fed for 3 months to C57BL/6J mice caused an increase 
in urine flow rate and sodium excretion rate, although no hypertension or kidney 
dysfunction was apparent (Noonan and Banks, 2000).  However, Song et al showed 
that rats fed a diet high in fats for 4 weeks had reduced fractional excretion of sodium 
and a blunted down-regulation of aldosterone-mediated effects, resulting in increased 
mean arterial pressure, which is associated with metabolic syndrome (Song et al., 
2004).   
 
The insulin-resistant nature of animals fed a high-fat diet, implies that a dysregulation 
of glucose handling occurs, therefore it was of interest to study renal glucose transport 
in the high-fat model.  This insulin-resistant model was set up by allowing control 
Wistar rats ad libitium access to 60% fat-as-calories chow (Research Diets, New 
Brunswick, USA) largely comprised of soybean oil and lard for 5 weeks.  
 
8.1.2.3 RYGB surgery 
 
There are three main treatment methods for obesity: 1) lifestyle changes, including a 
controlled diet and exercise regime (Tuomilehto et al., 2001;Knowler et al., 2009), 2) 
pharmacotherapy such as orlistat and sibutramine (Wadden et al., 2005;Powell and 
Khera, 2010), and 3) gastric bypass surgery (Rand and Macgregor, 1991;Sagar, 1995).  
Gastric bypass surgery involves the formation of a small stapled proximal stomach 
which limits the capacity for food intake (Kral, 1987).  Gastric bypass can be classed 
as either restrictive, including gastric banding and sleeve gastroectomy, or 
malabsorptive, such as jejunoileal bypass, a technique considered too extreme and 
therefore no longer used (Brolin et al., 2002) or hybrid, of which Roux-en-Y gastric 
bypass (RYGB) surgery is considered the ‘gold-standard’ treatment.   
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RYGB involves the transaction of the stomach into a small pouch, redirection of a 10 
cm duodenal segment, and anastomosis to a 50 cm jejunal loop that joins a 25 cm 
segment of the ileum (Bueter et al., 2010).  Thus, the majority of the stomach and the 
entire duodenum (biliopancreatic limb) are bypassed and food moves through the 
small gastric pouch immediately into the jejunum (alimentary limb), and then the 
ileum (common limb) before reaching the cecum (Figure 8.1). 
 
RYGB can be performed laparoscopically and has been shown to abolish 
hypertension and hypertriglyceridemia, as well as resulting in weight loss (Wittgrove 
et al., 1996;Lima et al., 2010).  This reduction in body weight, post-RYGB, has been 
attributed to an increase in postprandial PYY and GLP-1, thus providing enhanced 
satiety and an appropriate physiological environment for weight loss (Le Roux et al., 
2006). 
 
Figure 8.1 – Schematic diagram of the physiological intestinal alterations in RYGB 
surgery – A: before RYGB operation  indicates the movement of food, B: after 
RYGB operation  indicates movement of food and grey area is the bypassed region 
of the gastrointestinal system  
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Interestingly, RYGB surgery has also been shown to ablate both type I and type II 
diabetes (Pories et al., 1995;MacDonald, Jr. et al., 1997;Ukkola, 2009;Czupryniak et 
al., 2010), with the effect occurring rapidly, within 24 hours of surgery, and before 
any significant weight loss (Schauer et al., 2003;Andreelli et al., 2009;Hall et al., 
2010).  Follow-up studies between 6 and 168 months post-RYGB with human type II 
diabetic patients have shown on average 80% of patients exhibit abolished diabetes, 
and resolution was dependent on the length of diabetes and pancreatic reserve (Pories 
et al., 2001;Schauer et al., 2003;Sugerman et al., 2003;Torquati et al., 2005). 
 
However there is limited data on the impact of gastric bypass surgery on glucose 
homeostasis, as mediated by the gut-renal axis, following gastric bypass surgery.  
Thus RYGB is an interesting model in which to study renal and intestinal glucose 
handling and transport because, as well as its ability to treat obesity, RYGB also 
results in the immediate normalisation of glycaemia in diabetes.   
 
8.2 Aims of chapter  
 
The aims of this chapter are to study renal glucose transport across the BBM in type II 
diabetes as a comparison with the type I diabetes study in the previous chapter.  
Furthermore, glucose transport at the proximal tubule BBM was also assessed in 
models of metabolic syndrome induced by feeding studies, as a precursor to type II 
diabetes.  With the epidemic of metabolic syndrome and obesity escalating, renal 
glucose handling in models preceding type II diabetes is an increasing area of interest. 
The palliative RYGB surgery was studied in a rodent model to understand the role of 
renal and intestinal glucose transport in the improved glucose homeostasis following 
surgery. 
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8.3 Results 
8.3.1 Type II diabetes  
8.3.1.1 Animal parameters of the Goto-Kakizaki (GK) rat 
 
The GK rats had significantly reduced body weight compared with the age-matched 
lean Wistar rats (316.6 ± 5.2 g compared with 397 ± 7.4 g) and, although there was no 
change in kidney weight, the ratio of kidney-to-body weight was 16% higher in the 
GK animals (Table 8.1 - 1).  In keeping with the type II diabetic disease model, the 
rats exhibited significantly elevated plasma glucose concentrations of 20.3 ± 1.2 mM 
and an accompanying 7% increase in plasma osmolality (Table 8.1 - 2).  There was a 
23.9% increase in circulating insulin levels in GK rats compared with lean controls, 
although the elevation was not significant (Table 8.1 - 2).  Interestingly, the urine 
glucose concentration in the initial five GK animals studied was 14.2 ± 0.5 mM, at a 
plasma glucose level of 17.8 ± 0.4 mM (Figure 8.2).  However, in the final three type 
II diabetic rats assessed on consecutive days glycosuria was amplified to 59.3 ± 3.9 
mM, at a plasma glucose level of 24.3 ± 0.9 mM (Figure 8.2).  
 
Figure 8.2 – Scattergraph of the relationship between glycosuria and hyperglycaemia 
in 8-9 week lean (diamond points) and type II diabetic GK (square points) rats 
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Table 8.1 – 1) Body and kidney weight, and kidney-to-body weight ratio and 2) 
Plasma glucose, osmolality and basal circulating insulin measurements in 8-9 week 
lean and type II diabetic GK rats.  Values are expressed as mean ± SEM, n=8, 
***p<0.005, ****p<0.001 compared with lean. 
1 
 Lean GK 
Body weight (g) 397 ± 7.4 316.6 ± 5.2 **** 
Kidney weight (g) 2.51 ± 0.42 2.38 ±1.05 
Kidney:body weight ratio 6.33 ± 0.1 7.53 ± 0.35 *** 
 
2 
 Lean GK 
Plasma glucose (mM) 13.28 ± 0.41 20.26 ± 1.25 **** 
Plasma osmolality (mOsM) 329 ± 2 353 ± 3 **** 
Basal plasma insulin (ng.ml
-1
) 4.83 ± 1.12 6.35 ± 1.38 
 
8.3.1.2 Renal BBM vesicle glucose uptakes in GK type II diabetic rat  
8.3.1.2.1 Validation of BBM vesicles 
 
The BBM vesicles freshly-prepared from control lean Wistar animals and type II 
diabetic GK animals showed the same enrichment values (lean BBM vesicles were 
6.26 ± 1.04-fold enriched compared with 6.26 ± 0.68-fold enrichment in type II 
animals) as assessed with alkaline phosphatase marker enzyme.   There was also no 
significant change in intravesicular volume measured after 15 minute incubation using 
100 μM glucose concentration, with vesicle trapped space in lean animals 2.84 ± 0.23 
μl.mg protein-1 compared with 3.6 ± 0.6 μl.mg protein-1 in type II animals.  To verify 
the ability of BBM vesicle to accumulate glucose, sodium-dependent glucose 
transport was determined at different time points using 100 μM glucose.  At 40 
seconds, an early peak in glucose uptake was noted (Figure 8.3), as has been 
previously shown (Marks et al., 2003), which is due to a rapid influx of Na
+
 ions into 
the BBM vesicle.  There was complete inhibition of the overshoot in the presence of 
phloridzin, which was consistently shown throughout the glucose uptake experiments 
at this concentration of glucose (Figure 8.3).    
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Figure 8.3 – Representative graph of the time-dependent overshoot seen for renal 
BBM vesicle glucose uptake at 100μM glucose concentration, in the presence (dotted 
line) and absence of phloridzin (solid line)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.3.1.2.2 Renal BBM glucose transport in GK type II diabetic rats  
 
In renal BBM vesicles from GK animals there was a significant increase in SGLT-
mediated glucose uptake between 30-960 μM glucose concentration (Figure 8.4 - 1), 
with a 40% increase in the Vmax of SGLT-mediated glucose transport (Figure 8.4- 2).  
This was accompanied by a significant increase in Km (lean Km 147.1 ± 21.6 μM 
compared with GK Km 264.3 ± 46 μM) of SGLT-mediated glucose transport (Figure 
8.4 - 3).  Although there was no effect of type II diabetes on total glucose transport at 
20 mM, the phlorizin-insensitive uptake was augmented in the GK rats (Figure 8.5). 
GLUT-mediated transport was elevated from 1660.1 ± 380.8 pmoles.mg protein
-1
 in 
lean animals to 3809.5 ± 426.4 pmoles.mg protein
-1
 in type II diabetic animals. 
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Figure 8.4 – Effect of type II diabetes in GK rats (broken line) on SGLT-mediated 
glucose uptake (1) Glucose concentration curve (2) Vmax and (3) Km of glucose uptake 
derived from BBM vesicles incubated at glucose concentrations between 30-960 μM 
for 4 seconds.  Values are expressed as mean ± SEM, n=6-8, *p<0.05. ***p<0.005 
compared with lean control rats (solid line). 
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Figure 8.5 – Effect of type II diabetes on total glucose uptake (open bars) and GLUT-
mediated glucose uptake, in the presence of phloridzin (closed bars) using renal BBM 
vesicles incubated in 20 mM glucose for 4 seconds.  Mean ± SEM, n=6-8, 
***p<0.005 compared with lean control rats. 
 
 
 
 
 
 
 
 
 
 
 
 
8.3.1.3 Effect of type II diabetes on BBM expression of renal glucose transporters 
  
The proximal tubule expression of GLUT2, PKC-βI, GLUT5 and SGLT1 was 
assessed in BBM prepared from the GK animals, to assess the cause of the increased 
uptake outlined in section 8.3.1.2.2.  There was a significant elevation in both GLUT2 
and GLUT5, with an increase of 1.4- and 1.5-fold, respectively (Figure 8.6), in 
response to type II diabetes.  Expression of the GLUT2 activator PKC-βI exhibited a 
2-fold increase in type II diabetic animals and BBM expression of the other glucose 
transporter studied, SGLT1, was also significantly augmented in GK animals (Figure 
8.6).  
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Figure 8.6 - Effects of type II diabetes in GK animals (D, closed bars) on expression 
of GLUT2 and GLUT5, PKC-βI and SGLT1 at the proximal tubule BBM.  1) 
Western blots 2) quantification of western blots (expressed as percentage BBM 
expression), standardised to β-actin. Values are expressed as mean ± SEM, n=6-8, 
*p<0.05, ****p<0.001 compared with lean control animals (C, open bars) 
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8.3.2 Junk-food model 
 
The augmentation of glucose transport in both STZ-induced type I diabetes and the 
non-obese GK model of type II diabetes, raised the interesting question of whether a 
pre-diabetic metabolic model would also be associated with changes in expression of 
renal BBM glucose transporters.  The junk-food model was set up to assess this using 
an energy-rich diet of palatable processed foods over an 8-week time period to mimic 
a Western diet. 
 
8.3.2.1 Animal parameters following a junk-food diet 
 
Experimental animals were allowed ad libitum access to both chow and a combination 
of sugary and fatty human foods, including marshmallows and cheese.  Figure 8.7 – 1 
shows that rats consumed a similar amount of junk-food (20.82 ± 0.61 g) as control 
animals maintained on normal chow (20.53 ± 0.19 g).  31.4% of the administered 
junk-food was consumed and Figure 8.7 – 2 shows the amounts of each food eaten per 
animal per day.  The control animals had significantly reduced weight gain compared 
with the junk-food fed animals (Figure 8.8 - 1) and over the 8-week feeding period the 
experimental rats put on weight at a significantly accelerated rate compared with the 
control group (Figure 8.8 - 2).  There was a 20.1% increase in plasma glucose 
concentration in the junk-food fed animals (Figure 8.9 - 1) and a 25% increase in 
urine glucose concentration.  There was also a significant 327% elevation in 
circulating basal insulin levels in junk-food fed animals (Figure 8.9 - 2). 
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Figure 8.7 - 1) Daily weight of chow consumed by control and experimental animals 
(open bars) and junk-food consumed by experimental animals (closed bar) 2) Daily 
components of junk-food diet consumed by experimental rats.  Values are expressed 
as mean ± SEM, n=6-12 animals monitored daily for 55 days. 
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Figure 8.8 - Body weight increase in response to 8 weeks junk-food diet 1) Total 
weight gain in control chow-fed animals and experimental junk-food-fed animals at 
time of cull 2) Progressive weight gain in chow-fed (diamond points) and junk-food-
fed (square points) animals over 8 week feeding period. Values are expressed as mean 
± SEM, n=6-12, *p<0.05, ***p<0.005 compared with chow-fed animals 
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Figure 8.9 - 1) Effect of chow and junk-food diet on plasma (open bar) and urine 
(closed bar) glucose concentration and 2) plasma insulin levels. Values are expressed 
as mean ± SEM, n = 6-12, **p<0.01, ***p<0.005 compared with chow-fed controls 
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8.3.2.2 Effect of junk-food diet on glucose transporter expression at the proximal 
tubule BBM 
Kidneys from chow and junk-food fed animals exhibited no difference in weight, with 
chow-fed rat kidneys weighing 1.10 ± 0.02 g compared with 1.13 ± 0.03 g for junk-
food rat kidneys.  There was also no significant change in the enrichment values from 
the renal BBM vesicles prepared from both chow and junk-food fed animals (chow-
fed rat BBM vesicles were 6.34 ± 0.41-fold enriched compared with 7.08 ± 0.5-fold 
enrichment in junk-food fed rats).  There was a 5.8-fold increase in GLUT2 
expression at the proximal tubule BBM in junk-food fed animals, which was 
accompanied by a 1.7-fold increase in PKC-βI expression (Figure 8.10).  The junk-
food diet also caused a significant elevation in SGLT1 transporter expression at the 
renal BBM (Figure 8.10), and a 3-fold increase in GLUT5 expression.   
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Figure 8.10 – Effects of 8-week junk-food diet (JF, solid bars) on expression of 
GLUT2 and GLUT5, PKC-βI and SGLT1 expression at the proximal tubule BBM.  1) 
Western blots 2) quantification of western blots (expressed as percentage BBM 
expression) standardised to β-actin. Values are expressed as mean ± SEM, n=6-8, 
*p<0.05, **p<0.01, ***p<0.005 compared with chow-fed control animals (C, open 
bars) 
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8.3.3 High-fat diet       
 
The amplification of renal GLUT2, GLUT5, and SGLT1 expression in response to the 
energy-rich processed food fed during the junk-food study led to the question as to 
whether the transporters were responding to a fat-specific, obesity stimulus in the 
junk-food.  The high-fat, insulin-resistant model was used (animals were prepared by 
Dr. Cleasby, Royal Veterinary College, London) to assess this; Wistar rats were given 
ad libitum access to a 60% fat-as-calories chow over a 5-week period. 
 
8.3.3.1 Animal parameters following a high-fat diet 
 
Animals fed a high-fat diet exhibited a significant increase in body weight (Figure 
8.11), which was matched by a 9.3% increase in kidney weight (Figure 8.11).  There 
was also a significant increase in epididymal (EPI) fat pad mass from 1.91 ± 0.07 g in 
chow-fed animals to 3.23 ± 0.34 g in high-fat fed animals.  Although there was a 
significant 10.8% increase in fasted plasma glucose concentration of high-fat fed 
animals, values remained within the normal range (Table 8.2).  Both the chow and 
high-fat fed animals had no detectable glucose in the urine.  Basal insulin levels were 
increased by 51.3% in high-fat fed rats, with a 34.9% increase in circulating insulin 
after the insulin tolerance test (Table 8.2). 
 
Figure 8.11 – Final body (bar chart) and kidney weights (broken line) in rats fed 
chow or high-fat diet. Values are expressed as mean ± SEM, n=6-8, *p<0.05 
compared with chow body weight, 
#
p<0.05 compared with chow kidney weight. 
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Table 8.2 – Fasted plasma concentrations of glucose, basal insulin and insulin 
concentration following the insulin tolerance test. Values are expressed as mean ± 
SEM, n = 6-8, *p<0.05, ***p<0.005 compared with chow-fed controls 
 
 Chow High-fat 
Fasting plasma glucose (mM) 4.17 ± 0.14 4.67 ± 0.17 * 
Basal plasma insulin (ng.ml
-1
) 4.91 ± 0.87 10.07 ± 1.76 * 
Plasma insulin post-tolerance test (ng.ml
-1
) 15.5 ± 1.93 23.8 ± 1.94 *** 
 
 
 
8.3.3.2 Effect of high-fat diet on glucose transporter expression at the proximal 
tubule BBM 
 
There was no significant change in the alkaline phosphatase enrichment from renal 
BBM vesicles prepared from chow and high-fat fed animals, with 8.23 ± 0.75-fold 
enrichment and 7.25 ± 0.92-fold enrichment, respectively. A significant 3-fold 
increase in GLUT2 transporter expression was noted in the renal BBM vesicles 
prepared from animals fed the high-fat diet for 5 weeks compared with chow fed 
animals (Figure 8.12).  There was also an increase in the GLUT2 activator, PKC-βI, 
although no change in SGLT1 or GLUT5 expression was seen (Figure 8.12).   
 
 
 
 
 
 
 
 
  
  165 
Figure 8.12 – Effects of 5-week high-fat diet (HF, solid bars) on GLUT2 and 
GLUT5, PKC-βI and SGLT1 expression at the proximal tubule BBM.  1) Western 
blots 2) quantification of western blots (expressed as percentage BBM expression),   
standardised to β-actin.  Values are expressed as mean ± SEM, n=6-8, *p<0.05, 
***p<0.005 compared with chow-fed control animals (C, open bars) 
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8.3.4  Roux-en-Y Gastric Bypass (RYGB) surgery 
 
The increase in GLUT2 transporter in the outlined models of diabetes and obesity was 
investigated further in a rodent model of RYGB surgery.  As well as an effective 
treatment for weight loss in obesity, gastric bypass surgery also results in the rapid 
resolution of hyperglycaemia in type I and II diabetes.  The response of glucose 
handling to duodenal bypass was studied in rats 60 days after RYGB surgery. 
 
8.3.4.1 Animal parameters following RYGB surgery 
 
Before surgery, animals in both the sham and RYGB group were non-obese and had 
matched body weight (355.6 ± 6.37 g and 346.2 ± 4.26 g, respectively).  At 60 days 
post-surgery, the RYGB animals exhibited a 4% increase in mean body weight 
compared with a 30% increase in those subjected to sham surgery (Figure 8.13 - 1).  
There was no significant change in fasting plasma glucose concentrations between the 
sham (8.53 ± 0.59 mM) and RYGB (8.48 ± 0.83 mM) animals.  Consequentially, 
there was no difference between plasma osmolality measurements (313.2 ± 1.4 
mOsM and 313.4 ± 3.4 mOsM after sham and RYGB surgery, respectively); also both 
sham and RYGB-operated animals displayed no glycosuria but there was a 192.7% 
reduction in circulating insulin levels in animals 60 days after RYGB (Figure 8.13 - 
2).  Kidneys from RYGB animals exhibited a significant 20.6% decrease in weight 
compared with those from sham operated animals.   
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Figure 8.13 – Animal parameters following RYGB surgery 1) Body weight and 2) 
fasted basal plasma insulin levels in animals 60 days after sham (solid line) or RYGB 
(broken line) surgery.  Values are expressed as mean ± SEM, n = 8-20, ***p<0.005, 
****p<0.001 compared with sham surgery control. 
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8.3.4.2 Effect of RYGB surgery on glucose transporter expression at the 
proximal tubule BBM 
 
There was no change in renal BBM vesicle enrichment between the two surgical 
groups of animals, following sham surgery BBM vesicles were 5.66 ± 0.54-fold 
enriched compared with 6.34 ± 0.51-fold enrichment after RYGB surgery.  Following 
RYGB surgery, there was a 2-fold decrease in GLUT2 expression at the proximal 
tubule BBM (Figure 8.14).  This was accompanied by a significant reduction in PKC-
βI expression and a 2-fold decrease in GLUT5 expression; however, no change in 
SGLT1 expression was seen (Figure 8.14).   
 
Figure 8.14 – Effects of RYGB surgery (RY, solid bars) on GLUT2 and GLUT5, 
PKC-βI and SGLT1 expression at the proximal tubule BBM. 1) Western blots 2) 
quantification of western blots (expressed as percentage BBM expression),   
standardised to β-actin.  Values are expressed as mean ± SEM, n=6, *p<0.05 
compared with sham surgery controls (S, open bars)  
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8.3.4.3 Effect of RYGB surgery on gene expression of glucose transporters in the 
renal cortex  
 
There was a trend for reduced mRNA expression of glucose transporters in the renal 
cortex from animals post-RYGB surgery.  Although the decline in mRNA expression 
of SGLT1, SGLT2 and GLUT5 did not reach significance, the reduction was 52.1%, 
74.7% and 59.4%, respectively (Figure 8.15).  GLUT2 mRNA expression in renal 
cortex from animals post-RYGB surgery was significantly reduced, with a 79.8% 
decrease compared to that seen in animals after sham surgery (Figure 8.15).    
 
Figure 8.15 – Effects, after 60 day sham (open bars) or RYGB surgery (closed bars), 
on SGLT1, SGLT2, GLUT2 and GLUT5 mRNA expression in renal cortex.  Values 
are expressed as mean ± SEM standardised to β-actin, n=6-8, ***p<0.005 compared 
with sham surgery control animals   
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8.3.4.4 Effect of RYGB surgery on glucose transporter expression at the 
enterocyte BBM 
 
 The regional profile of BBM glucose transporter expression was studied in the small 
intestine after sham and RYGB surgery (Figure 8.16).  There was a 2-fold increase in 
GLUT2 expression at the BBM in the alimentary limb of RYGB animals, although 
this did not reach statistical significance (Figure 8.16).  Expression of GLUT2 in the 
bypassed biliopancreatic limb of RYGB animals was unchanged from that seen in the 
non-bypassed duodenum in sham operated animals (Figure 8.16).  Expression of 
GLUT5 was significantly reduced in the biliopancreatic limb of animals post-RYGB 
compared with that seen in animals after sham surgery (Figure 8.16).  However, no 
difference was noted between GLUT5 expression in the jejunum of sham animals and 
the alimentary limb of RYGB animals (Figure 8.16).  There was a significant increase 
in the jejunal GLUT2 activator, PKC-βII, and SGLT1 expression in the alimentary 
limb of RYGB animals, but no change in expression of GLUT2 in the biliopancreatic 
limb (Figure 8.16).     
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Figure 8.16 - Effects of RYGB surgery (RY, closed bars) on GLUT2 and GLUT5, 
PKC-βII and SGLT1 BBM protein expression in the small intestine 1) Western blots 
2) quantification of western blots (expressed as percentage BBM expression), 
standardised to β-actin.  Values are expressed as mean ± SEM, n=4-6, *p<0.05, 
**p<0.01 compared with sham surgery controls (S, open bars) 
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8.3.4.5 Effect of RYGB surgery on gene expression of glucose transporters in the 
small intestine   
 
The mRNA expression profile of intestinal glucose transporters from sham and 
RYGB surgery animals was also studied (Figure 8.17).  mRNA expression of GLUT2 
was increased significantly by 266%, in the alimentary limb from RYGB rats (Figure 
8.17 - 1).  No change in GLUT2 mRNA was noted in the duodenum or ileum from 
animals following sham surgery compared with the biliopancreatic limb following 
RYGB surgery (Figure 8.17 - 1). There was a 250% reduction in GLUT5 expression 
in the biliopancreatic limb following RYGB surgery, whereas GLUT5 mRNA 
expression in the alimentary limb showed no significant change, as did GLUT5 
mRNA expression in the common limb of RYGB animals (Figure 8.17 - 2). 
 
Figure 8.17 – Regional mRNA expression profile, 60 days after sham (open bars) or 
RYGB surgery (closed bars), on 1) GLUT2 and 2) GLUT5 in the small intestine.  
Values are expressed as mean ± SEM, standardised to β-actin, n=5-6, *p<0.05, 
***p<0.005 compared with sham control animals   
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8.4 Discussion 
 
Type II diabetes in the western population is reaching epidemic levels and the 
relationship between obesity, metabolic syndrome and type II diabetes has been well 
established.  In the studies presented here, renal glucose handling in these models has 
been assessed to understand potential mechanisms of glycaemia in type II diabetes, 
pre-diabetic diet-induced obesity, and following gastric bypass surgery.  The animal 
parameters and expression of glucose transporters at the proximal tubule BBM in each 
metabolic model studied are summarised in Table 8.3. 
 
 
Table 8.3 - Summary table of effects of type II diabetes, and metabolic models 
associated with the disease, on animal parameters and expression of glucose 
transporters at the proximal tubule BBM.  
# 
represents animals which were fasted 
before cull. 
 
 
 
Body 
weight 
Kidney 
weight 
Plasma 
glucose 
Urine 
glucose 
Plasma 
insulin 
Proximal tubule BBM expression of: 
GLUT2 PKC-βI GLUT5 SGLT1 
Type II 
diabetes 
↓ ↔ ↑ ↑ ↔ ↑ ↑ ↑ ↑ 
Junk food 
diet 
↑ ↔ ↑ ↑ ↑ ↑ ↑ ↑ ↑ 
High-fat diet
#
 ↑ ↑ ↑ ↔ ↑ ↑ ↑ ↔ ↔ 
RYGB
#
 ↓ ↓ ↔ ↔ ↓ ↑ ↓ ↓ ↔ 
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Type II diabetes was studied using GK rats, since this model has been shown to have 
minimal effect on obesity and renal physiology, but still maintains the disease 
phenotype of glycaemia and insulinaemia dysregulation.  In accordance with human 
type II diabetic patients, body weight was reduced in GK rats, but the kidney-to-body-
weight ratio was elevated.  Interestingly, there was a progressive rise in glucose 
excretion (Figure 8.2) from the initial five GK rats studied, where modest glycosuria 
with characteristic glycaemia was presented, to the final three type II diabetic rats 
examined, which exhibited a small 4 mM rise in plasma glucose and a significant 
elevation in glycosuria to levels similar to those in STZ-induced type I diabetes. The 
development of glycosuria in the later animals did not coincide with changes in SGLT 
or GLUT-mediated glucose transport or transporter expression, suggesting that the 
progressive increase in plasma glucose, as part of the disease phenotype in GK rats, 
reaches a threshold concentration after which further rises in filtered glucose cannot 
be reabsorbed, and glycosuria is amplified.  However, it is worth noting that glucose 
concentration measured in urine is a rough index of glucose excretion and glomerular 
filtration rate (GFR) experiments would be necessary to establish the net glucose 
excretion in these type II diabetic animals.   
 
In type I diabetes, insufficient insulin is produced due to autoimmune destruction of 
pancreatic β-cells and patients present with reduced plasma insulin levels (Foulis et 
al., 1986).  In contrast, type II diabetes is associated with normal or increased insulin 
levels due to peripheral insulin resistance (Saltiel and Kahn, 2001;Ahren et al., 
2004;Reaven, 2005).  At 4 weeks of age, GK rats have been found to exhibit deficient 
insulin secretion without the onset of peripheral insulin resistance (Picarel-Blanchot et 
al., 1996).  However, data from GK rats obtained in the present study at 8-9 weeks of 
age exhibited no significant change in plasma insulin concentration, a finding also 
shown by Berthelier et al although this study showed a decrease in the efficacy of 
insulin on glucose utilisation in the whole body in GK rats (Berthelier et al., 1997).   
 
To assess the efficacy of the purified BBM vesicles, sodium-dependent glucose 
transport across the proximal tubule BBM was demonstrated by measuring glucose 
uptake into the BBM vesicles (Figure 8.3).  The time-dependent overshoot at 100µM 
glucose was inhibited by phlorizin, a competitive inhibitor of SGLT-mediated glucose 
uptake.  The early phase of glucose uptake, in the absence of phlorizin, occurs where 
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sodium ions and glucose are co-transported into the vesicle by SGLT1 and SGLT2.  
When the sodium gradient of the intravesicular space matches that outside the vesicle, 
SGLT-mediated glucose uptake is abolished and accumulated glucose diffuses out of 
the intravesicular space via facilitative transporters.  The time-dependent overshoot 
was not seen in the presence of phlorizin, demonstrating that SGLT1 and SGLT2, are 
responsible for the majority of sodium-dependent glucose uptake at low glucose 
concentrations (100µM) (Marks et al., 2003).     
 
Uptake data using BBM vesicle prepared from type II diabetic rats show an elevation 
in SGLT-mediated glucose transport, more specifically, both Vmax and Km were 
augmented, and this was accompanied by an increase in SGLT1 expression at the 
proximal tubule BBM.  This data suggests that type II diabetes in GK rats causes an 
increase in the maximum capacity for SGLT-mediated glucose transport across the 
proximal tubule BBM, as well as a rise in transporter insertion; thus an increase in 
SGLT1 transporter expression correlates with elevated SGLT-mediated glucose 
uptake.  The lack of a working SGLT2 antibody prevents the assessment of total 
SGLT expression in the proximal tubule, although Hummel et al have recently shown 
that SGLT1 had 10-fold higher maximal transport rate for glucose transport than 
SGLT2 (Hummel et al., 2011).  Furthermore, they showed that human SGLT1 and 
SGLT2 expressed in human embryonic kidney cells exhibited an affinity for glucose 
of 2 mM and 5 mM, respectively; therefore, it is likely that a high percentage of 
SGLT-mediated glucose transport seen in the type II diabetic GK rats is due to 
SGLT1 (Hummel et al., 2011).  Despite this, the relationship between increased 
glucose uptake and SGLT2 expression in vivo has not been established.  Albertoni 
Borghese et al showed that there was an increase in α-methyl glucose uptake at 14 
days STZ-induced type I diabetes; although accompanied by a slight increase in 
SGLT2 expression at the BBM, the elevated transport could not be fully attributed to 
SGLT2.  Indeed, there was no positive correlation between SGLT-mediated transport 
and SGLT2 expression (Albertoni Borghese et al., 2009).  However, in STZ-induced 
type I diabetes it has been shown here (Chapter 7) and in previous studies 
(Dominguez et al., 1994a;Marks et al., 2003) that SGLT1 is not up-regulated in the 
insulin-dependent form of the disease.  In 5/6 nephrectomised rats, the resulting 
decrease in Vmax of SGLT-mediated glucose uptake was attributed to the marked 
reduction in SGLT2 mRNA, as no change was seen in expression of SGLT1 mRNA; 
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however, no data were available on the BBM expression of the transporter (Nakamura 
et al., 2004).  In vitro perfused tubule studies have shown that SGLT2 has a higher 
capacity for glucose transport (Vmax of 83 pmol/min per mm) than SGLT1 (Vmax of 
7.9 pmol/min per mm) (Barfuss et al., 1981).  Therefore, an increase in SGLT-
mediated glucose uptake when there is high glucose in the tubular fluid would be 
attributable to the high capacity SGLT2 transporter.  Interestingly, SGLT2 inhibitors 
currently in clinical trials such as dapagliflozin result in increased urinary glucose 
excretion and lower glycaemia in diabetes; however, these inhibitors cause between 
50-60% reduction in glucose uptake, strongly suggesting that SGLT1 and SGLT2 are 
responsible for approximately equal proportions of glucose reabsorption by the kidney 
in type II diabetes (Han et al., 2008;Komoroski et al., 2009).  Human studies have 
shown that the isolation and subculture of exfoliated proximal tubular epithelial cells 
from the urine of type II diabetic patients exhibit an increase in SGLT-mediated 
glucose transport, as well as augmented SGLT2 mRNA and protein expression, 
although no studies on SGLT1 were performed in these cells (Rahmoune et al., 2005).   
 
Elevated SGLT1 protein expression or SGLT-mediated glucose uptake were not seen 
in either short-term (Chapter 7) or chronic (Marks et al., 2003) STZ-induced type I 
diabetes, despite glycaemia in the type I model far exceeding that seen in GK rats in 
the present work.  Therefore, renal SGLT1 transporter expression does not respond 
solely to plasma (and therefore proximal tubular) glucose concentrations.  This 
conclusion is reinforced by the absence of a correlation between plasma glucose and 
SGLT1 expression in the type II diabetic GK studies presented here. 
 
In addition to the amplification in SGLT-mediated transport, a rise in GLUT-mediated 
transport at 20 mM glucose concentration was also noted in renal BBM vesicles from 
type II diabetic rats.  However, despite the augmentation of both SGLT- and GLUT-
mediated transport, total glucose uptake at 20 mM, in the absence of phlorizin, was 
not significantly altered.  SGLT-mediated transport did not reach saturation for either 
the lean or type II diabetic rats thus it is possible that, despite a higher Vmax and Km 
for transport, glucose uptake into BBM vesicles by SGLT may be matched in both 
groups at saturation.  Thus the increase in GLUT-mediated transport at this glucose 
concentration may not be sufficient to significantly elevate total glucose uptake at 20 
mM.  To study this, glucose transport, via both GLUT’s and SGLT’s, would need to 
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be measured between 960 µM and 20 mM.  The use of the GLUT inhibitor, phloretin, 
and an SGLT2 inhibitor, such as dapagliflozin, would enable the identification of the 
specific transporters involved in glucose transport across the proximal tubule BBM in 
response to type II diabetes.   
 
Elevated GLUT-mediated glucose transport was accompanied by increases in 
expression of GLUT2, its activator PKC-βI, and GLUT5 transporter, at the proximal 
tubule BBM.  This supports the relationship, originally postulated by Goestemeyer et 
al, between PKC-βI recruitment to the proximal tubule BBM and its signalling to 
shuttle GLUT2 to the BBM (Goestemeyer et al., 2007).  The higher expression of 
GLUT2 emphasises that increased GLUT-mediated glucose uptake occurs 
concomitantly with a rise in GLUT2 transporter expression.  Previous studies have 
shown that chronic STZ-induced type I diabetes also promotes an elevation in GLUT-
mediated transport, together with increases in both GLUT2 and GLUT5 proximal 
tubule BBM expression (Marks et al., 2003).  Therefore, the expression and capacity 
for glucose transport of renal GLUT2 and GLUT5 transporters may be responding to 
hyperglycaemia in both diabetes models, suggesting that increased tubular fluid 
glucose concentration in type I and type II diabetes results in the recruitment of 
GLUT2 and GLUT5 to the BBM.  However it is worth noting that GLUT-mediated 
transport in type II diabetes exceeds that seen in type I diabetes (Marks et al., 2003), 
despite higher plasma glucose levels in the latter model; therefore, GLUT-mediated 
glucose reabsorption does not correlate with hyperglycaemia in the GK rat.    
 
In vitro studies on the small intestine from the same GK rats used for renal glucose 
transport studies presented here were performed in our laboratory by Dr. E Debnam.  
Interestingly, using the everted sleeve technique, an increase in both GLUT- and 
SGLT-mediated glucose absorption was seen in both the jejunum and ileum (data not 
shown).  The up-regulation of glucose absorption in the small intestine in type II 
diabetes is also noted in the fatty type II diabetic OLETF rat, with hyperglycaemia in 
the disease believed to be the main cause, as insulin treatment reverses the augmented 
glucose absorption (Caspary, 1973;Csaky et al., 1981;Thomson, 1983;Fujita et al., 
1998).  Thus, glucose transport is up-regulated at the BBM via elevated abundance of 
GLUT’s and SGLT’s in both the small intestine and kidney during type II diabetes; 
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this represents how glucose homeostasis is likely regulated during the disease and 
poses a mechanism for the exacerbation of hyperglycaemia during diabetes.   
 
Interestingly, in both diet-induced models of insulin-resistance, the junk-food and 
high-fat feeding studies, GLUT2 expression was up-regulated.  The insulin receptor 
has been identified at sites all along the nephron, including the proximal tubule, with a 
higher proportion of expression at the basolateral, rather than brush-border, membrane 
(Hammerman, 1985;Feraille et al., 1995).  Thus it is possible that high circulating 
insulin provides a basolateral stimulus to promote GLUT2 recruitment to the proximal 
tubule BBM.  Circulating insulin levels in type II diabetes, another model of insulin 
resistance, are elevated (Alberti et al., 1992); however although there was a rise in 
plasma insulin levels in the GK rat, this did not reach significance.  Furthermore, in 
type I STZ-induced diabetes, where plasma insulin levels are down-regulated, GLUT2 
expression and GLUT-mediated glucose transport were elevated (Gepts, 1965;Marks 
et al., 2003).  Therefore the data presented here suggests that GLUT2 may exhibit 
increased expression at the proximal tubule BBM via an insulin-dependent or –
independent pathway, depending on glycaemia and disease state.    
 
Diabetes and diet-induced insulin-resistance is associated with an up-regulation in the 
resistin-like molecule RELMβ, a gut-derived hormone responsible for energy 
homeostasis, for example the hormone affects GLUT2 and SGLT1 expression in the 
jejunum; therefore, it is interesting to consider whether the hormone is having a 
similar effect on renal GLUT2 and SGLT1 (Shojima et al., 2005;Krimi et al., 2009).  
This could lend support to the idea that gut-derived hormones, such as GLP-1, control 
glucose transporter recruitment to the proximal tubule BBM (Marks et al., 2003). 
 
Although GLUT2 is able to transport fructose, GLUT5 is the main fructose 
transporter and is expressed in fructose-metabolising tissue such as the small intestine, 
adipocytes, skeletal muscle and kidney (Hajduch et al., 1998;Mate et al., 
2001;Hajduch et al., 2003).  Additionally, GLUT5 has a limited capacity for 
transporting glucose (Bell et al., 1990); therefore, the raised renal BBM expression of 
GLUT5 in type II diabetic rats, as well as in type I diabetes (Marks et al., 2003), may 
be associated with increased plasma and tubular fluid glucose concentration.  This is 
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emphasised by the type II diabetic GK model exhibiting a positive correlation 
between GLUT5 expression at the proximal tubule BBM and plasma glucose.   
 
Fructose is known to be involved in the pathogenesis of diabetic complications due to 
the non-enzymatic fructosylation of proteins, its action in the polyol pathway, and 
carbonyl stress (McPherson et al., 1988).  Also, increased fructose consumption 
results in glucose intolerance and hyperlipidaemia (Thorburn et al., 1989;Lee et al., 
1994) and it has been strongly correlated with the increased incidence of type II 
diabetes and obesity (Havel, 2005;Montonen et al., 2007).  Furthermore, type II 
diabetic patients also exhibit elevated serum fructose levels and excretion rates 
(Kawasaki et al., 2002); GLUT5 may be elevated at the renal BBM to handle the 
high-fructose load in the proximal tubular fluid.  The increased renal GLUT5 
expression at the BBM in response to type II diabetes in GK rats has also been noted 
in skeletal muscle (Stuart et al., 2007).  Additionally, GLUT5 was overexpressed in 
the duodenum from type II diabetic patients (Dyer et al., 2002).  Whether this is due 
to diabetes-induced changes in circulating fructose levels or whether it can be 
attributed to the ability of GLUT5 to transport glucose is currently unknown.    
Although the possibility of both factors affecting the transporter cannot be 
overlooked, the elevated GLUT5 expression at the BBM in both type I and II 
diabetes, where hyperglycaemia is noted suggests the latter is more likely.  However, 
GLUT5 transports low concentrations of glucose and has been shown to be 
unchanged by a glucose-rich diet (Gouron et al, 2003).  Elevated GLUT5 in type II 
diabetes is more likely to be a symptom of the disease (Rand et al., 1993;Burant and 
Saxena, 1994).  It is also seen in type I diabetes with elevated GLUT5 mRNA levels 
in the proximal straight tubule following chronic STZ-induced type I diabetes (Chin et 
al., 1997). 
 
Although there are many cell studies on renal glucose handling in response to a high-
glucose stimulus (Heilig et al., 1995;Phillips et al., 1999;Phillips et al., 1999;De Lima 
E Santos et al., 2009), there is limited data on the expression of renal GLUTs in type 
II diabetes.  Interestingly, studies with mesangial cells cultured from type II diabetic 
patients show enhanced GLUT1 expression (Liu et al., 2001).  Expression of GLUTs 
in GK rats was also altered in pancreatic β-cells, where a down-regulation of GLUT2 
expression was noted, although the resulting reduction in GLUT-mediated transport is 
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not sufficient to explain the profound reduction in glucose-stimulated insulin secretion 
seen in the GK model (Ohneda et al., 1993).  A reduction in GLUT4 recruitment to 
the plasma membrane in skeletal muscle from type II diabetic GK rats has also been 
demonstrated (Bitar et al., 2005), as well as a down-regulation of GLUT4 transporter 
in GK rat cardiac tissue (Desrois et al., 2004).  Although SGLT expression in GK rats 
has not been characterised before, chronic administration of a potent SGLT inhibitor 
in this rodent model of type II diabetes resulted in improved glucose tolerance and 
insulin resistance (Ueta et al., 2005).  Furthermore, SGLT-mediated glucose uptake in 
renal BBM vesicles was elevated in a genetic animal model of type II diabetes, 
C57BL/KsJ-db/db (Arakawa et al., 2001), suggesting that the up-regulation of SGLT-
mediated glucose transport in GK rats is a whole-body response to type II diabetes.  
 
The augmentation of glucose handling in type II diabetes in man has been previously 
shown and glucose uptake in the kidney is significantly elevated (Meyer et al., 2004).  
Furthermore, type II diabetic patients also exhibit a two-fold increase in post-prandial 
renal glucose release compared with those with normal glucose tolerance, which is 
due to renal gluconeogenesis (Meyer et al., 1998).  The isolation and subculture of 
human exfoliated proximal tubular epithelial cells from the urine of type II diabetics 
has shown an increase in GLUT2 and SGLT2 expression (Rahmoune et al., 2005).  
Studies in proximal tubules from diabetic obese Zucker rats identified an increase in 
renal GLUT2 protein and mRNA; however, the membrane localisation of the 
transporter was not studied.  Therefore, elevated expression of this transporter could 
have occurred at either the BBM or BLM (Kamran et al., 1997).  Zucker diabetic rats 
also exhibited an increase in renal SGLT1 and SGLT2 mRNA expression (Tabatabai 
et al., 2009).  However, it should be noted that the studies outlined above were carried 
out on models with obese phenotypes, whereas data presented in this chapter are from 
the GK rat model of type II diabetes that exhibit reduced body weight.   
 
Previous studies with the cafeteria diet have shown it to be a valid and useful model 
of human obesity (Planas et al., 1992;Kretschmer et al., 2005;Burneiko et al., 2006), 
and the diet is characterised by its ability to induce lipid-storage in adipose tissue, and 
oxidative stress (Milagro et al., 2006).  The diet of palatable junk-food does not 
necessarily stimulate a higher food intake; in fact, both Scoaris et al and studies 
presented here show that junk-food fed animals do not consume more food but, given 
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a choice of chow food, they consistently display a preference for junk-food (Scoaris et 
al., 2010).  The consumption of energy-rich junk food over an 8-week period resulted 
in obesity, as was the case in animals fed a high-fat diet for 5 weeks.  In this latter 
hyperlipidic diet, renal hypertrophy was also found, although no glycosuria was 
evident, whereas the junk-food diet was without effect on kidney weight, but caused 
glycosuria, albeit at supraphysiological levels.  Both the junk-food and high-fat diet 
resulted in augmented plasma glucose levels, although the latter was measured in the 
blood from fasted animals and glycaemia was maintained within the normal blood 
glucose range of 6 – 10mM for unfasted Wistar rats (Chalkley et al., 2002;Maurer et 
al., 2010).  The offspring from dams fed a junk-food diet throughout pregnancy and 
lactation exhibit increased insulin levels and adipocyte area, both of which are 
associated with the development of insulin resistance (Bayol et al., 2008).  Rats in this 
study by Bayol et al fed a junk-food diet exhibited increased basal circulating insulin 
levels, and insulin-resistance is strongly associated with this model (Brandt et al., 
2010).  Furthermore, rodents fed a high-fat diet rapidly develop insulin resistance.  
Todd et al showed that high-fat feeding leads to the accumulation of lipids and lipid 
intermediates within skeletal muscle, which is associated with increased activation of 
specific serine kinases (IKKβ and JNK) causing a reduction in insulin action (Todd et 
al., 2007).  This results in the impaired activation of the insulin signalling pathways 
from low-grade inflammation due to activation of the stress-activated NF-КB 
pathway; this inflammatory pathway interferes with proximal insulin signalling via 
the inhibition of IRS-1 function (Todd et al., 2007;Yaspelkis, III et al., 2007).  In 
agreement with this, rats fed a high-fat diet exhibit elevated epididymal fat pad mass 
and insulin resistance, with basal circulating insulin levels increased compared with 
chow-fed controls (Chalkley et al., 2002).  In contrast, others have noted that insulin-
resistance in response to the junk-food diet is not associated with the impairment of 
insulin signalling (Brandt et al., 2010) and that the molecular mechanisms causing 
insulin resistance in response to the junk-food diet are different from high-fat diet-
induced insulin resistance.  The data presented here show that rats fed a high-fat diet 
for 5 weeks were not hyperglycaemic, presumably due to compensatory 
hyperinsulinaemia, which is in agreement with data from the 5 weeks of age genetic 
Zucker rat model of obesity (Litherland et al., 2004). 
 
  
  185 
In response to high-fat induced obesity, PKC-βI expression was higher at the 
proximal tubule BBM and is likely to have resulted in the observed increase in 
GLUT2 at the BBM.  This elevation of GLUT2 and its activator PKC-βI was also 
seen in the junk-food fed animals, but to a much higher degree than in the high-fat 
model, suggesting an amplified response of GLUT2 in response to other components 
of the junk-food diet besides its high-fat content.  These data also signify that GLUT2 
expression at the proximal tubule BBM occurs in the pre-diabetic model (diet-induced 
obesity) and is likely to be an early-diabetic renal response to metabolic syndrome.  
 
Although fasted plasma glucose concentrations were raised in the high-fat model, they 
remained within the normal range; this implies that the increase in facilitative glucose 
transporter was independent of tubular glucose concentrations.  Furthermore, although 
elevated plasma glucose levels in the junk-food model were noted, the levels 
remained within a ‘normal’ range; this suggests it is unlikely that GLUT2 was 
recruited to the BBM in response to high glucose levels, as was the case in both type I 
and type II diabetes.  It is possible that insulin-resistance-induced sustained glycaemia 
at levels higher than control rats for a 5-week period for the high-fat diet and an 8-
week period for the junk-food study, which may result in recruitment of GLUT2 at 
the BBM via PKC-βI activation.  However, the physiological ramifications of this are 
uncertain, as the high-capacity transporter GLUT2, at the proximal tubule BBM, 
would not receive an elevated tubular load of glucose for reabsorption, as is the case 
in type I and II diabetes.  
 
Interestingly, elevated GLUT2 expression in response to a high-fat diet has been 
shown previously in neonatal brains from dams fed 30% and 40% fat-as-calories 
during pregnancy (Cerf et al., 2010).  The authors suggested that GLUT2 expression 
is up-regulated to alter neuronal glucose sensing in neonatal rats and results in 
dysregulation of the feeding response to programme the offspring to consume more 
food, and become more likely to develop obesity.  There is currently no data on renal 
glucose transporters in response to junk-food feeding in adult rats, although it has 
been shown that adipocytes from the offspring of dams fed a junk-food diet exhibit 
increased GLUT1 and GLUT3 expression (female offspring), and increased GLUT4 
mRNA (male offspring) (Bayol et al., 2008).  
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In contrast to the type II diabetic GK rat, BBM expression of SGLT1 was unaffected 
by the high-fat diet, a response also seen in type I diabetes.  The presence of 
euglycaemia in this model may explain the lack of response of SGLT1 to high-fat 
diet-induced obesity; however, in the junk-food model there was elevation in 
expression of SGLT1, despite modest glycaemia.  Although both obesity models 
exhibit insulin resistance and increased glycaemia, high-fat feeding may be 
considered a radical dietary intervention, whereas the junk-food diet has a more 
balanced caloric composition that better resembles a Western diet.  Renal hypertrophy 
is noted in response to high-fat diet, whereas the junk-food diet had no effect on 
kidney size.  Therefore, it is likely that SGLT1 expression at the proximal tubule 
BBM is unaffected by renal damage associated with hypertrophy and is not dependent 
on circulating basal insulin levels.  Furthermore, the high-fat diet had no effect on 
glycosuria and no change in SGLT1 expression, whereas the junk-food diet resulted 
in glycosuria, as well as an increase in SGLT1 expression.  This implies that the junk-
food diet creates a renal environment in which proximal tubule fluid contains glucose 
at a higher concentration than the increased levels of GLUT2 and SGLT1 are able to 
transport.  Thus, the junk-food diet presents a more realistic pre-diabetic model in 
which renal glucose transporter expression mirrors that seen in type II diabetes, 
whereas the high-fat diet also represents a clinically relevant model of pre-diabetes, 
because of the renal hypertrophy exhibited which reflects that seen in both type I and 
type II diabetes. 
 
Unlike both the STZ-induced type I diabetic model and the type II diabetic GK rat, 
the high-fat model had no effect on recruitment of GLUT5 to the proximal tubule 
BBM.  GLUT5 is primarily a fructose transporter, and although fructose feeding leads 
to obesity, there is little evidence that hyperlipidaemia affects circulating fructose 
levels; furthermore, animals were euglycaemic in response to the high-fat diet and 
there was no physiological stimulus for renal GLUT5 expression.  In addition to 
elevated dietary fructose resulting in obesity, it also increases urinary fructose 
excretion (Kizhner and Werman, 2002).  Nakayama et al showed proximal tubular 
hyperplasia in response to 60% fructose feeding.  The elevated fructose uptake in the 
junk-food model and type II diabetes via high GLUT5 expression at the proximal 
tubule BBM may result in tubulointerstitial injury (Nakayama et al., 2010).  It is 
worth noting that this is not the case for other obesity models, as demonstrated in 
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obese Zucker rats in which GLUT5 expression in adipocytes is up-regulated in 
response to insulin resistance (Litherland et al., 2004), suggesting that the absence of 
GLUT5 regulation in response to hyperlipidaemia may be specific to the kidney.  
 
Interestingly, GLUT5 expression at the proximal tubule BBM was elevated in 
response to the junk-food diet.  This is likely to be due to the high inverted sugar, also 
known as high-fructose corn syrup (HFCS) content within the components of the 
junk-food administered; this would increase fructose concentration in the plasma and 
thus proximal tubular fluid and may recruit GLUT5 to transport fructose across the 
BBM.  Renal GLUT5 mRNA and protein expression are low in prenatals, but rapidly 
increase during the weaning period on exposure to fructose in the diet, which implies 
that renal GLUT5 expression responds to fructose in the junk-food diet (Rand et al., 
1993).   
 
The RYGB model was used to try to understand the regulation of glucose transporters 
and to hypothesise mechanisms for the improved glycaemic status observed in obese 
patients with type II diabetes post-surgery.  However it is worth noting that this 
RYGB surgical model was studied in non-obese, non-diabetic control animals.  As 
expected, animals exhibited body-weight loss after RYGB surgery due to reduced 
intake of food; furthermore, a reduction in kidney weight was also observed (Bueter et 
al., 2010).  It has been suggested that improved glycaemia in patients post-RYGB, 
may be due to the early and more exaggerated peak in insulin levels, which is not seen 
in patients with gastric bands (Le Roux et al., 2006).  However, a time-course study 
of insulin resistance in patients after RYGB revealed that the abolition of insulin 
resistance occurs 6 days after surgery, before weight loss, and so it does not explain 
the lower blood glucose levels exhibited within 24 hours of RYGB (Wickremesekera 
et al., 2005).  In the studies presented here, although there was no alteration in plasma 
glucose or osmolality, basal circulating insulin levels were considerably reduced, 
which correlates with the elevated insulin sensitivity seen in type II diabetic and obese 
patients.  However, the lack of insulin resistance in the rats in these studies before 
surgery (they were neither obese nor diabetic) implies that lowered plasma insulin is a 
consequence of the removal of the duodenum, rather than in response to resolved pre-
surgery hyperinsulinaemia.  This adds weight to the ‘foregut’ theory for improvement 
of glycaemia, whereby bypassing of duodenum and proximal jejunum results in the 
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release of incretins, from the lower small intestine, which improve glycaemic control 
following RYGB surgery (Hickey et al., 1998;Pories et al., 2001). 
 
RYGB surgery resulted in lowered GLUT2 mRNA and protein expression, and PKC-
βI levels at the proximal tubule BBM and the reduction in GLUT2 expression at the 
BBM would result in lower glucose reabsorption and the normalisation of glycaemia.  
Although my data have shown higher GLUT2 and its activator PKC-βI expression at 
the BBM after 7 days hyperglycaemia, it is known that GLUT2 moves away from the 
BBM relatively quickly in response to overnight fasting (Marks et al., 2003).  This 
abolition of GLUT2 from the proximal tubule BBM occurred within 16 hours of food 
deprivation, a time-point which is similar to the elimination of hyperglycaemia in type 
II diabetic patients (Pories et al., 1995;MacDonald, Jr. et al., 1997).  Furthermore, 
proximal tubule BBM expression of the sugar transporters GLUT2 and GLUT5 is 
down-regulated after RYGB surgery, implying a renal halting of fructose and glucose 
transport.  Although there was a trend for reduced gene expression of GLUT5 this did 
not reach significance, whereas GLUT2 gene expression was significantly down-
regulated following RYGB surgery.  This suggests that the removal of GLUT5 from 
the proximal tubule BBM is a trafficking response to the surgery, as opposed to the 
GLUT2 response where RYGB surgery also reduced cellular levels of the transporter.   
 
In contrast, RYGB did not alter gene or protein expression of SGLT1 in the proximal 
tubule, implying that the renal involvement in the improvement of glycaemia 
immediately following RYGB surgery is solely modulated by GLUT2 and GLUT5.  
This is one of the few studies on renal handling of glucose in response to gastric 
bypass surgery and highlights the potential involvement of gut signals regulating renal 
glucose homeostasis.  However, the contribution of down-regulated GLUT2 
expression, at the proximal tubule BBM, to the abolished hyperglycaemia noted in 
patients following RYGB surgery is not known.  This could be further characterised 
by performing RYGB surgery on rodent models of metabolic syndrome, such as the 
high-fat or junk-food feeding-induced models of obesity, or type II diabetes, such as 
the ZDF or GK rat. 
 
Following RYGB surgery, gene expression of GLUT5 in the duodenum was reduced, 
as was expression of the transporter at the enterocyte BBM.  In rodents, the 
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distribution of GLUT5 is higher in the duodenum and proximal jejunum than more 
distal regions of the small intestine.  Therefore, since the main site of GLUT5 
expression is bypassed in RYGB surgery, nutrient exclusion at the duodenal BBM 
likely regulates GLUT5 expression.  Although this expression pattern was not seen 
for other sugar transporters in the duodenum in response to RYGB, it is known that 
GLUT5 in the small intestine is remarkably responsive to its substrate fructose, with 
increased expression in response to either high-fructose diets or in vivo perfusion of 
the small intestine with fructose (Jiang and Ferraris, 2001).     
 
GLUT2 levels at the jejunal BBM were unaffected by RYGB surgery, although the 
cellular pool of the transporter was elevated; furthermore, in these studies, the jejunal 
GLUT2 activator PKC-βII is up-regulated at the jejunal BBM, suggesting that 
signalling for GLUT2 expression may also be amplified in RYGB jejunum in 
response to a luminal glucose stimulus.  Additionally, GLUT2 at the jejunal BBM is 
known to rapidly increase in response to elevated levels of luminal sugars, a process 
that is rapidly reversed after the digestive period (Kellett and Helliwell, 2000);  
however, in the present studies, no feeding study was undertaken.  Therefore, the 
absence of changes in jejunal GLUT2 expression may not be an accurate reflection of 
alterations resulting from RYGB per se, but more a result of animals not having 
access to food immediately before being culled.  It has been shown previously that 
there is no phloridzin-insensitive, GLUT-mediated glucose uptake in the jejunum 
from sham or RYGB operated rats (Stearns et al., 2009).  However Stearns et al did 
not record details of food intake prior to killing animals and it is therefore possible 
that rapid shuttling of GLUT2 away from the enterocyte BBM, in response to reduced 
jejunal glucose content, could also explain their data (Stearns et al., 2009).  Therefore 
the elevated gene expression of GLUT2 in the jejunum seen in the data in the present 
study may serve to increase glucose absorption when the proximal intestine is 
removed.  
 
Intriguingly, expression of SGLT1 at the jejunal BBM was higher following RYGB 
surgery, as seen previously with expression of SGLT1 mRNA at 10am and 10pm 
(Stearns et al., 2009).  The 10am sampling time matched the time of cull for the 
present RYGB experiments.  However, Stearns et al also noted that jejunal glucose 
absorption was lower after RYGB surgery; they attributed this finding to a shift in cell 
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lineage, from absorptive to secretory cells and post-translational modifications of 
SGLT1 at the BBM.  This leads to the confounding situation in the jejunum where 
cellular levels and BBM expression of SGLT1 are increased, but the rate of SGLT-
mediated glucose transport is reduced.  
 
Morphologically, an increase in jejunum length and villus height occurs in response to 
RYGB surgery, which is likely to be due to the increased nutrient flow directly from 
the gastric pouch into the jejunum (Stearns et al., 2009).  Expanding jejunal mucosa 
has also been shown to be a consequence of increased incretin GLP-2 release, which, 
in contrast to the study by Stearns et al, causes an increase in SGLT1 jejunal BBM 
transport and expression (Cheeseman, 1997;Ramsanahie et al., 2004;Kaji et al., 
2009).  Therefore, the increase in SGLT1 at the jejunal BBM may be a result of the 
GLP-2 hormone up-regulation in response to RYGB surgery.    Furthermore, Moriya 
et al showed that SGLT-mediated glucose transport across the jejunal BBM triggers 
GLP-1 secretion, in addition to its’ role in recruiting GLUT2 to the BBM.  Glucose 
absorption in the jejunum is closely linked with GLP-1 release (Moriya et al., 2009).  
Intriguingly, it has been shown by Au et al that the rapid shuttling of GLUT2 to the 
jejunal BBM occurs via elevated GLP-2 secretion; however, at present, no data are 
available on circulating GLP-2 following RYGB surgery (Au et al., 2002).  The 
regulation of glucose transporters by incretins is an interesting phenomenon and there 
are many current studies based on using a peptidyl mimetic of GLP-1, such as 
exenatide (Young et al., 1999;Edwards et al., 2001), as a treatment for type II 
diabetes.  Exenatide has been shown to cause a blunted GLP-1 effect which stimulates 
insulin biosynthesis and secretion, as well as causing modest weight loss (Knop et al., 
2003).  Furthermore, alterations in GLP-1 levels are related to GLUT2 in different 
tissues: in the small intestine, the gut-derived incretin hormone GLP-1 is secreted in a 
GLUT2-dependent manner and in type I diabetes, GLP-1 treatment reduces liver 
GLUT2 mRNA (Villanueva-Penacarrillo et al., 2001;Cani et al., 2007).  Furthermore, 
the relationship between GLP-1 and GLUT2 has been shown in aging rats with down-
regulated glucose tolerance.  In response to GLP-1, reversal of the age-related decline 
in glucose tolerance occurred via modifications in pancreatic GLUT2 occurs (Wang et 
al., 1997).  It is possible that the post-prandial up-regulation of GLP-1 in rodents 
following RYGB surgery is associated with a reduction in renal GLUT2 expression, 
whereas the impaired GLP-1 signalling in type II diabetes may be associated with the 
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increase in GLUT2 expression at the proximal tubule BBM shown in the data 
presented here (Lugari et al., 2002;Le Roux et al., 2006).  Interestingly, duodenal-
jejunal bypass surgery causes an increase in jejunal GLP-1, but no impact was noted 
on glucose tolerance; however, the same study with GK rats showed a GLP-1 
receptor-mediated impact of bypass surgery on glucose tolerance in the type II 
diabetic model (Kindel et al., 2009;Kindel et al., 2010).  Furthermore, studies with 
GLP-1 receptor KO mice have shown blunted development of obesity and related 
insulin-resistance in response to high-fat feeding (Scrocchi et al., 1998;Ayala et al., 
2010).      
 
GLP-1 has been shown to cause an increase in renal blood flow and GFR (Unwin et 
al., 1990) and the GLP-1 receptor expression has been localised to the proximal 
convoluted tubules (Marks et al., 2003).  Furthermore, type I diabetes reduces the 
expression of renal GLP-1 receptor, potentially due to the activation of PKC-βI, 
which is known to desensitise GLP-1 receptor expression (Fehmann et al., 
1996;Widmann et al., 1996).  Therefore, the up-regulation of renal GLUT2, in 
response to both junk-food and high-fat diet may be a GLP-1 receptor-mediated 
response.  Interestingly, in normoalbuminuric type II diabetic patients, an increase in 
urinary excretion of GLP-1 has been shown, with a further increase in response to the 
development of diabetic nephropathy (Lugari et al., 2001).  Thus, the regulation of 
renal glucose transporters by locally-produced incretins presents an interesting 
perspective on physiological glucose homeostasis and RYGB surgery may prove a 
useful model to study these effects.   
 
 
 
 
 
 
 
 
  
  192 
8.5 Conclusions 
 
The metabolic models studied in this chapter have provided a better understanding of 
renal glucose handling.  Increased GLUT2 recruitment to the proximal tubule BBM, 
via PKC-βI activation, occurs in both experimental type I and type II diabetes, 
accompanied by an increase in GLUT-mediated glucose transport.  However, PKC-
βI-mediated GLUT2 expression at this membrane does not exclusively respond to 
hyperglycaemia, since proximal tubule BBM levels of GLUT2 are promoted in 
euglycaemic models of obesity and the well-established junk-food, pre-diabetic 
model.  Therefore PKC-βI-stimulated GLUT2 presence at the proximal tubule BBM 
may be influenced by augmented incretin levels in varying metabolic models.  
Furthermore, GLUT2 recruitment to the proximal tubule BBM is down-regulated in 
response to duodenal bypass, and operates via an insulin-independent pathway.   
 
GLUT2 and GLUT5 recruitment to the renal BBM are regulated by the same 
metabolic models used in the present study, with the exception of any GLUT5 
response to the euglycaemic, insulin-resistant high-fat model.  In contrast, SGLT1 
expression at the proximal tubule BBM is up-regulated in response to the pre-diabetic, 
insulin-resistant, junk-food diet model, and glucose transport is also elevated in type 
II diabetes, but not type I diabetes. Therefore, SGLT1 is not solely regulated by 
tubular fluid glucose concentrations, but it is unaffected by nutrient exclusion and 
incretin release from the small intestine in response to RYGB surgery.  Furthermore, 
the regulation of intestinal glucose intake may be altered by nutrient exclusion 
following RYGB surgery.    
 
The data presented in this chapter show that increased GLUT-mediated glucose 
transport, noted in type I diabetes, is also seen in type II diabetes, as well as in a pre-
diabetic junk-food model and hyperlipidaemia-induced obesity, emphasising the 
strong clinical link between lifestyle and the onset of type II diabetes.  Furthermore, in 
response to RYGB, which alleviates obesity and hyperglycaemia, GLUT2 expression 
at the renal BBM is abolished, suggesting that proximal tubule glucose transport is 
greatly influenced by disorders in carbohydrate metabolism.   
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9 Modulation of renal glucose transport by sweet 
taste sensing at the proximal tubule brush-border 
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9.1 Introduction 
 
Chapter 8 was concerned with the alterations in glucose handling at the proximal 
tubule BBM in response to metabolic changes during diabetes and the related 
metabolic syndrome and RYGB surgery.  However, the mechanisms controlling the 
expression of GLUT2, and other renal glucose transporters, are still largely unknown 
and therefore it was of interest to further study the regulation of glucose handling at 
the proximal tubule BBM.  
 
Taste sensing is vital for the recognition of nutrients in response to energy 
requirements and is mediated by a number of highly-promiscuous seven 
transmembrane receptors which have been cloned and characterised in the last few 
years (Conigrave and Brown, 2006;Egan et al., 2008;Engelstoft et al., 2008).  These 
chemosensors are located throughout the body, depending on their role, such as the 
pancreas (Taniguchi, 2004;Nakagawa et al., 2009), liver (Taniguchi, 2004;Kuang et 
al., 2005), and adipose tissue (Kuang et al., 2005;Wellendorph and Brauner-Osborne, 
2009), as well as in the classical location in lingual taste tissue (Matsumura et al., 
2009). Taste receptors include the free fatty acid (FFA) sensing receptors, FFA1-3, 
and the calcium-sensing receptor (CaSR), with the latter able to sense both calcium 
(Ca
2+
) and L-amino acids (Chattopadhyay et al., 1997;Conigrave et al., 
2000;Conigrave et al., 2006).  Amino acids are also sensed by the T1R1/3 
heterodimer, which comprises of the taste receptors T1R1 and T1R3; these receptors 
belong to the same G-protein-coupled receptor family C as the CaSR (Nelson et al., 
2002).  This family of taste receptors, T1R and T2R, was originally identified in taste 
buds of the oral cavity and has recently been shown to be distributed throughout the 
small intestine (Nelson et al., 2001;Dyer et al., 2005;Bezencon et al., 2007;Mace et 
al., 2007;Egan et al., 2008) and in airway smooth muscle and chemosensory cells 
(Deshpande et al., 2010;Tizzano et al., 2011). 
 
The T1R1/3 heterodimer is stereo-specific and can perceive most of the 20 standard 
L-amino acids, although not aromatic amino acids; T1R1/3 functions as an umami 
taste sensor, corresponding to its ability in lingual taste buds, where it is highly 
expressed, to respond to savoury taste of glutamate and aspartate (Li et al., 
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2002;Nelson et al., 2002;Damak et al., 2003;Zhao et al., 2003).  Interestingly, this 
taste sensor, T1R1/3, has also been found in brush cells in the small intestine, along 
with its mediator, the G-protein transducin, where its role in nutrient sensing is 
associated with glucose transport across the BBM (Hofer et al., 1996;Dyer et al., 
2005;Sbarbati and Osculati, 2005;Bezencon et al., 2007;Mace et al., 2009).  The 
activation of the T1R1/3 heterodimer by L-glutamate stimulates glucose absorption in 
the rat jejunum via an up-regulation in BBM expression of glucose transporter 
GLUT2 (Mace et al, 2009).  In addition, amino acid stimulation of T1R1/3 promotes 
BBM recruitment of the high-affinity glutamate transporter EAAC1 and internalises 
the oligopeptide transporter PepT1 in the enterocyte; thus, amino acid taste sensing, 
via T1R1/3, at the jejunal BBM mediates absorption of specific nutrients (Mace et al., 
2009). 
 
In addition to forming the umami taste sensing heterodimer, the T1R class of the G-
protein-coupled receptor family C also contains T1R2, which dimerises with T1R3 to 
form the sweet taste sensor T1R2/3.  Originally identified in taste buds in oral taste 
tissue, this sweet taste heterodimer demonstrates an intriguingly broad specificity for 
sweet substrates, including the sugars glucose, sucrose and fructose, as well as sweet 
proteins such as brazzein, sweet taste D-amino acids, and artificial sweeteners such as 
aspartame, cyclamate, saccharin and sucralose (Raybould, 1998;Hofer and 
Drenckhahn, 1999;Nelson et al., 2001;Li et al., 2002;Jiang et al., 2004;Assadi-Porter 
et al., 2010;Servant et al., 2010).  However, the sweet taste heterodimer is stereo-
selective for certain molecules, for example, unlike T1R1/3, T1R2/3 can respond to 
D-tryptophan, but not L-tryptophan (Li et al., 2002).  Furthermore, Xu et al showed 
that the artificial sweeteners aspartame and neotame bind the N-terminal domain of 
T1R2, whereas T1R3 is stimulated by cyclamate and down-regulated by the taste 
inhibitor lactisole (Xu et al., 2004).  The sweet taste heterodimer has, like T1R1/3, 
been identified at the brush-border of enterocytes, the same localisation as α-
gustducin, with the proximal and mid-intestine linked to peak levels of T1R2/3 (Hofer 
et al., 1996;Dyer et al., 2005;Stearns et al., 2010). 
 
As with the umami taste heterodimer, the sweet taste sensor, T1R2/3, was identified 
as a regulator of glucose absorption at the enterocyte BBM; the addition of 
membrane-impermeable glucose analogues to the lumen of the intestine caused the 
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stimulation of SGLT1, which implicated a glucose sensor in the modulation of this 
high-affinity glucose transporter (Dyer et al., 2003).  This finding was mirrored in 
weaning piglets, which exhibited an enhanced capacity to absorb dietary sugars via 
SGLT1 when fed high-saccharin in their diet (Moran et al., 2010).  Furthermore, 
Margolskee et al showed that the stimulation of SGLT1 in the small intestine in 
response to a 70% sucrose diet, or sucralose-sweetened water feeding, was blocked in 
T1R3 KO mice (Margolskee et al., 2007).  T1R-mediated alterations in SGLT1 
synthesis in response to artificial sweeteners have been hypothesised to be a result of 
signalling via cAMP (Margolskee, 2002;Mace et al., 2007). 
 
Interestingly, Mace et al have shown that intestinal sweet taste sensing also has an 
effect on enterocyte glucose absorption via the facilitative transporter GLUT2 (Mace 
et al., 2007).  A glucose concentration of 75 mM in the jejunal lumen is normally 
required for the rapid insertion of GLUT2 to the enterocyte BBM and this GLUT2 
response is mediated by SGLT1-dependent accumulation of glucose in the enterocyte.   
Elevated intracellular glucose levels cause a series of events involving the 
depolarisation of the BBM and an influx of Ca
2+
 ions into the cell, which result in the 
contraction of the terminal web and GLUT2 shuttling to the BBM (Figure 5.7) 
(Morgan et al., 2007;Mace et al., 2007).  At lower glucose concentrations (20 mM), 
irrespective of Ca
2+ 
stimuli, GLUT2 does not shuttle to the BBM; however, the 
addition of 1 mM sucralose, together with 20 mM glucose, causes the same GLUT2 
response as that seen using 75 mM glucose (Mace et al., 2007).  The response occurs 
within 15 minutes of luminal exposure to the stimulus and thus this short-term effect 
of sweet taste sensing via T1R2/3 was hypothesised to be a mode of secondary 
signalling to the glucose transporter GLUT2.  On binding to its substrates, the sweet 
taste heterodimer undergoes a conformational change that causes the G-protein 
subunit α-gustducin to dissociate from the enterocyte BBM into the cytosol, while the 
βγ-gustducin subunits remain anchored to the membrane, where they bind to and 
activate PLCβ2.  This activation promotes further inactive cytosolic PLCβ2 to be 
translocated to the BBM, which generates DAG, the lipid secondary messenger able 
to activate PKC-βII present at the enterocyte BBM (Rhee, 2001;Mace et al., 2009).  
Indeed, sucralose resulted in the up-regulation of PKC-βII, which when activated is 
responsible for GLUT2 recruitment to the jejunal BBM (Mace et al., 2007).  
Additionally, Mace et al showed that short-term T1R2/3 stimulation was without 
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effect on SGLT1 in the jejunum and hypothesised that sweet taste receptors may 
regulate short-term regulation of GLUT2 via PLCβ2 and long-term effects on SGLT1 
synthesis via cAMP (Mace et al., 2007).  
 
Sweet taste sensing, via the stimulation of T1R2/3 at the jejunal BBM results in the 
up-regulation of the glutamate transporter EAAC1 and internalisation of the 
oligopeptide transporter PepT1 (Mace et al., 2009).  Thus, as with umami taste 
sensing via T1R1/3, the sweet taste heterodimer can also mediate nutrient absorption 
across the jejunal BBM in response to luminal substrate load. 
 
T1R2/3, has been shown to be sensitive to sugars, such as sucrose, used at high levels 
(more than 100 mM), whereas the intense sweetness of artificial sweeteners, such as 
saccharin and aspartame, means that they are able to elicit a response from the sweet 
taste sensor at concentrations between 1-5 mM (Nelson et al., 2001;Li et al., 2002).  
Artificial sweeteners are widely used as a weight-loss aid and sugar-substitute for 
diabetics, although their efficacy in both is currently under debate in the light of their 
influence on glucose absorption as outlined above (Stellman et al., 1986;Ma et al., 
2010;Swithers et al., 2010).  Saccharin is a commonly used artificial sweetener 
commercially available as ‘Sweet n Low’ and rapidly absorbed by the small intestine 
(Renwick, 1985;Renwick, 1990), with peak concentrations in the blood 30-60 minutes 
post-feeding; however, a large proportion of this absorbed saccharin, between 66-
99%, is not metabolised (Kennedy et al., 1972;Byard and Goldberg, 1973;Lethco and 
Wallace, 1975;Colburn et al., 1981).  Renal clearance of saccharin is via filtration and 
tubular secretion and, therefore, the artificial sweetener is present at high 
concentrations at the proximal tubule BBM in response to oral or IV-infused 
saccharin administration; furthermore, saccharin is approximately 300 times sweeter 
than sucrose and has no effect on blood glucose concentration (Goldstein et al., 
1978;Bekersky et al., 1980).   
 
Although there are similarities between the process of glucose transport across the 
enterocyte and proximal tubule BBM, important differences have been identified.  For 
example, in the early S1 region of the proximal tubule SGLT2 the high capacity 
glucose transporter, is present at the BBM (Kanai et al., 1994;Wallner et al., 
2001;Wright, 2001).  Additionally, the studies presented in this thesis (Chapter 7) 
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reveal that GLUT2 recruitment to the proximal tubule BBM in response to glucose 
infusion is slower than that reported for GLUT2 shuttling to the jejunal BBM.  The 
movement of GLUT2 to the proximal tubule BBM is thought to occur via signalling 
from its activator PKC-βI and is observed in experimental type I diabetes, type II 
diabetes, and metabolic syndrome induced by either a high-fat or junk-food diet 
(Chapter 8).  Therefore, the recruitment of GLUT2 to the renal BBM is not mediated 
by hyperglycaemia alone, as previously believed (Chin et al., 1997;Marks et al., 
2003;Freitas et al., 2007).  To further understand this phenomenon, it was of interest 
to investigate the involvement of the known regulators of jejunal glucose absorption, 
such as taste receptors, in the kidney.  There are no previous studies on renal 
expression of T1R1, T1R2 or T1R3; although human embryonic kidney cells (HEK) 
have been widely used to express these taste receptors (Kuang et al., 2005;Assadi-
Porter et al., 2010).  
 
9.2 Aims of chapter  
 
The presence of taste receptors in the small intestine, where they modulate glucose 
transport by GLUT2 and SGLT1, together with the similarities between glucose 
transport across the BBM in the small intestine and proximal tubule, led to the aim of 
this chapter, which was to establish whether sweet taste receptors are expressed in the 
kidney.  The response of renal glucose transport, upon activation of these sweet taste 
receptors, was investigated.  The activity of these sensors, and their involvement on 
proximal tubule glucose transport was analysed using the same metabolic models 
used in Chapter 8, which are known to influence glucose transport across the proximal 
tubule BBM.   Furthermore intestinal sweet taste receptor expression was studied 
following RYGB surgery to analyse the effect of gastric bypass on sweet taste sensing 
by the small intestine.  
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9.3 Results 
9.3.1 Taste receptor mRNA expression in the kidney  
 
The presence of taste receptors in the kidney was established initially using RT-PCR 
to analyse mRNA in the renal cortex of control rats.  Figure 9.1 - 1 shows the mRNA 
expression of the components of the sweet taste heterodimer T1R2 and T1R3 in the 
kidney, where T1R3 has 2-fold higher expression that T1R2.  The positive control 
tissue, rat jejunum, also expresses mRNA for the sweet taste receptors, with T1R3 
exhibiting 3-fold elevated expression compared with T1R2 (Figure 9.1- 1).  Both 
T1R2 and T1R3 are expressed at an increased level in the kidney compared with the 
jejunum, with a 652% and 394% increase respectively.  Figure 9.1- 2 shows that the 
components of the umami taste heterodimer T1R1 and T1R3 are also expressed in the 
kidney cortex of control rats.  As with the sweet taste components, expression in the 
kidney is higher than in the jejunum, with T1R1 exhibiting a 350% elevation.  As 
previously shown (Bezencon et al., 2007;Mace et al., 2009), the umami taste 
heterodimer T1R1/3 is expressed in the jejunum of control rats, with mRNA 
expression of T1R3 exhibiting a 2.4-fold increase compared with T1R1 (Figure 9.1- 
2).   
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Figure 9.1 – Detection of taste receptor mRNA in the jejunum and kidney cortex: 1) 
mRNA expression of sweet taste heterodimer subunits, T1R2 (pink) and T1R3 
(black), in control jejunum (solid bars) and kidney (slatted bars),  2) mRNA 
expression of umami taste heterodimer subunits, T1R1 (blue) and T1R3 (black), in 
control jejunum (solid bars) and kidney (slatted bars).  Values are expressed as mean 
± SEM, n=7-12, **p<0.01, ***p<0.005, ****p<0.001 compared with jejunum.  
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9.3.2 Detection of sweet taste dimer component proteins in the kidney 
 
To study further sweet taste sensing receptors in the kidney, commercially available 
antibodies (Santa Cruz Biotechnology) raised against the extracellular domain of 
T1R2 and T1R3 were used in renal membrane preparations from different species. 
 
9.3.2.1 Detection of T1R2 and T1R3 protein in whole membrane from kidney 
 
To assess whether the mRNA detected in section 9.3.1 translated into detectable 
protein levels, whole membrane preparations from control rat kidney cortex and 
jejunal mucosa were analysed using the ‘dot blot’ method.  Figure 9.2 shows the 
expression of T1R2 in the whole membrane from kidney and jejunum; as with the 
mRNA data, expression of T1R2 protein appeared to be higher in the kidney than the 
jejunum.  T1R3 was also expressed in the whole membrane preparation from kidney 
although its expression was similar in the kidney and jejunum (Figure 9.2). 
 
Figure 9.2 – Dot blot detection of sweet taste heterodimer components T1R2 and 
T1R3 in whole membrane prepared from control rat kidney cortex and jejunal mucosa 
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9.3.2.2 Detection of renal sweet taste receptors in other renal cell types 
 
To establish the specificity of the sweet taste receptor antibodies and the expression of 
these receptors in other renal cell types, whole membrane preparations from mouse 
kidneys and the porcine proximal tubule cell line (LLC-PK1) were studied using 
western blotting.  Bands were detected between the 128 kDa and 93 kDa molecular 
weight markers on the gel, corresponding to the reported molecular weight of T1R2 
(95.8 kDa) and T1R3 (93.4 kDa) respectively.  Figure 9.3 shows the expression of the 
sweet taste receptor T1R2 in mouse kidney whole membrane preparation; however, 
there was no expression in cultured porcine proximal tubule cells.  This result was 
matched with T1R3 probing (Figure 9.3), with the antibody detecting the receptor in 
mouse kidney whole membrane preparation, but not in LLC-PK1 cells. 
 
Figure 9.3 – Detection of sweet taste receptor heterodimer components T1R2 and 
T1R3 by western blotting of whole membrane prepared from control mouse kidney 
cortex and porcine proximal tubule cells (LLC-PK1) 
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9.3.2.3 Detection of renal sweet taste receptors at the proximal tubule BBM 
 
The expression of sweet taste receptors T1R2 and T1R3 was studied in BBM 
preparations from the kidney cortex of control rats to assess whether, as in the 
jejunum, T1R2/3 could be associated with transport systems at the BBM in the 
proximal tubule.  Renal BBM vesicles were probed for the sweet taste heterodimer 
components with western blotting.  Figure 9.4- 1 shows the detection of both T1R2 
and T1R3, at 95.8 kDa and 93.4 kDa respectively, in BBM vesicles prepared from 
control rat kidney cortex. Both proteins were also detected in jejunal BBM prepared 
from the positive control tissue, where T1R2 and T1R3 are known to be strongly 
expressed in the jejunal mucosa (Dyer et al., 2005;Mace et al., 2007).  As seen with 
the mRNA and whole membrane protein results, T1R2 and T1R3 levels at the 
proximal tubule BBM were significantly higher than at the jejunal enterocyte BBM.  
There was a 2.9- and 3-fold elevation in T1R2 and T1R3 expression at the renal 
compared with the jejunal BBM (Figure 9.4 - 2).  
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Figure 9.4 – Detection of sweet taste heterodimer components, T1R2 (pink) and 
T1R3 (black) in BBM prepared from the kidney (slatted bars) and jejunum (solid 
bars) from control rats: 1) western blotting 2) quantification of western blots 
(expressed as percentage BBM expression) standardised to β-actin.  Values are 
expressed as mean ± SEM, n=6, **p<0.01, ***p<0.005 compared with jejunum. 
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9.3.3 Effects of acute high plasma glucose and osmolality on expression of sweet 
taste receptors at the proximal tubule BBM 
 
The response of renal sweet taste receptors at the proximal tubule BBM to either acute 
hyperglycaemia induced by a 2 hour IV infusion of 1.1 M glucose or high plasma 
osmolality induced by a 2 hour IV infusion of 1.09 M mannitol was studied.  As 
shown in Chapter 7, acute hyperglycaemia caused an immediate and significant 
elevation in plasma glucose levels and therefore proximal tubular lumen levels.  
Within 15 minutes, plasma glucose concentration was elevated to 23 ± 2.6 mM, levels 
which were maintained for the 2 hour period.  Figure 9.5 - 1 shows the western 
blotting of renal BBM probed for T1R2 and T1R3, with IV infusion of 154 mM saline 
or 0.08 M mannitol in saline, used as controls for the effects of glycaemia and high 
osmolality effect, respectively.  Quantification of T1R2 and T1R3 at the proximal 
tubule BBM showed no alteration to their expression in response to acute 
hyperglycaemia (Figure 9.5 - 2).  It was also shown that mannitol infusions at either 
low (0.08 M) or hyperosmotic concentrations (1.09 M) had no impact on sweet taste 
receptor expression at the proximal tubule BBM (Figure 9.5 - 2). 
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Figure 9.5 – Effect of acute hyperglycaemia or high osmolality, induced by IV 
infusion of 1.1 M glucose (with 154 mM saline as control) or 1.09 M mannitol (with 
0.08 M mannitol as control) respectively on sweet taste heterodimer components, 
T1R2 (pink) and T1R3 (black) at the proximal tubule BBM:  1) Western blots 2) 
quantification of western blots (expressed as percentage BBM expression of saline 
control) and standardised to β-actin. Values are expressed as mean ± SEM, n=6, p>0.5 
compared with 154 mM saline  
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9.3.4 Effect of chronic hyperglycaemia on sweet taste receptors at the proximal 
tubule BBM 
 
To assess further the response of the renal sweet taste sensing heterodimer to simple 
sugars, chronic hyperglycaemia was used to assess the effects of long-term, high-
glucose tubular fluid luminal concentration.  As was the case in Chapter 7, chronic 
hyperglycaemia was studied using the STZ-induced model of type I diabetes. 
 
9.3.4.1 Effect of type I diabetes on mRNA expression of sweet taste receptors in 
the kidney and jejunum 
 
The effect of chronic hyperglycaemia, established with STZ-induced type I diabetes, 
on gene expression of sweet taste receptors in the kidney and jejunum was studied 
using RT-PCR.  Since acute hyperglycaemia following a high-glucose infusion 
(section 9.3.3) had no effect on sweet taste receptor expression at the proximal tubule 
BBM, longer-term gene expression of T1R2 and T1R3 was studied 10 and 30 days 
after induction of type I diabetes.  Figure 9.6 - 1 shows that mRNA expression of 
T1R3 in the kidney cortex was significantly elevated by 58-fold at 10 and 30 days 
after induction of diabetes when compared with T1R2 mRNA expression at the same 
time point after induction of diabetes.  There was also a significant decrease in renal 
T1R2 mRNA expression after 10- and 30-day hyperglycaemia, with 97% and 96% 
reduction, respectively; T1R3 mRNA expression in the kidney was unaffected  by 
both 10- and 30-day type I diabetes (Figure 9.6 - 1).  In the jejunum, chronic 
hyperglycaemia induced by 10-day type I diabetes had no significant effect on T1R2 
or T1R3 expression; however, after 30 days there was a 643% increase in T1R2 and a 
443% elevation in T1R3 expression (Figure 9.6 - 2).   
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Figure 9.6 – Effect of chronic hyperglycaemia studied in 10- and 30-day STZ-
induced type I diabetic rats on mRNA expression of sweet taste receptors T1R2 (pink) 
and T1R3 (black) in the kidney cortex (1) and jejunum (2), standardised to β-actin.  
Values are expressed as mean ± SEM, n=7-12, *p<0.05, **p<0.01, ***p<0.005 
compared with control animals. 
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9.3.4.2 Effect of type I diabetes on the expression of sweet taste receptor proteins, 
T1R2 and T1R3, at the proximal tubule BBM 
 
Protein levels of the components of the sweet taste heterodimer T1R2 and T1R3 were 
studied in response to chronic hyperglycaemia established by 7-day STZ-induced 
diabetes.  Figure 9.7 – 1 shows the western blot of renal BBM vesicles probed with 
T1R2 and T1R3 antibodies.  Despite changes in T1R2 and T1R3 renal mRNA 
expression (Figure 9.6), renal hypertrophy (Table 7.3), and chronic hyperglycaemia 
for 7 days, there was no significant change in T1R2 or T1R3 protein levels at the 
proximal tubule BBM following 7-day type I diabetes (Figure 9.7 - 2).         
 
Figure 9.7 – Effect of chronic hyperglycaemia studied with 7-day STZ-induced 
diabetes (slatted bars) on sweet taste receptors T1R2 and T1R3 at the proximal tubule 
BBM: 1) Western blots 2) quantification of western blots (expressed as percentage 
BBM expression) standardised to β-actin.  Values are expressed as mean ± SEM, n=4-
6, p>0.5 compared with vehicle injected controls (open bars)  
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9.3.5 Effects of different metabolic models on the expression of sweet taste 
receptors at the proximal tubule BBM 
 
Studies presented in this thesis have established the influence of different metabolic 
conditions on glucose transport at the proximal tubule BBM (Chapter 8).  Therefore to 
further understand the renal sweet taste heterodimer, it was of interest to study 
whether the expression of T1R2 and T1R3 at the proximal tubule BBM was also 
affected by metabolic dysregulation. 
 
9.3.5.1 Type II diabetic Goto-Kakizaki (GK) rat model 
 
Protein levels of both components of the sweet taste receptor heterodimer were 
studied at the proximal tubule BBM of 8-9 weeks old GK rats. Figure 9.8 – 1 shows 
that the protein levels of T1R2 and T1R3 in renal BBM vesicles prepared from GK 
rats were significantly elevated compared with lean rats.  Quantification of western 
blots for both T1R2 and T1R3 sweet taste receptors, showed a significantly higher 
expression, with a 3.5-fold increase for both at the proximal tubule BBM of GK rats 
compared with lean animals (Figure 9.8 - 2). 
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Figure 9.8 – Effect of type II diabetes (slatted bars) on sweet taste receptors T1R2 
and T1R3 at the proximal tubule BBM in lean control rats (C) and GK type II diabetic 
rats (D): 1) Western blots 2) quantification of western blots (expressed as percentage 
BBM expression) standardised to β-actin.  Values are expressed as mean ± SEM, n=8, 
**p<0.01, ***p<0.005 compared with lean controls (open bars)  
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9.3.5.2 High-fat diet-induced metabolic syndrome model 
 
Expression of sweet taste receptors at the proximal tubule BBM were assessed in 
response to metabolic syndrome, induced by feeding a high-fat diet (60% fat-as-
calories chow) for 5 weeks (Figure 9.9 - 1).  There was no significant change in T1R2 
and T1R3 expression at the renal BBM in response to the high-fat diet (Figure 9.9 - 
2).   
 
Figure 9.9 – Effect of high-fat diet (slatted bars) on sweet taste receptor expression at 
the proximal tubule BBM: 1) Western blots 2) quantification of western blots 
(expressed as percentage BBM expression) standardised to β-actin. Values are 
expressed as mean ± SEM, n=6, p>0.5 compared with chow-fed controls (open bars)  
 
1     
  Chow           High-fat 
T1R2    
Chow             High-fat 
T1R3         
 
Actin    
 
2 
 
 
 
 
 
 
 
0
20
40
60
80
100
120
140
160
T1R2 T1R3
%
 B
B
M
 e
x
p
r
e
ss
io
n
95.8 kDa 
93.4 kDa 
42 kDa 
  
  213 
9.3.5.3 Junk-food diet-induced metabolic syndrome model 
 
Expression of T1R2 and T1R3 in response to metabolic syndrome induced by feeding 
rats a junk-food diet for 8 weeks is shown in Figure 9.10 - 1.  This well-established 
model of the western diet resulted in significantly elevated levels of T1R2 and T1R3 
protein at the proximal tubule BBM compared with the chow-fed control rats, with a 
2.2- and 2-fold increase in BBM expression, respectively (Figure 9.10 - 2).   
 
Figure 9.10 – Effects of junk-food diet (slatted bars) on sweet taste receptor 
expression at the proximal tubule BBM:  1) Western blots 2) quantification of western 
blots (expressed as percentage BBM expression) standardised to β-actin.  Values are 
expressed as mean ± SEM, n=6-12, ****p<0.001 compared with chow-fed controls 
(open bars)  
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9.3.5.4 Roux-en-Y gastric bypass (RYGB) model 
9.3.5.4.1 Effect of RYGB surgery on renal sweet taste receptor mRNA 
expression  
 
RYGB surgery was performed on control rats and studies were performed 60 days 
following the gastric bypass surgery.  T1R2 mRNA expression in the renal cortex was 
significantly down-regulated by 73%, compared with the sham-operated controls 
(Figure 9.11).  However, there was no statistically significant difference between 
T1R3 mRNA expression in the kidney cortex following sham and RYGB surgery 
(Figure 9.11). 
 
Figure 9.11 – Effects of RYGB surgery (slatted bars) on sweet taste receptor mRNA 
components T1R2 (pink) and T1R3 (black) in the renal cortex. Values are expressed 
as mean ± SEM, n=6-10, ****p<0.001, compared with sham-operated control 
animals (open bars). 
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9.3.5.4.2 Effect of RYGB surgery on expression of renal sweet taste receptor 
proteins at the proximal tubule BBM  
 
The effect of RYGB surgery on renal sweet taste receptors T1R2 and T1R3 at the 
proximal tubule BBM was assessed using western blotting (Figure 9.12).  Protein 
levels of both components of the sweet taste heterodimer were unaffected 60 days 
after RYGB surgery (Figure 9.12 - 1), with no statistical difference between proximal 
tubule BBM expression of T1R2 and T1R3 compared with the sham-operated 
controls (Figure 9.12- 2). 
 
Figure 9.12 – Effects of RYGB surgery (slatted bars) on sweet taste receptor 
components T1R2 (pink) and T1R3 (black) at the proximal tubule BBM:  1) Western 
blots 2) quantification of western blots (expressed as percentage BBM expression) 
standardised to β-actin. Values are expressed as mean ± SEM, n=6, p>0.5 compared 
with sham surgery controls (open bars). 
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9.3.5.4.3 Effect of RYGB on expression of sweet taste receptor mRNA 
expression in specific regions of the intestine 
 
The gene expression profile of sweet taste receptors T1R2 and T1R3 in mucosal 
scrapes from three specific regions of the small intestine was studied 60 days after 
RYGB surgery (Figure 9.13).   
 
A significant 60% decrease in T1R2 mRNA expression in the by-passed 
biliopancreatic limb, corresponding to the duodenum of sham-operated control 
animals, was seen (Figure 9.13 - 1).  However, no difference between T1R2 mRNA 
expression in the alimentary limb corresponding to the jejunum of the sham-operated 
control was noted (Figure 9.13 - 1).  Following RYGB surgery, there was also no 
difference between T1R2 mRNA expression in the common limb corresponding to 
the ileum of sham-operated controls (Figure 9.13 - 1).   
 
The expression profile of T1R3 in all three regions of the small intestine was 
unaffected by RYGB surgery.  Although a 25% increase in T1R3 expression was seen 
in the alimentary limb compared wiith the jejunum from sham-operated control 
animals, this did not reach statistical significance (Figure 9.13 - 2).  Furthermore, 
there was no significant difference between T1R3 expression in the duodenum or 
ileum compared with the biliopancreatic and common limbs, respectively (Figure 9.13 
- 2).   
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Figure 9.13 – Effects of RYGB surgery (closed bars) on sweet taste receptor mRNA 
components (1) T1R2 (pink) and (2) T1R3 (black) in specific regions of the small 
intestine.  Following RYGB, the duodenum becomes the biliopancreatic limb, the 
jejunum becomes the alimentary limb, and the ileum becomes the common limb. 
Values are expressed as mean ± SEM, n=5-8, ****p<0.001, compared with sham-
operated control animals (open bars). 
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9.3.5.4.4 Effect of RYGB surgery on expression of T1R2 and T1R3 protein 
at the intestinal BBM 
 
The expression of T1R2 and T1R3 proteins following RYGB surgery was studied 
with western blotting using BBM prepared from mucosal scrapes from each region of 
the small intestine (Figure 9.14 - 1 / Figure 9.15 – 1).  Following RYGB surgery a 
significant 2-fold decrease in T1R2 in the by-passed biliopancreatic limb was noted, 
together with a 3.5-fold reduction in T1R2 in the alimentary limb compared with 
duodenum and jejunum, respectively, of sham-operated rats (Figure 9.14- 2).  Despite 
an increase in T1R2 at the BBM of the common limb after RYGB surgery, this did 
not reach statistical significance (Figure 9.14 - 2).  Levels of T1R3 protein at the 
BBM of the by-passed biliopancreatic limb were reduced, however, this was not 
statistically significant when compared with the duodenum from sham-operated 
control animals (Figure 9.15 - 2).  T1R3 protein levels at the BBM of the alimentary 
limb were significantly decreased following RYGB surgery, although there was no 
significant difference in levels of T1R3 protein at the BBM from the ileum from 
control rats in comparison with the common limb from rats 60 days post-RYGB 
surgery (Figure 9.15 - 2). 
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Figure 9.14 – Effects of RYGB surgery (closed bars) on expression of sweet taste 
receptor T1R2 protein in the specific regions of the small intestine.  Following 
RYGB, the duodenum becomes the biliopancreatic limb, the jejunum becomes the 
alimentary limb and the ileum becomes the common limb:  1) Western blots 2) 
quantification of western blots (expressed as percentage BBM expression) 
standardised to β-actin.  Values are expressed as mean ± SEM, n=6, ***p<0.005, 
****p<0.001 compared with sham-operated control animals (open bars).  
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Figure 9.15 – Effects of RYGB surgery (closed bars) on expression of sweet taste 
receptor T1R3 protein in specific regions of the small intestine. Following RYGB, the 
duodenum becomes the biliopancreatic limb, the jejunum becomes the alimentary 
limb and the ileum becomes the common limb:  1) Western blots 2) quantification of 
western blots (expressed as percentage BBM expression) standardised to β-actin.  
Mean ± SEM, n=6, ***p<0.005, ****p<0.001 compared with sham-operated control 
animals.  
1       Duodenum 
        Sham  RYGB 
T1R3  
Actin   
     Jejunum 
        Sham  RYGB 
T1R3  
Actin     
        Ileum 
        Sham  RYGB 
T1R3  
Actin   
 
2  
 
 
 
 
 
0
20
40
60
80
100
120
140
160
180
200
Duodenum Jejunum Ileum
T
1
R
3
 e
x
p
r
e
ss
io
n
 (
%
)
***
93.4 kDa 
93.4 kDa 
93.4 kDa 
42 kDa 
42 kDa 
42 kDa 
  
  221 
9.3.6 Effect of artificial sweetener infusion on glucose transport and sweet taste 
receptor expression in the proximal tubule  
9.3.6.1 Animal parameters following saccharin infusion 
 
The function of sweet taste receptors localised at the proximal tubule BBM was 
assessed using a 2 hour IV infusion of 154 mM saline alone or containing saccharin at 
1.37 mM concentration.  The infusate osmolality was not statistically different from 
the osmolality of the saline infusate used as a control (Table 9.1 - 1).  Also, there was 
no difference in plasma osmolality in response to the artificial sweetener infusion 
compared with saline infusion (Table 9.1 - 1).  Although there was a 1.2-fold increase 
in plasma glucose concentration following the saccharin infusion, this was not 
statistically significant (Table 9.1 - 1).  The infusion of 1.37 mM saccharin had no 
impact on the body weight of animals or renal hypertrophy (Table 9.1- 2).    
 
Table 9.1 – Animal parameters following saccharin IV infusion 1) Infusate osmolality 
and its effect on plasma osmolality 2) Body and kidney weights and renal BBM 
vesicle enrichment of alkaline phosphatase marker enzyme in rats following IV 
infusion of either 154 mM saline or 1.37 mM saccharin in 154 mM saline for 2 hours.  
Mean ± SEM, n=6, no significant change between infusions, p>0.5.  
1 
 Saline Saccharin 
Plasma glucose (mM) 5.39 ± 0.2 6.27 ± 0.8 
Infusate osmolality (mOsM) 327 ± 4 329 ± 8 
Plasma osmolality (mOsM) 309 ± 0.9 310 ± 0.9 
 
2 
 Saline Saccharin 
Body weight (g) 398 ± 11.8 409.7 ± 15.3 
Kidney weight (g) 1.04 ± 0.08 1.01 ± 0.02 
BBM vesicle enrichment 6.81 ± 0.61 6.64 ± 0.57 
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9.3.6.2 Effect of saccharin infusion on the expression of renal sweet taste dimer 
components  
 
Renal BBM prepared from saccharin-infused animals displayed no difference in BBM 
vesicle purity compared to the response of saline infusion alone (Table 9.1- 2).  
Following a 2 hour saccharin infusion, renal BBM vesicles were prepared and probed 
for T1R2 and T1R3 using antibodies for western blotting (Figure 9.16 - 1).  A 
significant 2- and 2.8-fold increase was seen in levels of T1R2 and T1R3 protein 
respectively, at the proximal tubule BBM after 2 hour saccharin infusion compared 
with saline infusion alone (Figure 9.16 - 2). 
 
Figure 9.16 – Effect of artificial sweetener on expression of sweet taste receptors, 
T1R2 (pink) and T1R3 (black), at the proximal tubule BBM, studied by IV infusion of 
1.37 mM saccharin in 154 mM saline (slatted bars) for 2 hours 1) western blotting 2) 
quantification of western blots (expressed as percentage BBM expression) 
standardised to β-actin. Values are expressed as mean ± SEM, n=6, *p<0.05, 
***p<0.005 compared with 154 mM saline infusion (open bars)  
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9.3.6.3 Renal BBM glucose transport in response to saccharin infusion  
 
In renal BBM vesicles prepared from rats following a 2 hour IV infusion of saccharin, 
there was a significant increase in Vmax of SGLT-mediated glucose transport, as 
measured by glucose uptake between 30-960 μM concentrations, from 959.4 ± 90.5 
pmol.mg prot
-1
 in saline-infused control animals to 2333.2 ± 447.1 pmol.mg prot
-1
 in 
saccharin-infused animals (Figure 9.17 - 1).  Despite a 26% increase in Km of SGLT-
mediated glucose transport, this did not reach statistical significance (Figure 9.17 - 2).  
Furthermore, renal GLUT-mediated glucose transport, as measured by phloridzin-
sensitive uptake at 20 mM glucose concentration, was unaffected by saccharin IV 
infusion (Figure 9.18). 
 
Figure 9.17 – Effect of artificial sweetener on SGLT-mediated glucose uptake, 
studied by IV infusion of 1.37 mM saccharin in 154 mM (closed bars) for 2 hours (1) 
Vmax and (2) Km of glucose uptake derived from BBM vesicles incubated at glucose 
concentrations between 30-960 μM for 4 seconds.  Values are expressed as mean ± 
SEM, n=6-8, *p<0.05 compared with 154 mM saline infusion (open bars) 
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Figure 9.18 – Effect of artificial sweetener on total glucose uptake (open bars) and 
GLUT-mediated glucose uptake (closed bars) studied by IV infusion of 1.37 mM 
saccharin in 154 mM for 2 hours, using renal BBM vesicles incubated in 20 mM 
glucose for 4 seconds.  Mean ± SEM, n=6-8, p>0.5 compared with 154 mM saline 
infusion. 
 
 
 
 
 
 
 
 
 
 
9.3.6.4 Effect of saccharin infusion on the expression of renal glucose 
transporters 
 
The 2 hour IV infusion of the sweetener saccharin was without significant effect on 
expression of the facilitative fructose transporter GLUT5 at the proximal tubule BBM 
(Figure 9.19).  Although GLUT2 exhibited a decrease in response to saccharin 
infusion, this was not statistically significant (Figure 9.19).  There was no significant 
change in the levels of the GLUT2 activator PKC-βI at the proximal tubule BBM, 
however, this also did not reach statistical significance (Figure 9.19).  The sodium-
dependent glucose transporter SGLT1 was significantly up-regulated in response to 
saccharin infusion, with a 2.3-fold increase in protein levels at the proximal tubule 
BBM (Figure 9.19).    
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Figure 9.19 – Effect of artificial sweetener on expression of GLUT2 and GLUT5, 
PKC-βI and SGLT1 at the proximal tubule BBM studied by IV infusion of 1.37 mM 
saccharin in 154 mM saline (closed bars) for 2 hours: 1) western blotting 2) 
quantification of western blots (expressed as percentage BBM expression) 
standardised to β-actin. Values are expressed as mean ± SEM, n=6, **p<0.005 
compared with 154 mM saline infusion (open bars) 
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9.3.7 Relationship between T1R2 and T1R3, and SGLT1 expression at the 
proximal tubule BBM 
 
The expression of components of the sweet taste heterodimer T1R2/3 at the proximal 
tubule BBM in different metabolic models was found to match the expression of 
SGLT1 in these models (data from Chapter 8).  Figure 9.20 displays the expression of 
T1R2, T1R3 and SGLT1 as compared with the controls for each metabolic model.  In 
the junk-food model and type II diabetic model, T1R2, T1R3 and SGLT1 levels were 
significantly elevated at the proximal tubule BBM compared with the respective 
control groups (Figure 9.20).  However after 7-day STZ-induced type I diabetes or a 
high-fat diet or ost-RYGB surgery, there was no significant alteration in renal T1R2, 
T1R3 or SGLT1 observed (Figure 9.20).   
 
Figure 9.20 – Effect of different metabolic models on the expression of T1R2 (pink), 
T1R3 (black) and SGLT1 (grey) at the proximal tubule BBM. Values expressed as a 
percentage BBM expression, standardised to β-actin and compared with control 
groups for each study   
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9.3.8 Relationship between expression of T1R2 and T1R3 at the proximal 
tubule BBM 
 
As indicated by mRNA analysis in section 9.3.1, in control conditions T1R3 mRNA 
in the kidney was expressed at higher levels than T1R2 mRNA (Figure 9.1).  
Therefore, the expression of the sweet taste heterodimer T1R2/3 assessed at the 
proximal tubule was also expressed as a percentage of expression of T1R2 compared 
with that of T1R3 in each metabolic model used (Table 9.2).  T1R3 was consistently 
present at the proximal tubule BBM at higher levels than T1R2, as shown by the 
percentage of T1R2:T1R3 not exceeding 100% (Table 9.2); these increased levels of 
T1R3 relative to T1R2 reached statistical significance in every metabolic model 
studied, irrespective of whether the sweet taste receptors in the experimental group 
were elevated compared with the control for the study (Table 9.2). 
 
Table 9.2 – Relationship between the expression of renal sweet taste receptors T1R2 
and T1R3 in response to various metabolic models quantified as percentage 
expression of T1R2 to T1R3.  Values expressed as mean % ± SEM, n=5-12, *p<0.05, 
**p<0.01, ***p<0.005, ****p<0.001 compared with T1R3 expression. 
 
 Model T1R2:T1R3 (%) 
7-day type I 
Control 48 ± 2.4* 
Diabetic 35.7 ± 2.3* 
Type II 
Lean 54 ± 5.5* 
Diabetic 51.7 ± 5.7* 
Junk-food diet 
(metabolic syndrome) 
Chow 57.1 ± 0.3**** 
Junk-food 61.4 ± 2.7* 
High-fat diet 
(metabolic syndrome) 
Chow 56.1 ± 9.6** 
High-fat 58.2 ± 0.8* 
RYGB 
Sham 45.8 ± 4.8*** 
RYGB 50.8 ± 3.3**** 
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9.4 Discussion 
 
Glucose reabsorption in the kidney is an area of considerable interest because of its 
contribution to glucose homeostasis in both normal and metabolic disease models 
such as diabetes.  The importance of renal glucose uptake has prompted the 
development of SGLT2 inhibitors as a method to reduce glucose reabsorption in 
diabetes, and thus as a means of lowering blood glucose concentrations.  Furthermore, 
glucose accumulation within the proximal tubule cell, arising from increased glucose 
uptake, is a potential cause of diabetic nephropathy, a major cause of ESRD.  
Therefore, the identification of novel agents to influence glucose reabsorption, such as 
the SGLT2 inhibitor dapagliflozin, is of potential therapeutic value in the treatment of 
diabetes by lowering blood glucose levels and preventing diabetic nephropathy.  This 
chapter is concerned with the presence of sweet taste sensors in a newly-identified 
location at the proximal tubule BBM.  Furthermore, this chapter focuses on the 
function of sweet taste receptors in glucose transport across the proximal tubule BBM 
and the response of these sweet sensors in different models of metabolic 
dysregulation.  Table 9.3 summarises the results of this chapter and conclusions have 
been made on the involvement of T1R2/3 in renal glucose reabsorption which raises 
the possibility that sweet taste receptors may be vital therapeutic targets in the 
treatment of hyperglycaemia and diabetic nephropathy in diabetes. 
 
Table 9.3 - Summary table of effects of type II diabetes, and metabolic models 
associated with the disease, on expression of sweet taste receptors and SGLT1 at the 
proximal tubule BBM. SGLT1 data taken from chapter 8.  
# 
represents animals which 
were fasted before cull.  
 
 T1R2 T1R3 SGLT1 
Type I diabetes (7 day) ↔ ↔ ↔ 
Type II diabetes ↑ ↑ ↑ 
Junk-food diet ↑ ↑ ↑ 
High-fat diet* ↔ ↔ ↔ 
RYGB* ↔ ↔ ↔ 
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The heterodimer of T1R2 and T1R3 is a broadly-acting sweet taste receptor that acts 
through α-gustducin, to activate adenylyl cyclase leading to an increase in cAMP, or 
which acts through the βγ-subunit of gustducin to activate a PLCβ2-dependent 
pathway (Cui et al., 2006;Bachmanov and Beauchamp, 2007).  The sweet taste 
heterodimer has been shown to be located throughout the intestinal tract, where it is 
associated with glucose absorption, as well as in lingual taste tissues (Hoon et al., 
1999;Dyer et al., 2005;Bezencon et al., 2007;Stone et al., 2007;Bigiani and Cuoghi, 
2007;Mace et al., 2009;Moon et al., 2010).  Although a previous study identified 
TAS1R3 gene expression in the swine kidney, as well as in other tissues, including the 
heart, lung and pancreas, the finding in the kidney was not investigated further and 
has not been noted in other species (Kiuchi et al., 2006).  Interestingly, Pluznick et al 
have identified olfactory receptors, traditionally involved in nasal detection of 
odorants, in distal tubules in the kidney (Pluznick et al., 2009).  In the kidney, these 
receptors signal via adenylate cyclase and the olfactory G protein Golf to modulate 
GFR and rennin secretion. 
 
In the present study, gene expression of both components of the sweet taste sensing 
heterodimer T1R2 and T1R3 in the renal cortex has been identified under normal 
conditions.  Furthermore, these taste receptors have been shown to be present in both 
whole membrane and BBM preparations, suggesting a similarity to the enterocyte 
taste sensing mechanism, where T1R2/3 is localised at the jejunal BBM (Mace et al., 
2007).  The present study has also shown the presence of the mRNA for both 
components of the umami taste heterodimer T1R1 and T1R3 in the kidney cortex; this 
novel expression poses interesting questions about possible amino-acid sensing in the 
proximal tubule.  However, T1R1/3 expression in the kidney cortex was considerably 
higher than in the jejunum, suggesting a role for these receptors under normal 
conditions in the kidney, which may not be applicable in the small intestine.   
 
9.4.1 The umami taste sensor 
 
A potential role for the renal T1R1/3 heterodimer could be in the sensing of glutamate 
in the proximal tubule during ammoniagenesis.  This process of generating ammonia 
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in the proximal tubule cell for secretion across the BBM and into the lumen is vital in 
regulating acid excretion by the kidney (Good and Knepper, 1985;Nagami, 2004;Van 
de Poll et al., 2004).  In states of insulin-resistance such as obesity, metabolic 
syndrome and type II diabetes, there is reduced ammonium excretion, and this 
increases the tendency for acidic urine, leading to uric acid and mixed urate and 
oxalate stones (Powell et al., 2000;Daudon and Jungers, 2007;Palladino and Stanley, 
2010).  Indeed approximately 20% of diabetics suffer from renal stones compared 
with only 8% in non-diabetics; interestingly, metabolic syndrome patients also have 
hyperuricaemia, a more acid urine and increased risk of renal stones (Maalouf et al., 
2004;Liebman et al., 2007).  Although the reasons for this reduced ammonium 
excretion are not yet fully understood, possible explanations are that either there is 
impaired proximal tubular ammoniagenesis or that there are disturbances in the 
complex pathway of ammonium excretion by the kidney.  Decreased ammoniagenesis 
could result from a defect in glutamine uptake into proximal tubular cells, for 
example, reduced SNAT3 protein for glutamine and EAAC1 for glutamate (Mu and 
Welbourne, 1996;Moret et al., 2007;Busque and Wagner, 2009).  A reduction in 
ammoniagenesis could also be a result of a defect in the production of ammonia, for 
example, through altered mitochondrial metabolism.  Furthermore, it could be 
explained by disturbed ammonium secretion along the proximal tubule via NHE3 
disruption (Biemesderfer et al., 1993;Ambuhl et al., 1996;Gagnon et al., 1999).  
 
In the jejunum, the umami taste receptors T1R1 and T1R3 are responsible for sensing 
glutamate and aspartate in the lumen and the heterodimer T1R1/3 signals via 
transducin to activate PKC-βI through a similar pathway to T1R2/3 sweet taste 
sensing. Activated PKC-βII promotes BBM expression of EAAC1, the glutamate 
transporter; EAAC1 and T1R1/3 have been shown to have the same specificity for 
glutamate.  Furthermore, glutamate transport via EAAC1 provides the substrate for 
ammoniagenesis (Li et al., 2002;Mace et al., 2009).  In contrast to the small intestine, 
PKC-βI activation in the S2/S3 segment of the proximal tubule reduces the BBM 
expression of EAAC1 and NHE3. These PKC-mediated effects could influence 
ammoniagenesis: first, by limiting the uptake of glutamate into the proximal tubule 
cell via EAAC1; second, by reducing NHE3-mediated ammonium secretion into the 
tubular fluid (Karim et al., 1999;Pedrosa et al., 2004;Fournier et al., 2004;Padovano 
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et al., 2009).  Renal taste sensing, in a similar manner to that in the jejunum, might be 
involved in the regulation of renal EAAC1, and potentially NHE3 (Mace et al., 2009).  
 
Another role for umami sensing in the proximal tubule could be in oligopeptide 
transport via the proton-dependent PepT1 and PepT2; both these transporters have 
been found in the proximal tubule BBM, with the Pep-T1 high-capacity transporter 
localised in the early S1 segment and the PepT2 high-affinity transporter present in 
the late S2/S3 segment (Shen et al., 1999).  Interestingly, in the jejunum, stimulation 
of the umami taste receptor with glutamate results in the internalisation of PepT1 at 
the BBM in a PKC-βII-dependent manner (Mace et al., 2009).  Due to the similarities 
in nutrient transport between the jejunum and proximal tubule, it is interesting to 
speculate whether the umami taste receptor in the kidney is involved in the regulation 
of PepT1 and PepT2 oligopeptide transporters.  Further studies on the effect of 
stimulating the renal umami taste heterodimer, T1R1/3, on PepT1 and PepT2 activity 
is specifically intriguing as these oligopeptide transporters are also responsible for the 
uptake of a variety of pharmacological agents into the proximal tubule cell (Meredith 
et al., 2000;Daniel and Kottra, 2004).    
 
9.4.2 The sweet taste sensor 
 
The sweet taste heterodimer T1R2/3 was considered more applicable to my work, 
because it is known to be involved in the control of intestinal glucose absorption.  
Thus, T1R2/3 was studied in relation to glucose transport across the proximal tubule 
BBM.  In addition to the mRNA expression of T1R2 and T1R3 observed in the 
kidney cortex, expression of these sweet taste receptors was also identified in whole 
membranes prepared from the kidney cortex of rats and mice.  This is in contrast to a 
study by Kitagawa et al, which showed T1R3 mRNA to be absent in the mouse 
kidney, with expression only noted in the circumvallate papillae of the tongue, and in 
the testis (Kitagawa et al., 2001).  However, the porcine proximal tubule cell line did 
not express either T1R2 or T1R3, although this is more likely to be a result of 
antibody specificity than expression per se in LLC-PK1 cells.  Interestingly, the cell 
line originates from pigs which exhibit close homology to humans (Valentin et al., 
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1999) therefore it would be interesting to study the expression of T1R2 and T1R3 in 
human kidney tissue.  
 
Sweet taste receptors were also found at the proximal tubule BBM, and, as with the 
mRNA expression for the umami taste sensor, levels were considerably elevated when 
compared with those seen in the jejunum.  This may indicate that sweet taste sensing 
in the kidney is more significant than in the jejunum.  However, expression of renal 
sweet taste receptors is unaffected by acute or chronic hyperglycaemia, despite 
chronic hyperglycaemia being the stimulus for the increased levels of GLUT2 at the 
proximal tubule BBM via PKC-βI.  This suggests that unlike in the jejunum, renal 
sweet taste receptors are not related to GLUT2 expression at the BBM.  Interestingly, 
STZ-induced type I diabetes affected expression of T1R2 mRNA in the kidney cortex, 
implying that although BBM levels of the sweet taste receptor are not affected by 
diabetes at an early stage of the disease, gene-related alterations in their expression do 
occur.  Although renal T1R3 mRNA expression was unaffected in type I diabetes, its 
heterodimer partner T1R2 was decreased to the same degree at early (10 days) and 
late (30 days) time points following the induction of type I diabetes.  Therefore, the 
only alterations in the sweet taste heterodimer occur in T1R2 early in type I diabetes 
and are maintained through the disease.   
 
Human studies have shown that T1R2 and T1R3 transcripts are both down-regulated 
in the duodenal mucosa biopsies from type II diabetics, and the sweet taste receptors 
exhibit an inverse correlation with plasma glucose; thus, the duodenal sweet taste 
receptors are responsive to type II diabetes (Young et al., 2009).  The relationship 
between type II diabetes and sweet taste receptors was studied in the kidneys from 
normotensive GK rats.  These type II diabetic rats were shown in Chapter 8 to exhibit 
up-regulated glucose transport via PKC-βI activated GLUT2, GLUT5, and SGLT1.  
In this type II diabetic model, the sweet taste receptors T1R2 and T1R3 were also 
elevated at the proximal tubule BBM.  Therefore, unlike GLUT5, GLUT2, and its 
activator PKC-βI, the sweet taste receptor expression profile in type II diabetes is 
different from that seen in type I diabetes.   
 
The elevated renal sweet taste expression seen in kidneys from GK rats was also 
evident in kidneys from animals fed a junk-food diet for an 8-week period.  Renal 
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T1R2 and T1R3 expression was increased in response to this Western diet, although 
to a lesser degree than during type II diabetes.  This could be explained by the insulin-
resistance obesity in the junk-food diet model.  However, in response to a high-fat 
diet, another insulin-resistant model, there were no alterations in sweet taste receptor 
expression at the proximal tubule BBM.  This raises the question of whether there is a 
component of the junk-food diet that can specifically affect the sweet taste receptors 
in this dietary model.  Intriguingly, there has been a massive rise in HFCS use in soft 
drinks and junk foods, such as pastries, desserts and various processed foods within 
the last thirty years.  HFCS is a widely-used sweetener, commonly consisting of a 
mixture of 55% fructose and 45% glucose, which varies from the 50:50 ratio in 
sucrose, and this causes its intense sweetness, making it a cost-effective sweetener to 
add to foods (Fulgoni, III, 2008;Moeller et al., 2009).  In the present study, long-term 
feeding of junk-foods high in inverted sugar syrup, another name for HFCS, such as 
digestive biscuits, flapjacks and marshmallows, would be expected to raise levels of 
fructose and glucose in the plasma.  As a result, the elevated levels of these sugars in 
tubular filtered fluid may result in enhanced stimulation of sweet taste receptors at the 
renal BBM; an effect which would not occur in rats fed a high-fat diet alone.  Recent 
studies highlight that HFCS may be detrimental to health and a major reason for the 
global obesity epidemic, with insulin resistance established as a side-effect of a high-
fructose intake (Forshee et al., 2007;Johnson et al., 2009).  Thus elevated fructose 
consumption correlates with the development of type II diabetes.  Furthermore, 
fructose consumption is also associated with renal tubular injury and the very early 
stages of diabetic nephropathy, potentially as a side-effect of elevated uric acid in 
response to raised levels of circulating fructose (Boot-Handford et al., 1981;Sanchez-
Lozada et al., 2007;Bomback et al., 2010)).  The enhanced renal sweet taste sensing 
in junk-food fed animals may even be involved in fructose-induced renal tubular 
injury. 
 
9.4.3 Sweet taste sensing and hormonal regulation 
 
Interestingly, dysregulation of sweet taste sensing in diabetes is not confined to the 
kidney.  Sweet hypogeusia, the reduced ability to taste sweet substances, was 
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identified in 73% of type I diabetic patients, whereas the incidence was only 16% in 
non-diabetics (Le Floch et al., 1989).  Also, type II diabetics display a blunted taste 
response to sweet foods (Perros et al., 1996;Gondivkar et al., 2009).  Therefore 
impaired sweet taste sensing in diabetes may result in the increased consumption of 
sugary foods to achieve sweet satiety, and may exacerbate the hyperglycaemia 
associated with these disorders.  
 
Chronic alterations in plasma leptin levels have been hypothesised to underlie the 
changes in sweet taste threshold and sensitivity, and increased serum leptin has been 
shown to affect gustatory mechanisms in diabetic and obese conditions (Ninomiya et 
al., 2002;Shimizu et al., 2003;Nakamura et al., 2008).  Leptin, the product of the 
obese (ob) gene, is a hormone predominantly released from adipose tissue and 
regulates food intake and body weight by binding to the leptin receptor (Ob-Rb) in the 
hypothalamus, however, the Ob-Rb has also been identified in peripheral organs such 
as adipose tissue, lung, liver and kidney (Cao et al., 1997;Wang et al., 1997a;Pralong 
and Gaillard, 2001).  Leptin binding to Ob-Rb on taste-sensitive cells causes the 
specific inhibition of peripheral neural and behavioural responses to sweet taste 
sensing in lean mice; inhibition occurs due to Ob-Rb activation causing increased 
outward currents and reduced cell excitability, followed by a reduction in sweet taste 
sensing conveyed to the brain (Kawai et al., 2000).  In Ob-Rb deficient db/db diabetic 
mice there is no suppression of sweet taste sensing because leptin cannot bind and 
activate its receptor.   
 
Energy excess or deprivation may affect the sensitivity of some nuclei in the central 
nervous system (CNS) that are involved in taste perception, which in turn act on the 
gustatory receptors (Plata-Salaman et al., 1993;Sudakov, 1993).  This was shown in 
diabetic and high-fat diet-induced obese rats where a heightened response to 
sweeteners was seen in the chorda tympani nerve, a branch of the facial nerve that 
serves taste buds in the front of the tongue (Kawai et al., 2000;Shimizu et al., 2003).  
Patients have shown a reduced acuity for sweet tastes following RYGB surgery, 
whereas the bitter taste threshold was unaffected (Bray et al., 1976;Burge et al., 
1995).  This has also been shown in rodent studies with sham-operated animals 
exhibiting a higher preference for sucrose than RYGB-operated (Tichansky et al., 
2010).  In the studies presented here, the sweet taste heterodimer in the proximal 
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tubule was unaffected by RYGB surgery, however there was reduced expression in 
the proximal small intestine, therefore reduced sugar preference following RYGB 
may be related to intestinal T1R2/3 expression.  Interestingly, following RYGB 
surgery, patients exhibit reduced preference for meat and lower protein intake, which 
can result in malabsorption, and this may be caused by changes in T1R1/3 umami 
taste sensing (Burge et al., 1995).   
 
In addition to a reduced preference for high concentrations of saccharin, rats fed a 
high-fat diet exhibited a significant decrease in mRNA expression of T1R3 in taste 
buds, as well as a trend towards reduction of the molecules involved in the signalling 
pathway for taste transduction (Chen et al., 2010).  In contrast, chronically restricting 
the control chow diet by 50% caused an increase in preference for saccharin when the 
sweetener was used at a concentration of 0.04 M (Chen et al., 2010).  Although there 
was no change in T1R2 or T1R3 mRNA expression in taste buds, there was a 
significant increase in expression of leptin receptor (Chen et al., 2010).  A junk-food 
diet results in raised leptin levels, primarily due to elevated adiposity, since when 
leptin concentration was corrected for body fat mass, there was no difference between 
junk-food fed and controls (De et al., 1998).  Furthermore, a high-fat diet causes an 
elevation in circulating leptin levels in rodent models and man (Maffei et al., 
1995;Considine et al., 1996).  Therefore, this hormone has a depressive effect on 
sweetener intake and restricting the diet causes increased Ob-Rb and increased 
preference for saccharin via elevated taste cell excitability.  In response to RYGB 
surgery, plasma leptin is significantly decreased, a finding in both patient and rodent 
RYGB models due to a reduction in adiposity, similar to that seen in chronically-
fasted conditions (Rubino et al., 2004;Borg et al., 2006;Cariani et al., 2008;Korner et 
al., 2009).  This emphasises that changes in metabolic state are able to modulate the 
sensitivity to gustatory stimuli, as well as the sensory pleasure of sweetness and the 
hedonic reactions of rats to sweeteners.   
 
Although these studies were based on oral taste signalling pathways, it is interesting 
to note that the leptin receptor is present in the kidney.  Leptin is cleared principally 
by the kidney and serum leptin concentrations are increased in patients with chronic 
renal failure; as well as the binding of the hormone to the leptin receptor (Ob-Rb) in 
the kidney, leptin can also bind megalin and cubulin at the proximal tubule BBM 
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(Moestrup and Verroust, 2001;Wolf et al., 2002).  Therefore, leptin-mediated effects 
on sweet taste sensing may not only have a bearing on taste in the mouth and 
intestinal tract, but leptin may have a whole-body effect on sweet taste sensing, 
including in the proximal tubule.   
 
GK type II diabetic rats are hyperleptinaemic whereas in type I STZ-induced diabetes, 
circulating leptin levels are decreased (Havel et al., 1998;Maekawa et al., 2006).  A 
high-fat diet and RYGB surgery were without effect on renal sweet taste receptors, 
whereas junk-food feeding caused an elevated expression of sweet taste receptors at 
the proximal tubule BBM, suggesting a dissociation between oral taste signalling and 
renal taste sensing.  Plasma leptin may be responsible for the changes in sweet taste 
sensing at the proximal tubule BBM as, with the exception of increased leptin in 
response to the high-fat diet, changes in circulating leptin levels are mirrored by 
T1R2/3 expression.  However, in response to long-term saccharin feeding, diabetic 
ob/ob mice exhibit delayed onset of hyperglycaemia, thus the stimulation of sweet 
taste sensors can occur in this leptin-deficient rodent model (Bailey et al., 1997).  It 
would therefore be of interest to study the influence of circulating leptin on the renal 
sweet taste sensor.   
 
Unlike sweet taste sensing in the oral taste cells, which stimulates peripheral gustatory 
nerves and brain gustatory pathways, sensing in small intestinal enteroendocrine cells 
results in the release of incretins.  These gut-derived hormones comprise GIP and 
GLP-1 and are released from the BLM of enteroendocrine cells; incretins can either 
act locally on enterocytes or activate afferent neurones in the gut villi or enter the 
blood stream to act as systemic hormones to augment the release of pancreatic insulin 
(Jang et al., 2007;Shin et al., 2008).  Therefore, sweet taste sensing in the small 
intestine is not only involved in paracrine control of glucose absorption, but also 
affects whole-body glucose homeostasis, such as the increased appetite and weight 
gain associated with increased circulating insulin; a theory known as the Egan & 
Margolskee hypothesis (Margolskee et al., 2007).  However, knowledge of plasma 
insulin levels in these metabolic models, type I and II diabetes and metabolic 
syndrome offers no further understanding of the mechanisms involved in taste 
receptor activation.  The present study showed that type I diabetes was associated 
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with low levels of circulating insulin, whereas there was no change in insulin levels in 
GK rats, and high levels were seen in both the metabolic syndrome models; therefore, 
sweet taste receptors are probably activated via an insulin-independent pathway.  
Furthermore, the plasma glucose levels in these metabolic models were extremely 
varied, although all exhibit significantly augmented levels compared with controls.  
Blood glucose levels of the STZ-induced type I diabetic model was nearly two-fold 
higher than in the GK type II diabetic model, and both high-fat feeding and junk-food 
diet increased plasma glucose levels, but maintained them within the normal range.  
Under normal conditions, the late S3 region of the proximal tubule would not be 
exposed to high luminal glucose levels as the majority is reabsorbed in the early 
S1/S2 region.  However, in the STZ-induced type I and GK type II model of diabetes 
T1R2/3 expression is unchanged and up-regulated, respectively; hyperglycaemia in 
these models would result in elevated glucose in the tubular fluid and thus, it is likely 
that the renal sweet taste heterodimer exerts a response that is independent of a 
glucose stimulus.  This is an unusual finding considering the specificity for the sweet 
taste heterodimer, T1R2/3, for simple sugars, as well as other sweet substrates 
including artificial sweeteners.  Li et al have previously shown a dose-dependent 
activation of T1R2/3 to sucrose in the very high millimolar range and, although acute 
IV infusion of glucose was administered at an infusate concentration of 1.1 M, the 
equivalent concentration in the plasma, and thus early proximal tubular fluid, never 
exceeded 50 mM (Li et al., 2002).  Despite the tendency for these supraphysiological 
levels of glucose to cause osmotic diuresis and dehydration, they are unlikely to elicit 
a sweet taste response (Small and MacCuish, 1987;Tanaka et al., 2000;Chiasson et 
al., 2003).  This is in agreement with data presented here, where IV infusion of 
glucose and mannitol, which incurred hyperglycaemia and osmotic shock 
respectively, had no effect on T1R2/3 expression at the proximal tubule BBM.   
 
Interesting studies by Shin et al found that GLP-1 is specifically co-localised with 
T1R3 and the sweet taste signalling molecules α-gustducin and PLCβ2 in a subset of 
lingual taste cells (Shin et al., 2008).  The presence of gut hormones in the taste bud 
highlights an important parallel between gustatory and intestinal epithelia; 
furthermore, it has been postulated that GLP-1 and glucagon signalling modulate oral 
sweet taste sensitivity (Shin et al., 2008).  Au et al have shown that the structurally 
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related GLP-2 can rapidly promote expression of GLUT2 at the intestinal BBM.  This 
suggests that the glucagon family of peptide hormones is potentially important in the 
control of epithelial glucose transport (Au et al., 2002).  Intriguingly, Marks et al have 
identified the expression of glucagon receptor mRNA in the proximal tubule and 
showed that glucagon stimulates GLUT-mediated glucose transport (Marks et al., 
2003•).  Therefore, it is possible that glucagon signalling may influence sweet taste 
sensing in the kidney.  Glucagon, the 29-amino acid hormone synthesised by 
pancreatic α-cells, binds to the GLP-1 receptor and, through GTP-binding 
heterotrimeric Gs-proteins, activate adenylate cyclase activity, leading to increased 
intracellular cAMP levels (Mayo et al., 2003).  Furthermore, glucagon binding to the 
GLP-1 receptor also results in increased signalling through the PLC/IP3/Ca
2+
 
pathway, resulting in PKC activation and elevated gluconeogenesis (Li et al., 2006).  
Clinical studies have shown that hyperglucagonaemia is often associated with the 
onset and progression of type II diabetes; also raised levels of blood glucagon in both 
obese and non-obese type II diabetes have been well-established (Unger, 1978).  
Indeed, the long-term infusion of glucagon into mice produced metabolic and renal 
phenotypes of type II diabetes and diabetic nephropathy, including increased fasting 
blood glucose, impaired glucose tolerance, development of microalbuminuria, 
mesangial expansion and increased extracellular matrix (ECM) deposition in the 
glomeruli (Li et al., 2008).        
 
Studies carried out in type I diabetic rodents and humans have shown that proximal 
tubule levels of GLP-1 receptor are down-regulated, possibly due to PKC-mediated 
effects; the infusion of GLP-1 into type I diabetics results in restoration of glycaemia 
by reducing the high circulating glucagon levels (Creutzfeldt et al., 1996;Behme et 
al., 2003;Marks et al., 2003;Marks et al., 2003).  Patients suffering from metabolic 
syndrome exhibit high plasma levels of GLP-1; however, in response to duodenal-
jejunal exclusion gastric bypass surgery, improved glucose tolerance occurs in GK 
diabetic rats.  The GLP-1 antagonist exendin-[9-39] abolished this improvement 
(Kindel et al., 2009;Yamaoka-Tojo et al., 2010).  Thus glucose tolerance was 
hypothesised to be a result of elevated GLP-1 levels in plasma.   
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9.4.4 Sweet taste sensing and renal glucose transport 
 
As previously stated in this section, an increase in adiposity and obesity does not 
appear to be the cause of the elevated expression of sweet taste receptors, otherwise 
the high-fat diet would have an impact on T1R2 and T1R3.  However, it is possible 
that the adiposity and obesity in the junk-food diet is a more physiological pre-
diabetic state than the high-fat diet.  These data from the different diet-induced 
metabolic syndrome model echo the conclusion from data obtained in the present 
study on type I diabetes.  The augmented PKC-βI-mediated expression of GLUT2 at 
the proximal tubule BBM occurs independently of activation of the sweet taste 
receptors T1R2 and T1R3.  This is emphasised by the unaffected T1R2/3 levels in 
response to hyperosmotic mannitol, which, as described in Chapter 7, results in the 
recruitment of GLUT2 and PKC-βI to the proximal tubule BBM.  Thus, it is likely 
that GLUT2 recruitment to the proximal tubule BBM can occur via a sweet taste 
receptor-dependent pathway, as is the case in type I diabetes and high-fat diet-induced 
metabolic syndrome, as well as in osmotic shock conditions.   Alternatively, GLUT2 
is shuttled to the proximal tubule BBM via a sweet taste receptor-dependent pathway, 
as seen in type II diabetes and junk-food-induced metabolic syndrome.  It cannot be 
overlooked that there is increased mRNA expression of T1R2 in response to short and 
long-term type I diabetes; however, 7 days hyperglycaemia, though sufficient to result 
in the recruitment of GLUT2 to the proximal tubule BBM, does not stimulate an 
increase in T1R2 protein.  It is possible that T1R2 responds at a slower rate than 
GLUT2, as shown by type II diabetes, diet-induced metabolic syndrome and RYGB 
models, which were studied over longer time periods (5-weeks to 8-9 weeks).  
Interestingly, altered GLUT5 transporter expression at the proximal tubule BBM 
parallels changes in T1R2/3 expression, with STZ-induced type I diabetes being the 
exception to this relationship, where GLUT5, but not T1R2/3, is up-regulated.  
Therefore, it is possible that fructose transport in the proximal tubule may be 
stimulated by sweet taste sensing at the tubular epithelium.    
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9.4.5 Artificial sweeteners 
 
Artificial sweeteners are increasingly used to aid weight-loss and as a sugar-substitute 
for diabetics, since they have no calorific value and are not believed to affect blood 
glucose levels.  However, these aspects of artificial sweeteners are currently under re-
examination in light of their effect on intestinal glucose absorption.  Sucralose, 
commercially available as ‘SucraPlus’ or ‘Splenda’, is often used to stimulate T1R2/3 
due to its stability and intense sweetness (it is approximately 600-fold sweeter than 
sucrose and twice as sweet as saccharin).  However, clinical studies suggest that 
artificial sweeteners blunt sugar sensing due to their intense sweetness; indeed, the 
consumption of sucralose results in reduced food intake and decreased body weight 
(Mann et al., 2000).  Sucralose would be interesting to study, as it is able to enhance 
the recruitment of GLUT2 to the enterocyte BBM to a higher degree than saccharin 
(Mace et al., 2007).  Sucralose induces a dose-dependent increase in kidney weight in 
long-term, 52 week, sucralose feeding studies; furthermore, high sucralose feeding 
has also been associated with an increased incidence of chronic nephropathy (Mann et 
al., 2000;Sims et al., 2000).  Only 5-10% of an oral sucralose dose is absorbed by the 
small intestine and plasma sucralose has a half-life between 2 and 5 hours with 
absorbed sweetener found to accumulate in the liver, kidney and gastrointestinal tract 
(Sims et al., 2000).  The more intense sweetness of sucralose, coupled with its 
established effects on intestinal glucose transport, make this sweetener an interesting 
artificial sweetener to study in relation to the involvement of renal sweet taste 
receptors and plasma glucose uptake in long-term, high glucose-induced tubular 
damage.   
 
Since artificial sweeteners are able to elicit a stronger response from T1R2/3 than 
simple sugars at a lower concentration, the question was posed whether sweet taste 
receptors in the proximal tubule are responsive to artificial sweeteners in the 
circulation (Li et al., 2002).  The present study shows that the stimulation of sweet 
taste receptors at the proximal tubule BBM, via IV infusion of saccharin, induced a 
rapid up-regulation in T1R2 and T1R3 expression.  Interestingly this was 
accompanied by elevated SGLT-mediated glucose transport and SGLT1 expression 
but the artificial sweetener had no influence on GLUT-mediated glucose transport or 
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renal expression of PKC-βI, GLUT2 or GLUT5.  Thus it is clear that unlike in the 
jejunum, acute activation of the renal sweet taste heterodimer does not elicit GLUT2 
recruitment to the BBM.  Longer-term studies using STZ-induced type I diabetes or 
the GK rat model of type II diabetes, where GLUT2 expression is elevated at the 
proximal tubule BBM would result in the proximal cell being primed with glucose; 
examination of the effect of saccharin on glucose-primed proximal tubule cells may 
be useful, since data in Chapter 7 show that renal GLUT2 cannot be recruited to the 
BBM in the short-term, unless in response to high osmolality.  The necessity for a 
glucose stimulus, in addition to an artificial sweetener, to stimulate GLUT2 
recruitment to the BBM has been shown in the jejunum where the administration of 
20 mM glucose with sucralose was necessary to elicit the translocation of GLUT2 
(Mace et al., 2007;Mace et al., 2009).   
 
Intriguingly the elevated SGLT-mediated glucose transport at the proximal tubule 
BBM occurred despite the absence of changes in blood glucose levels.  Although 
plasma saccharin levels were not analysed in these experiments, it is likely that levels 
of plasma saccharin were raised.  Lethco et al observed 56-87% saccharin, which was 
fed in the diet over 7 days, was not metabolised and excreted via renal tubular 
secretion as well as filtration (Lethco et al., 1975).  Therefore, in response to IV 
infusion of the sweetener in the studies presented here, the levels in the tubular fluid 
are likely to be high; however the artificial sweetener may exert an effect at either the 
BLM or BBM.  Furthermore, SGLT1 expression in the proximal tubule was elevated 
in junk-food fed and type II diabetic rats, where levels of the sweet taste receptors 
T1R2 and T1R3 were also augmented.  Thus, renal sweet taste receptor activation 
occurs in parallel with SGLT1 up-regulation at the proximal tubule BBM suggesting a 
strong relationship between this high-affinity glucose transporter and the sweet taste 
heterodimer.     
 
Previous studies have identified the involvement of the SLC5 family of glucose 
transporters in sugar sensing; human SGLT3, expressed in Xenopus oocytes, 
depolarises plasma membranes in response to extracellular glucose and thus can 
sense, but not transport, sugars (Diez-Sampedro et al., 2003).  Interestingly, a recent 
study identified a single amino acid mutation in the SGLT3 protein that can convert 
the sugar sensor into a sugar transporter (Bianchi et al., 2010).  Data in the present 
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study shows that SGLT1 expression is related to the sweet taste sensors at the 
proximal tubule BBM, while the high-capacity transporter GLUT2 is unaffected by 
saccharin-mediated sweet taste receptor stimulation.  Thus, the renal T1R2/3 
heterodimer appears to mediate a finely-tuned mechanism for the control of renal 
glucose reabsorption, whereby glucose uptake occurs via the up-regulation of SGLT1.  
This echoes data from the small intestine, where sweeteners have been shown to 
increase SGLT1 and SGLT-mediated glucose transport, in addition to their role in the 
recruitment of GLUT2 to the enterocyte BBM (Mace et al., 2007;Stearns et al., 2010).  
It is important to study SGLT2 in this context, since it is a higher capacity transporter 
at the proximal tubule BBM; indeed studying the expression of SGLT2 in response to 
sweeteners would aid the further understanding of the relationship of T1R2/3 to 
SGLT-mediated glucose transport.   
9.4.6 Sweet taste sensing and glucose absorption in response to gastric bypass 
surgery 
 
In response to duodenal bypass as a result of RYGB surgery, the expression of 
GLUT2 was down-regulated at the proximal tubule BBM, along with PKC-βI, but 
SGLT1 and sweet taste receptor expression was unaffected.  Although these data 
emphasise the relationship between the expression of SGLT1 and T1R2/3, they also 
provide further evidence that T1R2/3 is not involved in the expression of GLUT2.  
However, it is worth noting that mRNA expression of the sweet taste receptor T1R2 
was reduced in the renal cortex from animals after RYGB surgery.  Therefore, the 
intracellular pool of only one component of the renal sweet taste heterodimer was 
depleted in response to RYGB surgery.  RYGB surgery has been shown to affect 
hormone signalling, in particular GLP-1 signalling; however, as described above, 
these factors do not appear to be solely responsible for sweet taste sensing. 
 
Interestingly, the reduction in renal expression of T1R2 following RYGB surgery was 
also seen in T1R2 protein and mRNA expression in the bypassed duodenal 
biliopancreatic limb.  RYGB surgery involves the re-sectioning of the duodenum to 
the alimentary limb, therefore dietary load moves directly into the jejunum and 
renders the biliopancreatic limb ineffectual (Figure 8.1).  However, the T1R2 sweet 
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taste receptor is also down-regulated at the alimentary limb BBM, which is the first 
part of the small intestine to be exposed to high dietary glucose; therefore, expression 
of T1R2 is unlikely to be responsive to a direct sweet stimuli present in the intestinal 
fluid.  Protein levels of the T1R3 sweet taste receptor expressed in the alimentary 
limb BBM were reduced, despite T1R3 mRNA expression being unaffected by 
RYGB surgery, along the entire small intestine.  This is the first analysis of T1R2/3 
expression in the small intestine following this surgical model and may provide an 
explanation for the reduced sweet taste preference observed following RYGB surgery 
in both human and rodent models (Burge et al., 1995;Tichansky et al., 2010;Hajnal et 
al., 2010).  
 
 
Studies of intestinal glucose transport following RYGB surgery discussed in Chapter 
8 showed reduced expression of GLUT5 in the duodenum; therefore, its expression 
may be a consequence of sweet taste sensing of the carbohydrate load in the lumen, as 
hypothesised above for proximal tubule GLUT5–sweet taste heterodimer expression.  
However T1R2/3 expression in the RYGB model provides evidence that sweet taste 
receptors and SGLT1 expression at the enterocyte BBM are unrelated, since studies in 
Chapter 8 show that expression of SGLT1 is up-regulated in the alimentary limb 
following RYGB surgery, whereas expression of both T1R2 and T1R3 are reduced.   
 
Although hormones, such as insulin, GIP and GLP-2 are known
 
to modulate 
enterocyte glucose transport, glycaemic status is also known to influence glucose 
absorption (Csaky et al., 1981;Maenz and Cheeseman, 1986;Pennington et al., 
1994;Cheeseman et al., 1996;Cheeseman, 1997).  Thus, STZ-induced type I diabetes 
promotes glucose uptake across the jejunal BBM via SGLT1 and GLUT2 (Debnam et 
al., 1988;Burant et al., 1994;Debnam et al., 1995;Kellett and Brot-Laroche, 2005).  
Interestingly, in the present study using the jejunum from 30-day STZ-induced 
diabetic rats, there was an elevation in mRNA expression of T1R2 and T1R3.  
Therefore, unlike in RYGB surgery, where glucose transport is not related to the 
expression of sweet taste receptors, in type I diabetes the previously established 
positive relationship between sweet taste sensing and enterocyte glucose absorption is 
confirmed (Dyer et al., 2005;Margolskee et al., 2007;Mace et al., 2007;Mace et al., 
2009).   
  
  244 
 
9.4.7 Characteristics of renal sweet taste sensing 
 
It is worth noting that previous studies have suggested that sweet taste receptors are 
internalised on activation (Tan et al., 2004).  Thus. the elevated brush-border 
expression of T1R2/3 seen in the proximal tubule in type II diabetic and junk-food fed 
rats may be a consequence of, under basal conditions, reduced activation of the renal 
sweet taste heterodimer.  However, this does not appear to be the case in renal sweet 
taste sensing, since in response to saccharin expression of both T1R2 and T1R3 were 
elevated.  Therefore, this represents a major difference in sweet taste receptor 
activation in the kidney in comparison with that in the small intestine and in lingual 
taste buds.  
 
In the present work in all metabolic models studied, the renal expression of T1R3 
mRNA and protein was significantly higher than T1R2 (Table 9.2).  Interestingly, 
mRNA expression of the umami taste receptor component T1R3 was also found to be 
higher compared with T1R1 expression.  Previous studies have shown that T1R3 is 
able to function as a homodimer, as well as part of the sweet and umami taste 
heterodimer: for example, for sensing of the dissacharide trehalose (Nelson et al., 
2001;Ariyasu et al., 2003).  T1R3 has been found to be located in the liver, bile duct 
carcinoma cells, stomach, lung, and pancreatic α and β-cells (Taniguchi, 2004;Toyono 
et al., 2007;Nakagawa et al., 2009).  Li et al identified a fraction of T1R3-expressing 
cells that did not express T1R1 or T1R2; furthermore, allelic variations of only the 
Tas1r3 gene influence taste responses to a wide range of artificial sweetener 
concentrations and sugars (Li et al., 2002;Inoue et al., 2007).  Studies using the T1R3 
knockout mouse have emphasised the importance of this taste receptor, since in this 
model animals display no preference for artificial sweeteners with diminished 
behavioural and nerve responses to sweet and umami compounds (Damak et al., 
2003). Hass et al suggested that T1R3 dimerises with different, and hitherto unknown, 
components in brush-border cells of the small intestine.  Interestingly, T1R3 has also 
been shown to function as a gustatory calcium-magnesium receptor, as well as its 
involvement in sweet and umami taste sensing (Tordoff et al., 2008;Hass et al., 2010).  
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Therefore in the kidney, T1R3 may be more highly expressed, than T1R1 or T1R2, 
because of its role in sweet and calcium-magnesium tasting, as well as being a 
component of the sweet (T1R2/3) or umami (T1R1/3) taste heterodimer.     
 
9.4.8 Novel locations and roles for taste sensors 
 
Recent studies have linked chemosensation of luminal constitutes not only to the 
regulation of central nervous system activity, but also to local control of absorptive 
and secretory processes (Sclafani et al., 1976;Mace et al., 2007;Gulbransen et al., 
2008).  Bitter and sweet taste receptors recently identified in airway smooth muscle 
have been shown to trigger protective reflexes such as bronchoconstriction 
(Deshpande et al., 2010;Tizzano et al., 2011).  Bitter taste receptors have also been 
found in nasal chemosensory cells where stimulation of these receptors invokes 
changes in respiration; whereas T1R3 in pancreatic β-cells has been implicated in 
stimulating insulin secretion (Nakagawa et al., 2009;Tizzano et al., 2010).  
 
The presence of taste receptors in the kidney raises interesting questions concerning 
their potential role in nutrient sensing and reabsorption.  As hypothesised above, renal 
T1R1/3 umami taste sensing is potentially involved in amino-acid transport and 
oligopeptide transport, with implications for ammoniagenesis or drug reabsorption.  
Expression of T1R2/3 sweet taste heterodimer in the kidney is altered by metabolic 
status, and data in the present study suggest that T1R2/3 sensing may have 
implications for glucose reabsorption during the feeding of a junk-food diet and in 
type II diabetes.  There are many possibilities for taste sensing in the proximal tubule 
that may have a wider involvement in the regulation of nutrient reabsorption by the 
kidney, for example, the CaSR, located at the proximal tubule BBM is likely to have a 
sensory function (Riccardi et al., 1998).  Recent evidence implicates the stimulation 
of the widely-distributed CaSR as mediating the japanese kokumi taste, as well as the 
established role of CaSR in amino-acid sensing (Conigrave et al., 2000;Conigrave et 
al., 2006;Ohsu et al., 2010).  Thus taste sensing in the kidney may affect nutrient 
transport via mechanisms other than those studied in this chapter.  
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9.5 Conclusion 
 
Sweet taste sensing is important for nutrient recognition in response to energy 
requirements.  Data presented in this chapter have established that components of the 
sweet taste heterodimer T1R2 and T1R3 are expressed in the kidney, specifically at 
the proximal tubule BBM.  Furthermore, the stimulation of T1R2 and T1R3 by 
artificial sweeteners, and their up-regulation in response to junk-food feeding and type 
II diabetes is associated with the increased Vmax of SGLT-mediated glucose transport 
and expression of SGLT1 at the renal BBM.  However, a high glucose stimulus, 
acutely or chronically induced, did not alter levels of T1R2 and T1R3 at the proximal 
tubule BBM, suggesting a specific response of the heterodimer to sweetener intensity.  
GLUT2 at the proximal tubule BBM was up-regulated by a sweet taste receptor-
SGLT1-dependent and -independent pathway, depending on the nature of the 
metabolic disease stimulus.  This may have implications for the widespread use of 
artificial sweeteners and the potential relationship with the increasing incidence and 
prevalence of obesity-related diabetes. Glucose reabsorption across the proximal 
tubule BBM may be one cause of diabetic nephropathy; thus, the identification of 
sweet taste receptors and their influence on glucose reabsorption implicates these 
sensors in the novel treatment of junk-food and sweetener-induced metabolic 
syndrome and type II diabetes.  Targeting renal sweet taste receptors would reduce 
blood glucose levels in these conditions, which could, in turn, slow the progression of 
nephropathy; however, the question remains ‘How do renal taste receptors affect the 
renal pathophysiology associated with metabolic syndrome and diabetes?’.  By 
answering this question it may be possible to elucidate the role of taste receptors in a 
renal regulatory system that is responsive to changes in tubular fluid composition.    
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10 Discussion 
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10.1  Aims of thesis 
 
Diabetic nephropathy occurs as a consequence of hyperglycaemia-induced renal cell 
damage with tubular injury in the disease postulated to be the result of elevated 
GLUT-mediated glucose entry into proximal tubule cells, in a manner similar to that 
seen in mesangial cells (Brosius and Heilig, 2005).  Previous studies have established 
that in type I diabetes PKC-βI-dependent GLUT2 recruitment to the proximal tubule 
BBM occurs as a direct result of hyperglycaemia, resulting in up-regulated glucose 
transport across this membrane (Marks et al., 2003;Goestemeyer et al., 2007).  
However type II diabetes is the prevalent form of the disease in which sufferers 
develop insulin-resistance; therefore type II diabetes presents an interesting model to 
characterise the factors moduliating glucose reabsorption across the proximal tubule 
cell in the presence of a basolateral insulin stimulus.  The development of type II 
diabetes is strongly linked to the current epidemic of obesity and metabolic syndrome; 
consequently, it was important to characterise glucose transport across the proximal 
tubule BBM in rodent models of metabolic dysregulation.  In addition, the novel 
modulation of renal glucose transport across the BBM, by sweet taste receptors, was 
studied using recently characterised mediators of jejunal glucose transport as a model. 
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10.2 Discussion 
    
The work presented here shows that, in euglycaemic conditions, renal GLUT2 is 
expressed in low abundance at the proximal tubule BBM.  This finding contrasts with 
that of previous studies (Marks et al., 2003;Marks, 2004;Goestemeyer et al., 2007).  
The expression of GLUT2 at the renal BBM during euglycaemia parallels findings 
seen in the jejunum, where GLUT2 is expressed at low levels at the enterocyte BBM 
before a meal (Gouyon et al., 2003).  In addition, elevated levels of GLUT2 occur at 
the BBM of proximal tubule cells and enterocytes in response to type I diabetes 
(Corpe et al., 1996;Boyer et al., 1996;Sharp et al., 1997;Marks et al., 2003;Marks, 
2004).  However, a major difference between BBM glucose transport in the small 
intestine and kidney has been shown in the studies presented here: in the proximal 
tubule increased GLUT2 expression at the BBM requires a glucose stimulus of at 
least 7 days, whereas Helliwell et al found higher levels of GLUT2 at the jejunal 
BBM within minutes following raised luminal levels of glucose (Helliwell et al., 
2003).  This highlights the importance of a rapid-response high-capacity glucose 
transporter in the small intestine to absorb the high-luminal carbohydrate load seen 
postprandially.  In contrast, glucose concentration in proximal tubular fluid does not 
normally reach the levels seen in the small intestine; thus, renal glucose reabsorption 
at the BBM utilises SGLT1 and SGLT2, with elevations in GLUT2 occurring during 
periods of metabolic dysregulation.  Interestingly, studies presented in this thesis have 
also shown that extreme osmotic stress increases the recruitment of GLUT2 to the 
proximal tubule BBM via a separate, rapid-response, PKC-βI-dependent signalling 
pathway; however the physiological relevance of this model is limited. 
  
In type I and II diabetes, glucose is stored in the proximal tubule cell as glycogen; 
however, during obesity, the glycogen status of the cell is not known (Rasch, 
1984;Williams et al., 2002;Bamri-Ezzine et al., 2003;Ohta et al., 2007).  In models of 
both forms of diabetes, GLUT2-mediated glucose uptake into the proximal tubule cell 
is elevated; however, GLUT2 is also expressed at the BLM.  Thus, under 
hyperglycaemic conditions, GLUT2 is able to transport glucose into the proximal 
tubule cell from the circulation, as well as from the tubular lumen.  The facilitative 
transport of glucose is dependent on the glucose levels in the proximal tubule cell, 
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which will be altered if glucose is rapidly converted into glycogen.  Further studies 
are therefore necessary to elaborate on the directional flow of glucose across the 
proximal tubule cell, as well as cellular glucose utilisation during periods of elevated 
GLUT2 expression.  Such studies could use polarised proximal tubule cells such as 
the porcine LLC-PK1 cell line plated on transwell plates to study glucose fluxes, 
following exposure of the basolateral and brush-border surfaces to medium containing 
high glucose levels.  This in vitro experimental set-up would also enable the addition 
of specific GLUT and SGLT inhibitors to the medium to allow analysis of specific 
transporters contributing to glucose flux across the proximal tubule cell.  
 
Previous studies have shown that type I diabetes stimulates glucose transport across 
the proximal tubule BBM via GLUT2; a strong positive correlation between the 
expression of GLUT2 and PKC-βI has also been noted in the disease (Marks et al., 
2003;Goestemeyer et al., 2007).  The present study has validated this finding in 7-day 
STZ-induced diabetic rats, as well as observing similar effects of type II diabetes on 
elevated GLUT-mediated glucose transport across the BBM, and augmented GLUT2 
and PKC-βI levels.  Additionally, in all the metabolic models used, expression of 
GLUT2 at the BBM is paralleled by PKC-βI abundance.  Indeed, following gastric 
bypass surgery the reduced GLUT2 levels were matched by a decline in PKC-βI 
expression.  Therefore, it is likely that PKC-βI at the proximal tubule BBM provides 
the signal for trafficking of GLUT2 from intracellular or basolateral locations to the 
brush-border.  The activation of PKC-βI at the proximal tubule BBM is an important 
area of interest and could be studied using the specific PKC-βI inhibitor 
Ruboxistaurin (LY-333531).  Ruboxistaurin is currently under development by Eli-
Lily for the treatment of diabetic complications such as retinopathy and nephropathy 
(Tuttle et al., 2005).  To study further the relationship between PKC-βI and GLUT2, 
Ruboxistaurin could be administered to rodents suffering metabolic dysregulation 
such as the feeding-induced obesity models used in this thesis.  The data presented 
here suggests the need for a specific PKC-βI inhibitor in the treatment of diabetes to 
abolish the recruitment of GLUT2 to the proximal tubule BBM, so reducing glucose 
entry into the cell in this disease with its pathological consequences.  
 
In the studies presented here, PKC-βI-mediated GLUT2 expression at the proximal 
tubule BBM can occur in conditions of metabolic dysregulation accompanied by 
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unaltered blood glucose concentration, such as the response to high-fat feeding or 
gastric bypass surgery.  In both models, neither PKC-βI nor GLUT2 exhibit any 
correlation with plasma glucose levels; therefore, GLUT2 appears to respond to 
factors that are not directly associated with glycaemia.  The stimulus responsible for 
increased GLUT2 expression at the BBM is unknown, but it may be endocrine, 
involving GLP-1 and GIP.  The studies presented here indicate that expression of 
GLUT2 at the proximal tubule BBM operates via an insulin-independent pathway.  
Data from the junk-food-induced pre-diabetic and hyperlipidaemia-induced obesity 
models demonstrate a close association between dietary intake and the onset of altered 
renal glucose handling, which was also observed in diabetes.  Interestingly, GLUT2 
may be responding to a basolateral insulin stimulus, similar to the relationship seen in 
the small intestine (Pennington et al., 1994;Tobin et al., 2008).  However, in STZ-
induced type I diabetes, where circulating insulin levels are low, augmented GLUT-
mediated glucose uptake and GLUT2 expression have been noted (Alberti et al., 
1992;Marks et al., 2003).  This implies that insulin alone is not responsible for 
GLUT2 expression, although further studies to ascertain the response of the insulin 
receptor in the proximal tubule to different models of metabolic dysregulation are 
necessary to confirm this.  Furthermore, to fully understand the causative agent of 
renal GLUT2 up-regulation in diabetes and metabolic syndrome, analysis of a wide 
array of cytokines, such as IL-6, and hormones would be important. 
 
Studies presented here provide further evidence for a relationship between obesity and 
the development of type II diabetes.  GLUT2 at the proximal tubule BBM appears to 
be a renal response to metabolic stress, as well as the observed response to mannitol-
induced osmotic shock.  The implications of increased facilitative glucose uptake 
across the proximal tubule BBM during physiological stress for the cell are unknown. 
 
The recruitment of GLUT2 to the jejunal BBM has been shown to be dependent on 
the activation of PKC-βII: the movement of PKC-βII to the BBM and its activation in 
this location occurs via a Ca
2+
-dependent and sweet taste receptor pathway (Mace et 
al., 2007;Morgan et al., 2007;Mace et al., 2009).  The study by Goestemeyer et al 
implies that the stimulation of GLUT-mediated glucose transport into proximal tubule 
cells required elevated cellular calcium levels (Goestemeyer et al., 2007).  However, 
no studies have been performed to ascertain whether a sweet taste sensing pathway 
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occurs in the kidney.  In the studies presented in this thesis, components of the sweet 
taste heterodimer sweet taste receptors T1R2 and T1R3 were identified in the kidney.  
Although the localisation of these sweet taste receptors has not been studied, the 
presence of mRNA in the kidney cortex and protein at the proximal tubule BBM 
strongly implies that one renal location is the proximal tubule.  In addition to 
identifying other areas of the kidney where T1R2 and T1R3 resides 
immunofluorescence could also provide information as to whether the expression of 
the sweet taste receptors corresponds to the heterodimerisation of the T1R2/3 
complex.  Alternatively, the use of a pull-down assay with BBM vesicles would allow 
the further understanding of the formation of the T1R2/3 complex.     
 
The up-regulation of T1R2 and T1R3 at the proximal tubule BBM occurred in 
response to the artificial sweetener saccharin.  The T1R2/3 heterodimer has been 
previously shown to rapidly stimulate GLUT2-mediated absorption across the jejunal 
BBM (Mace et al., 2009).  However, studies in Chapter 9 of this thesis have shown 
that augmented renal expression of T1R2 and T1R3 occurs in the same metabolic 
models that cause the up-regulation of SGLT1.  The relationship between T1R2/3 and 
SGLT1 has been demonstrated further by assessing the short-term response to 
saccharin.  The rise in Vmax of SGLT-mediated glucose transport across the proximal 
tubule BBM following saccharin IV infusion was accompanied by elevated levels of 
SGLT1 at the proximal tubule BBM.  However, the membrane expression of SGLT2 
could not be elucidated in response to artificial sweeteners, or indeed any of the 
metabolic models used in this thesis, due to lack of a reliable antibody for SGLT2.  As 
a major contributor to glucose reabsorption, it is important to evaluate SGLT2 
expression in these models, especially in the model of type II diabetes, where an 
elevation in both Vmax and KT for SGLT-mediated glucose transport was observed, 
which was accompanied by augmented SGLT1 expression.  Although recent studies 
by Hummel et al strongly indicate that SGLT1 plays a larger role in glucose 
reabsorption than originally believed (Hummel et al., 2011), it is important to study 
the SGLT2 response to metabolic dysregulation.  In particular, the influence of 
saccharin-mediated sweet taste receptor activation on SGLT-mediated glucose 
transport may not solely be a result of elevated SGLT1 expression, but also an effect 
on SGLT2.    
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The relationship between glucose transporters and T1R2/3 in the proximal tubule is 
intriguing.  The data presented in this thesis suggest that PKC-βI-dependent GLUT2 
recruitment to the BBM can occur via a T1R2/3-dependent and -independent pathway 
(Figure 10.1 - 1).  In response to type I diabetes, osmotic shock, and a high-fat diet, 
PKC-βI mediated GLUT2 recruitment to the BBM is elevated, whereas T1R2/3 levels 
remain unchanged (Figure 10.1 - 1).  The same is true in response to RYGB surgery, 
where PKC-βI mediated GLUT2 movement away from the BBM is not associated 
with changes in T1R2/3 levels.  Furthermore, in these models, SGLT1 expression is 
also unaffected, suggesting that PKC-βI-induced GLUT2 expression at the proximal 
tubule BBM involves an unknown factor.   
 
In type II diabetes and pre-diabetes induced by junk-food feeding, PKC-βI-mediated 
GLUT2 recruitment to the BBM is elevated, together with augmented levels of 
T1R2/3 and SGLT1.  Therefore, in these models, T1R2/3 may signal via PKC-βI to 
recruit GLUT2 to the proximal tubule BBM by a similar pathway to that seen at the 
jejunal BBM, that is SGLT-mediated glucose entry can stimulate GLUT2 expression 
at the proximal tubule BBM.  In addition, elevated SGLT-mediated transport at the 
renal BBM observed in type II diabetes and following artificial sweetener infusion, 
but not in type I diabetes, is likely to involve up-regulation of T1R2/3 (Figure 10.1 - 
2).  The relationship between sweet taste sensing and glucose uptake across the 
proximal tubule BBM can be further studied by long-term stimulation of T1R2/3 by 
artificial sweeteners.  In addition, the use of T1R2/3 inhibitors in models where renal 
SGLT-mediated glucose uptake is significantly up-regulated, for example type II 
diabetes and saccharin infusion, would further study the role of sweet taste sensing in 
glucose transport described in this thesis.  Furthermore, KO mice for both T1R3 and 
gustducin, the major signalling molecule involved in sweet taste sensing, may provide 
insights into alternative roles, other than for glucose reabsorption, of renal sweet taste 
sensing.  The hypothesised role of T1R2/3 in the stimulation of glucose reabsorption 
implicates the heterodimer as a potential therapeutic target for patients suffering both 
pre-diabetes or type II diabetes.  
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Figure 10.1 – The two proposed signalling pathways responsible for the regulation of glucose transport across the proximal tubule BBM in response to metabolic 
dysregulation and stress models; A: Recruitment of GLUT2 to the proximal tubule BBM, mediated by PKC-βI, occurs independently of SGLT1 and T1R2/3, in 
response to high-fat feeding, osmotic shock and type I diabetes; B: Recruitment of GLUT2 to the proximal tubule BBM, mediated by PKC-βI, occurs 
concommitantly with up-regulated  SGLT1 and T1R2/3, in response to a junk-food diet and type II diabetes  
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11 Conclusions 
 
In conclusion, the studies described in this thesis lead to a hypothesis implicating two 
distinct pathways in the regulation of glucose uptake across the proximal tubule BBM.  
During periods of metabolic dysregulation associated with diabetes, sodium-
dependent and –independent glucose transport is altered, which can lead to 
hyperglycaemia, the main diabetic phenotype.  Exploitation of the mediators of these 
transporters, such as T1R2/3, may pave the way for the development of potential anti-
hyperglycaemic treatments for diabetes and pre-diabetes. 
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